AuthorIndexâ€”1987jnm.snmjournals.org/content/28/12/local/back-matter.pdf ·...

Abbottsmith. C, 568(ab)Abdel-Dayem, HM, 676(ab),

730(ab)Abdel-Nabi, H, 7 IO(ab)Abdi.E, 712(ab)Abe, Y, 658(ab), 706(ab)Abendschein, DR. 1322Aboul-Enein, HY, 255Abrams, D, 402Abrams, DN, 487Abrams, P. 573(ab), 650(ab)Abrams, PG. 615(ab)Abreu, SH, 586(ab)Aburano, T, 714(ab),

731(ab)Acio, E, 1508Ackerhalt, R, 360Ackerman, RH, 656(ab),

698(ab)Ackermann, RF, 612(ab)Ackery, DM, 372, 658(ab)Adam, Mi, 1599Adam, WE, 458Adams, HR. 587(ab)Adams, R, 722(ab)Adler, LP, 704(ab)Adler, S, 681(ab)Adler, SS, 655(ab), 702(ab)Adriaens, P, 731(ab)Aharonson, E, 161Ahiem, C, 692(ab), 7 1((ab)Ahmad, M, 260(ab), 610(ab),

703(ab)Ahmed, A, 615(ab)Ahn, YS, 690(ab)Ahonen, A, 910Aiache, J-M, I 199Ajmani, AK, 407(ab)Akamatsu, K, 628(ab)Akanabe, H, 717(ab)Aksut, G, 638(ab)Alanko, K, 442Alavi, A, 431, 565(ab),

584(ab), 594(ab), 601(ab),633(ab), 639(ab), 655(ab),685(ab), 686(ab), 694(ab),699(ab), 702(ab), 733(ab),736(ab), 1447, 1667

AIaVI,J, 1667Alavi, JB, 594(ab)Alazraki, N, 596(ab),

606(ab),613(ab),642(ab),706(ab)

Alazraki, NP, 168Al-Bitar, I, 597(ab)Aibriglit, M, 599(ab)Alcock, N, 1844Alderson, P0, 203, 723(ab)Alfieris, 0, 666(ab)Ali, A, 564(ab), 628(ab)Au, S. 626(ab)Allard, C, 698(ab)Allard, CD, 695(ab)Allard,J, 1911Allenberg, J, 406(ab)

Allidina, Y, 620(ab)Allison, RWG, 526Allo, MD, 575(ab)AlIred, iF, 726(ab)Al.Nahas, A, 647(ab)Alpert, J, 632(ab)Alpert, NM, 656(ab),

698(ab)Alves, W, 699(ab)Alyea, K, 261(ab), 568(ab),

569(ab)Amano,M, 607(ab)Amberson, SM, 188, 1366Ambrose, J, 676(ab)Ambrose, KR, 720(ab),

724(ab)Amico, 5, 254, 582(ab)Amor,M,654(ab)Amox,DO, 637(ab)Anaise, D, 731(ab), 733(ab)Anazawa, Y, 1901Andersen, AR, 407(ab),

559(ab)Anderson, BO, 1233Anderson, J, 707(ab)Anderson, LD, 692(ab),

71 1(ab)Ando, K, 700(ab), 703(ab)Ando,T, 579(ab),672(ab),

673(ab)Andrade, R, 718(ab)Andrea, RY, 585(ab),

614(ab)Andrews, J, 659(ab)Anees, A, 564(ab)Anelli, 5, 1888Anghileri, L.J, 563(ab)Antar, MA, 732(ab)Antich, P, 704(ab)Antico, V, 550(ab)Antico, VF, 550(ab)Antoine,J-M,563(ab)Antonelli, D, 632(ab)Antoni,G, 1037Antonovic, R, 615(ab)Aoki, 5, 569(ab)Aoki, Y, 703(ab)Apicella, A, 68 1(ab), 852Appelbaum, F, 692(ab)Appledorn, CR, 55 1(ab),

652(ab)Apstein, M, 596(ab)Arano, Y, 571(ab), 712(ab),

720(ab), 730(ab), 1027Araujo, L, 558(ab), 682(ab)Ardalan, B, 599(ab)Areeda, J, 588(ab)Arger, PH, 733(ab)Arimizu, N, 648(ab)Armitage, DL, 644(ab)Arnett@CD, 624(ab),

635(ab), 1164Arnold, J, 405(ab)Arnold, 3M, 405(ab)Arnold, iS, 405(ab)

Arnstein, NB, 664(ab)Arora, GD, 262(ab), 407(ab)Arora, SS, 927Arsenault, A, 654(ab)Artoul, 5, 632(ab)Arzoumanian, A, 649(ab)Asano,S, 1061Ascoop, CAPL, 579(ab)Ash,3,62l(ab)Ash,JM,646(ab)Ashburn, WL, 596(ab)Ashford, JW, 645(ab)Atassi, K, 597(ab)Atcher,RW,617(ab),

693(ab), 861Atkins, FB, 586(ab)Atkins, HL, 47, 680(ab),

710(ab), 731(ab), 733(ab)Attic, M, 1447Atwood, JE, 631(ab)Aug. F, 654(ab)AVigad, I, 298Axeirod, M, 1393Axeisson, B, 1861Ayers, JWT, 685(ab)Azares, M, 723(ab)Azuma,M, 627(ab),628(ab)

Babich,J, 1230Bacharach, SL, 557(ab),

631(ab), 671(ab)Badenhorst, PN, 402Badger, C, 692(ab)Badger, CC, 692(ab)Badillo, FL, 704(ab)Bading, JR. 650(ab)Bagchi, A, 366, 622(ab)Bahar, H, 1408Bahk, YW, 447Bahn, MM, 587(ab), 61 l(ab)Bai, L-Q, 635(ab), 1164Baidoo, KE, 729(ab)Bailey, DL, 677(ab), 844,

1925Baillet, G, 666(ab)Bairamian, D, 53Bairey, CN, 589(ab), 597(ab)Baja, 5, 431Bakker, AR, 675(ab)Balaban, E, 1365Balaban, EP, 229Baldwin, GP, 587(ab)Balk, E, 408(ab)Ball, ME, 641(ab), 663(ab),

698(ab)Ball, 5, 632(ab)Ballinger, JR. 563(ab),

669(ab), 1364Balseiro, J, 629(ab), 678(ab)Bandstra, E, 718(ab)Banner, H, I 107Barak, Y, 666(ab)Bardy, A, 563(ab)Barkan, A, 685(ab)Barkel, DA, 550(ab), 660(ab)

Barker, W, 852Barker, WW, 681(ab)Barlai-Kovach, M, 614(ab),

632(ab), 1671Barnes, WE, 667(ab), 1920Barot-Ciorbaru, R, 658(ab)Barrio, JR, 587(ab), 61 1(ab),

624(ab)Barron,BJ, 1290Barson, WG, 568(ab)Bands, PC, 1488Bartholomew, RM, 25,

637(ab), 692(ab), 71 1(ab),712(ab), 714(ab)

Bartynski, B, 907Bashkoff, E, 676(ab)Basmadjian, GP, 264(ab)Bassett, LW, 564(ab)Basso,L, 112, 558(ab)Batjer, H, 591(ab)Batjer, HH, 633(ab), 634(ab)Battey, LL, 589(ab), 591(ab),

674(ab)Bauer, S, 621(ab)Baulieu, F, 658(ab), 7 16(ab)Baulieu, JL, 658(ab), 716(ab)Baum,GL, 161Baum, ML, 1506Baum, RP, 706(ab)Bauman, JM, 260(ab),

261(ab), 266(ab)Baumgardner, W, 6l5(ab)Baumgartner, W, 663(ab)Baxter, L, 655(ab)Baylin, SB, 685(ab)Bazin, i-P. 680(ab)Beals, E, 979Beatty, SM, 615(ab)Beauchamp, G, 605(ab)Beaumier, PL, 34, 615(ab),

691(ab)Beauregard, J, 637(ab)Beck, Ti, 683(ab)Becker, D, 735(ab)Becker, DV, 58l(ab),

687(ab)Becker, LC, 400, 620(ab),

630(ab)Beckers, C, 578(ab), 610(ab),

644(ab)Beekhuis, H, 684(ab)Beerbohm, D, 641(ab)Beers, BA, 715(ab), 1736Beierwaltes, W, 618(ab)Beierwaltes, WH, 706(ab),

979, 1625Beihn, R, 1453Bekerman,C, 648(ab),1103Belfer, B, 161Belier, GA, 580(ab), 618(ab),

653(ab)Belsey, R, 383Belzberg, A, 254Benade,AJS,622(ab)Bendriem, B, 68l(ab)

Benedetto, AR, 258,930,950,1066,1233,1784

Benjamin, SB, 604(ab),690(ab)

Bennett, C, 648(ab), I 103Bennett, GW, 631(ab),

678(ab), 697(ab)Benoit,L,945Benson,DF, 645(ab)Benson, LN, 621(ab)Benua,R,41l(ab)Berbaum, KS, 1134Berg,GW, 587(ab)Berg, J, 566(ab), 570(ab),

576(ab), 661(ab)Bergmann,SR,1322,1563Bergqvist, L, 1424Berkopec, JM, 65 l(ab)Berlad,G, 618(ab)Berman, D, 643(ab)Berman, DS, 325, 56l(ab),

588(ab), 589(ab), 597(ab),654(ab), 674(ab)

Bernstein, ID, 692(ab)Bertelli, P, 613(ab)Bertram, 3, 595(ab)Bertrand, A, 654(ab)Besnard, JC, 658(ab)Besser,GM, 319,973Bettinardi, V, 566(ab)Beven,T, 135Bhatia, 5, 673(ab)Bianco-Arco, A, 1807Bice, AN, 612(ab), 662(ab),

683(ab), 700(ab)Bida,GT, 61l(ab), 624(ab)Bidaut, LM, 696(ab)Biedermann, M, 620(ab)Biello, DR. 837Biersack, Hi, 569(ab),

592(ab), 593(ab), 659(ab),67l(ab)

Biersack, H-i, 712(ab)Biersack, Hi, 1763Bieszk, iA, 1308Bietendorf, i, 597(ab)Bigler, RE, 581(ab), 617(ab),

653(ab), 687(ab)Bigner, DD, 603(ab), 710(ab)Billingburst, MW, 1511Billings, i, 360, 571(ab),

725(ab), 1012Billingsley, iD, 629(ab),

663(ab)Bingham, L, 637(ab)Binney, G, 658(ab)Binor,Z,628(ab)Birmingham, Mi, 1419Bitoh, K, 609(ab)Bitran, i, 648(ab), 1103BjÃ´rklund,B, 712(ab)Black, RR, 7l8(ab)Blake, GM, 683(ab)Blanchard, H, 716(ab)Blanchet, M, 621(ab)

Pagenumbersfollowedby (ab)indicateabstracts.N preceding a page number indicates an article appearing in

Newsline.

1932 TheJournalof NuclearMedicine

AuthorIndexâ€”1987

Coleman

Blasberg, RG, 70l(ab)Blast, Mi, 265(ab)Blau,M, 354, 1012Blaufox,MD, 6l2(ab), 1393Blend, Mi, 552(ab), 666(ab),

694(ab)Block, D, 634(ab)Blokiand, iAK, 675(ab)Blood, DK, 663(ab)Blue, PW, 544Blumhardt, R, 1725Bock, Wi, 591(ab)Bockisch, A, 7 12(ab)Boddy, SAM, 1284Boer,RO, 1488Bolli, R, 654(ab)Bob, NR, 655(ab)Bomanji, J, 319, 637(ab),

647(ab), 973, 1284, 1907Bonakdarpour, A, 605(ab)Bono, MD, 651(ab)Bonow, RO, 557(ab),

63l(ab), 67l(ab)Bonte, F, 570(ab)Bonte, Fi, 262(ab), 407(ab),

408(ab), 591(ab), 623(ab),633(ab), 634(ab), 698(ab)

Boogaerts, M, 690(ab)Bookman, M, 636(ab)Boonkifticharoen, V, 209Boothe, TE, 636(ab)Borchert,RD, 1335Borges-Neto, 5, 579(ab),

654(ab)Borkon, M, 615(ab), 663(ab)Boruchowsky, 5, 298Bosslet, K, 693(ab)Botsch, H, 406(ab)Bofti, J, 665(ab)Botvinick, E, 580(ab),

608(ab), 669(ab), 673(ab)Boucher, C, 666(ab)Boucher, CA, 632(ab),

662(ab), 67l(ab), 1531Boucher, P, 654(ab)Boudreau, Ri, 342, 407(ab),

638(ab)Boudreau, RM, 735(ab)Bouffant, JA, 640(ab), 1401Bouloux, PM-G, 973Boumpas, DT, 1508Bourel, D, 637(ab)Bourgoignie, ii, 613(ab),

1383Bourguet, P, 637(ab),

688(ab), 707(ab)Bourguignon, M, 592(ab)Bowen, JR. 716(ab)Boyce, TM, 654(ab), 663(ab)Boykin, MW, 266(ab)Boyko, 0, 714(ab)Brachman, MB, 56l(ab),

563(ab), 647(ab), 658(ab),686(ab)

Bracht-Krauss, D, 458Bradley, Gi, 675(ab)Brady, T, 572(ab), 1401Brady,Ti,871,1616Brandes, Si, 625(ab)Brassel, F, 592(ab), I763Braun, H, 600(ab)Brauns, N, 567(ab)Braunstein, G, 686(ab)Brechbiel, MW, 668(ab), 861

Brem, H, 645(ab)Brendel, AJ, 627(ab),

685(ab)Brennan, K, 652(ab)Brennan, KM, 649(ab),

655(ab), 725(ab)Brennan, MF, 640(ab),

650(ab)Brenner, D, 593(ab)Bretagne, iF, 688(ab),707(ab)

Bretan, PN, Jr. 598(ab)Brewer, EJ, 262(ab)Bnchant, C, 669(ab)Bricker, JA, 649(ab)Bncker,iT, 262(ab)Bride, B, 659(ab)Briggs,RC, 188,1366Brihaye, C, 409(ab)Bril, T, 686(ab)Brill, AB, 203, 63 1(ab),

697(ab)Brill, DR. N 1087Bntton,KE,319,637(ab),647(ab),973,1284,1907

Brodack, iA, 561(ab)Brodack, JW, 625(ab),

727(ab)Broder,G, 616(ab)Brodie,JD, 1251Brodin, T, 7 lO(ab)Broich, K, 569(ab)Bronca, GT, 562(ab)Brooks, KM, 1688Brooks, RA, 53Brown, B, 560(ab)Brown,BA,573(ab),619(ab)Brown, C, 639(ab)Brown,D, 647(ab)Brown, DE, 563(ab)Brown, GS, 619(ab)Brown, i, 646(ab)Brown,KA, 945Brown, M, 55 l(ab), 586(ab),673(ab),927

Brown,ML,550(ab),55 l(ab), 660(ab)

Brown, P. 692(ab)Brown, PH, 1826Brown, RKJ, 564(ab), 1683Brown, 5, 692(ab)Brucer, M, N1647Bruch, PM, 562(ab)BrOcke, T, 1657Brugger, A, 591(ab)Brunken, RC, 598(ab)Brunneman,SR.688(ab)Brust, K, 692(ab)Bryson, N, 593(ab), 728(ab)Buatti, AU, 732(ab)Buchbinder, 5, 577(ab)Buckley, M, 666(ab)Budinger, TF, 588(ab),

594(ab), 608(ab), 649(ab),655(ab), 717(ab), 725(ab)

Budzynski, AZ, 657(ab)Buell,U, 600(ab),620(ab)Bullard, DE, 710(ab)Buncher,CR, 1521Bunn,PA, 602(ab)Bunn, PA, ir, 42, 281Burakoff, Si, 693(ab)Burbidge, 5, 342Burke, A, 633(ab)

Burke, iF, 559(ab)Burnett, OL, 672(ab)Burns, HD, 594(ab), 729(ab)Burns, Ri, 644(ab)Burow,DM, 264(ab),

265(ab)Burt, RW, 649(ab), 1511Burton, H, 646(ab)Busemann-Sokole, E, 1592Bushnell, DL, 1920Busuttil, RW, 653(ab), 1683Butler, JA, 574(ab)Buxton,DB, 558(ab),

61 1(ab)Buxton, RB, 656(ab),

698(ab)Buysschaert, M, 605(ab)Byrd, B, 266(ab)Byrd, BF, 260(ab), 261(ab),266(ab)

Byrd, BL, 721(ab)Byse, BL, 178

Cadranel, S, 715(ab)Cagle, LA, 562(ab)Cahoon, i, 608(ab)Cahoon, iL, 608(ab)Calabrese, i, 60l(ab)CaIdwell, iC, 668(ab)CaIdwell, RL, 62 1(ab)Calhoun,iM, 1478Callahan, AP, 657(ab)Callahan, ii, 586(ab)Callahan, Ri, 614(ab),

695(ab)Caliwood, K, 262(ab)Camin, L, 662(ab), 675(ab)Camin, LL, 13Camli, U, 700(ab)Campbell, i, 673(ab)Campbell, 5, 13Campeau, Ri, 262(ab)Cance, WG, 582(ab)Canning, LR, 191Cannon, Pi, 663(ab)Cannon, RO, III, 557(ab),671(ab)

Cantineau, R, 409(ab),655(ab)

Canup,DS,652(ab)Cappa, 5, 699(ab)Carden,iL, 708(ab)Carey, i, 618(ab)Carey, JE, ir, 334Carichner, SL, 552(ab)Caride, Vi, 7l9(ab)Carlo,Di,25,637(ab),

692(ab),711(ab),712(ab),7l4(ab)

Carison, W, 97Cannel, A, 354Carney, K, 583(ab)Carpenter, AT, 13Carrasquillo, J, 709(ab)Carrasquillo, iA, 42, 281,

602(ab), 614(ab), 636(ab),65 1(ab), 693(ab), 710(ab),722(ab)

Carrera, GF, 665(ab), 1268Carrier, L, 803Carroll, LR, 697(ab)Carroll, Mi, 574(ab),

648(ab), 694(ab)Carroll, RG, 604(ab)

Carson, B, 645(ab)Carson, RE, 587(ab), 701(ab)Carter,A, 1279Casset, D, 7l6(ab)Castro, R, 662(ab), 675(ab)Castronovo, FP, ir, 535Catz, Z, 184, 658(ab),

7 12(ab)Caudry, M, 627(ab)Caufriex, A, 686(ab)Cauwe, F, 669(ab)Cawthon, MA, 266(ab)Cawthorn, R, 679(ab)Ceccarelli, C, 1888Cedarholm, iC, 666(ab)Cercek, B, 674(ab)Cerqueira, MD, 710(ab)Cesaro,P,623(ab)Chachati,A,829Chaitman, BR, 580(ab)Chambers, M, 263(ab)Champion, MC, 563(ab)Chan, SM, 603(ab), 708(ab),

709(ab), 1303, 1441Chandramouly, B, 580(ab)Chandramouly, BS, 675(ab)Chang, C-H, 692(ab),

71 l(ab)Chang, i, 360Chang, JM, 717(ab)Chang, iY, 681(ab), 852Chang, SL, 622(ab), 7l7(ab)Chang, 55, 650(ab)Channing, MA, 701(ab)Chao, lB. 650(ab)Chaovapong, W, 561(ab)Chaplin, SB, 191, 729(ab)Chapman, D, 643(ab)Charalel, I, 574(ab)Charkes, ND, 399, 575(ab),1835

Charlier, AA, 6l0(ab)Chartrand, R, 803Charuzi, Y, 674(ab)Chassen, 5, 596(ab)Chatal, i-F, 1807Chatterjee, K, 580(ab)Chatterton, BE, 605(ab)Chawluk, i, 633(ab),

702(ab), 1667Chawluk, iB, 431, 601(ab)Cheesman, EH, 731(ab)Chehabi, HH, 633(ab)Chen, BC, 63l(ab)Chen, CT, 682(ab)Chen, D, 595(ab)Chen, DCP, 638(ab),

664(ab), 691(ab), 694(ab),713(ab)

Chen,GTY,682(ab)Chen,HY,638(ab)Chen, 1W, 568(ab), 718(ab)Chen, iJS, 575(ab), 685(ab)Chen, KY, 691(ab), 7l3(ab)Chen, MT. 650(ab)Chen, WL, 676(ab)Chen, Y, 645(ab)Chen, YT, 676(ab)Cherrier, F, 654(ab)Chervu LR, 907Chesler, DA, 662(ab)Chetanneau, A, 1807Cheung, N.Kv, 1577Chi, DY, 625(ab)

Child,iS, 598(ab)Chilton, HM, 257Chin, M, 608(ab)Chinol, M, 7 12(ab), 1465Chiou, PF, 676(ab), 687(ab)Chiou, RK, 603(ab)Chiron, C, 592(ab)Cho, K, 1401Choi, H-O, 91Chonacky. Ni, 1062Christian, PE, 5 14, 563(ab),

604(ab), 1204, 1926Christiansen, C, 960Christin,A,1554Christin, P, 647(ab)Chrisiman, DR. 1251Chu, RYL, 261(ab)Chu, YK, 7l7(ab)Chugani, DC. 6l2(ab)Chugani, HT, 646(ab)Chumpradit, 5, 725(ab)Chung, 5K, 447Churchwell, AL, 589(ab),

59l(ab), 642(ab), 666(ab),674(ab)

Ciarleglio, CA, 604(ab),690(ab)

Cicero, 5, 705(ab)Ciliax, Bi, 724(ab), 726(ab)Cinofti, L, 623(ab)Civelek, AC, 575(ab)Clark,DB, 1484Clark,0, 583(ab)Clarke, DO, 1820Clarke, H, 733(ab), 734(ab)Clarke, HS, ir, I 171aarke, 5, 674(ab)aarke, SEM, 253, 561(ab),

1820Claunch, B, 597(ab)Clements, iP, 945Cleynhens, B, 73 1(ab)Ointhorne, NH, 577(ab),

64l(ab), 661(ab), 695(ab)Cloninger, K, 97Cloninger, KG, 589(ab),642(ab)

Clorius, iH, 406(ab),408(ab), 410(ab)

Clothier, i, 61 1(ab)Ouu@, ML, 637(ab)Coakham, HB, 603(ab)Coakley,AJ, l187Coates,G,903, 1213Cochavi, 5, 675(ab)Code, RF, 703(ab)Coenen,HH,6l2(ab),

634(ab)Cohen,MB,562(ab),677(ab)

Cohen,PF,659(ab)Cohen,RM,701(ab)Cohen,SA,683(ab)Coicher,D, 722(ab),861,1924

Cole,P. 663(ab)Cole,PD, 575(ab)Cole,WC,83, 265(ab),

560(ab)Coleman,LE,66l(ab)Coleman, RE, 410(ab),

566(ab), 577(ab), 603(ab),625(ab), 678(ab), 696(ab),697(ab),7l0(ab),l584

1933AuthorIndexâ€¢1987

Collen

Collen, Mi, 604(ab), 690(ab)Coller, 85, 584(ab), 7l8(ab),

720(ab)Colleul, P, 590(ab)Collier, BD, 559(ab),

574(ab), 585(ab), 592(ab),622(ab), 638(ab), 665(ab)

Collier, DB, 1268Coffins, Pi, 605(ab)Colombo, A, 63l(ab)Colombo,F, 1870Connelly,BT,47Conrad, GR, 562(ab),

649(ab), 1134Constable, AR, 733(ab)Conte,Fa, 1335Conti, PS, 640(ab), 683(ab),

693(ab)Conway,T, 625(ab)Cook, D, 264(ab)Cook, DES, 264(ab)Cooke, D, 675(ab)Cooley, L, 1550Cooley, LA, 7l6(ab)Coon, W, 713(ab)Cooney, JM, 620(ab)Coonrod, DV, 1435Cooper, AJL, 1844Cooper, KE, 717(ab)Cooper, MD, 624(ab),

682(ab)Coornaert, 5, 707(ab)Corbally, MT. 650(ab)Corbus, HF, 405(ab)Cordasco, EM, 718(ab)Corlija, M, 679(ab)Cornelius, E, 7ll(ab),

7l3(ab)Cornelius, EA, 573(ab)Corrao, J, 632(ab)Correla, JA, 656(ab), 698(ab)Costa, DC, 593(ab)Costanza, M, 550(ab)Cotter, 0, 666(ab)Couch, MW, 582(ab), 1745Coupal, ii, 1484Coveney, iR, 732(ab), 1881Cox,PH, 135Coyne, MG, 563(ab)Crass,JR,638(ab)Crawford, CR, 66l(ab)Creutzig, H, 562(ab),

576(ab), 680(ab)Criley, M, 1315Croft, BY, 616(ab), 1367Cronin, EB, 1047, 1775Crook, JE, 721(ab)Crowley,JJ,1435Curran, JJ, 810Curry, PVL, 674(ab)Curtet,C, 1807Cusick, JF, 622(ab)CZCTnIak,A, 298

Dabiens, i, 716(ab)Dach, JL, 679(ab)DaCosta, M, 629(ab),

664(ab)Dae, M, 580(ab), 608(ab),

669(ab),673(ab)Dagher, A, 633(ab)Dahalan,R,595(ab)Dahl,CM, 1861Dahlbom, M, 682(ab),

696(ab)Dailey, N, 589(ab)Dalal, KB, 7l7(ab)D'Amago, PH, 642(ab)D'Amato,P, 642(ab)Damske,B,631(ab)Dana@is,5, 716(ab)Danforth, i, 580(ab)Daniels, D, 622(ab)Dann,R,431Dannals, R, 61 l(ab)Dannals, RF, 600(ab),

61 l(ab), 612(ab), 624(ab),626(ab), 635(ab), 645(ab),699(ab), 701(ab), 726(ab)

Danpure, Hi, 574(ab),648(ab), 694(ab)

D'Argenio, D, 595(ab)Darnault, P, 688(ab),

707(ab)Datz.,FL,168,514,563(ab),

604(ab), 820, 1204, 1926Daube-Witherspoon, ME,

587(ab), 607(ab), 64l(ab),1717

Davenport, R, 713(ab)Davie, JM, 582(ab)Davies, RA. 643(ab), 669(ab)Davis, G, 560(ab)Davis, J, 692(ab)Davison, A, 13, 593(ab),

601(ab), 602(ab), 728(ab)Day, DE, 708(ab)Dazord,L,637(ab)Dean,GW, 1758Deanfield, JE, 989De Bakker, C, 690(ab)Debets, R, 702(ab)de Bruine,iF, 178DeCoskey, D, 644(ab)Dc Coster, P, 669(ab)Deecke, I, 1657Defer,G, 623(ab)DeGrado, TR, 635(ab),

667(ab)DeGraff,W, 617(ab)Dehmer,Gi, 102, 1363Deisenhammer, E, 59l(ab)De.Jesus, OT, 572(ab)deiong,JMBV, 178de iong, MMTh,1020DeKosky, ST, 1484de Kraker, i, 308DeLand,FH, 816,1484deLandsheere, C, 989DeLaney, M, 629(ab),

664(ab)Delaval, Ph, 637(ab)Delisle, Mi, 582(ab)Delmon, L, 354Del Vecchio, 5, 614(ab),

636(ab)Demer, LL, 1262Demonceau,G, 409(ab)Dempsey, M, 626(ab)De Nardo, GL, 83DeNardo, Si, 83Dence, CS, 462Denney, RK, 615(ab)Dennis@DR. 1704DePasquale, E, 673(ab)Depper, 3, 610(ab)DePuey, EG, 589(ab),

642(ab), 652(ab), 672(ab),

673(ab)DePuey, G, 642(ab)Derenzo, SE, 608(ab)De Roo, M, 690(ab), 731(ab)Desai,AG, 438DeSombre, ER, 572(ab)De Souza,M, 621(ab)Detry, .JMR, 578(ab),

644(ab)Deugnier, Y, 707(ab)Deuschl, G, 406(ab)Deutsch, AM, 664(ab)Deutsch, E, 626(ab), 1491,1870

Deutsch, SD, 664(ab)De Vos,Ci,583(ab)Devous, M, 570(ab)Devous, MD, Sr. 262(ab),

407(ab), 408(ab), 591(ab),623(ab), 633(ab), 634(ab),698(ab)

Dewanjee, MK, 667(ab)Dewey, 5, 624(ab)Dewey, SL, 635(ab)Dhansay, MA, 622(ab)Dhawan,V, 600(ab),

700(ab), 1844Dhekne,RD. 261(ab),

262(ab), 265(ab), 1290Diamantstein, T, 6l0(ab)Diamond, P, 716(ab)DiChiro,G,53Dickson, DR. 726(ab)DieM, V, 705(ab)Digby, WM, 696(ab)Digenis, GA, 816DiGiulio, W, 1341Diksic, M, 136, 234, 471,

625(ab), 633(ab), 636(ab),1123,1783

Dillehay, GL, 577(ab),6l6(ab)

Dilley, WG, 582(ab)DilIman, RO, 637(ab)Dilmanian, FA, 697(ab)Di Lorenzo, C, 715(ab)Diltz, EA, 578(ab)Dinsmore, RE, 1616DiPaola, M, 680(ab)DiPaola, R, 680(ab)DiResta, GR, 650(ab)DiSimone, RN, 544Divgi,C,41l(ab)Dmowski, WP, 628(ab)Doherty, PW, 712(ab),732(ab),1192

Domstad,PA,816,1484Donath, A, 1554Donnelly, T, 610(ab)Dornfest, Di, 703(ab)Dorsey, DA, 645(ab)Dose, EV, 705(ab)Douglas, IHS, 886Douglas, KP, 108Douglass, K, 645(ab)Douglass, KR, 699(ab)Dozio,N, 583(ab)Drago,SR.378Drane, WE, 810, 1640Drew, H, 615(ab), 645(ab)Driedger, AA, Nl0Druck, MN, 644(ab)Duara,R,681(ab),852Dubiansky, V, 1408

Dubovsky, EV, 622(ab),629(ab), 663(ab), 735(ab)

Dubovsky, J, 629(ab),663(ab)

Ducassou, D, 623(ab)du Cret, RP, 407(ab),

638(ab)Duensing, DI, 680(ab)Duensing, DT, 679(ab)Dulac, 0, 592(ab)Duncan, C, 6l5(ab)Duncan, iS, 557(ab)Duncan, RC, 1383Dunn, D, 97, 589(ab),

642(ab), 666(ab), 674(ab)Dunn,WL, 1751Dupras, G, 654(ab), 662(ab)Duranceau, A, 605(ab)Duray, P, 603(ab), 709(ab),

1303Duray, PH, 708(ab), 1441Durwen, HF, 1763Duvaufemer,R, 707(ab)Duwel, CMB, 567(ab)Dworkin, Hi, N277, Nl099Dydek, GJ, 544

Eary, i, 573(ab), 650(ab),692(ab)

Eary, iF, 34, 615(ab),692(ab)

East,M, 7l3(ab)Ebbe, SN, 7l7(ab)Ebifegha, ME, 703(ab)Ebina, A, 1901Eckelman, WC, 568(ab),

674(ab)Edgerton, ER, 576(ab),

577(ab), 66l(ab)Edholm,PR, 565(ab)Edwards, B, 495, 722(ab),

729(ab)Edwards,5,1820Eeckhout, E, 630(ab)Eenige van, Mi, 567(ab)Efange, 5, 601(ab)Efange,SMN, 1012Ege, GN, 715(ab)Egerton-Vernon, J, 526Ehrenkaufer, RE, 625(ab)Ehrhardt, GJ, 656(ab),

708(ab), 722(ab), 729(ab)Ehrhardt, iC, 209Ehrlich, LE, 1540Ehrmann, D, 640(ab)Eisenberg, B, 685(ab),

694(ab)Eisner,RL,97, 564(ab),

577(ab), 589(ab), 59l(ab),642(ab), 666(ab), 674(ab),705(ab)

Ekas, R, 668(ab)Elisei,R, 1888Elkanovitch, R, 452Ell,P3,593(ab)Ellis, BI, 244Ellis,i,640(ab)Ellis, K, 670(ab)Elmaleh, D, 632(ab)Elmaleh, DR. 134, 727(ab),728(ab)

Elson, MK, 603(ab), 65l(ab),665(ab)

El-Tahtawy, A, 599(ab)

Embon, OM, 733(ab)Embry, 5, 568(ab)Emons, D, 1218Emran, A, 681(ab)Emran, AM, 636(ab)Endo,K, 252, 342, 568(ab),

7l2(ab), 719(ab), 720(ab),730(ab),1027

Endo,M, 567(ab),703(ab)Engelstad, BL, 565(ab),

590(ab), 599(ab), 626(ab)Engleman,K, 639(ab)English,D, 1471Ensminger, W, 659(ab),707(ab)

Epps, LA, 729(ab)Epstein, A, 691(ab), 713(ab)Epstein, AL, 83Erlandsson, K, 58l(ab)Ernstoff, M, 71 l(ab)Ernstoff, MS. 573(ab), 1441Erwin, WD, 564(ab),

590(ab), 628(ab)Eshima, D, 613(ab), 647(ab),732(ab),1180

Esteban,JM, 861Estour, B, 71 l(ab)Estrada, MC, 4l0(ab),

696(ab), 697(ab)Etani, H, 70l(ab)Evangelatos,GP, 1430Evans, A, 633(ab)Evans,AC,234,471,

695(ab),698(ab),1123Evans, DG, 596(ab)Evans,H, 260(ab)Ewer, MS. 929Ezquerra, NF, 6l8(ab),675(ab)

Fa@bender, D, 567(ab)Fabiano, A, 576(ab)Fagnani,F,712(ab)Fagnani, R, 714(ab)Fahey, FH, 604(ab), 629(ab),

678(ab), 690(ab), 1408Fahey, PJ, 616(ab)Fajman, WA, 564(ab)Fallon, if, 76Fand,I, 683(ab)Farde, L, 625(ab)Farhangi, M, 708(ab)Faulkner, D, 669(ab)Fawcen, D, 703(ab)Fawcett, HD, 260(ab),

265(ab)Fawdry, RM, 510Fawwaz, RA, 723(ab)Fazekas,F,1667Fazio, F, 566(ab), 699(ab),70l(ab),1870

Fefer,A, 690(ab)Feiglin, DHI, 718(ab)Feindel, W, 234, 1123Feinendegen, LE, 59l(ab),

924Feld,T, 592(ab),674(ab),

729(ab), 730(ab)Feiu, AL, 998Fell,D, 608(ab)Ferbert, D, 600(ab)Fernandez, A, 1771Fernandez-Ulloa, M, 718(ab)Ferrant, A, 610(ab)

1934 The Journal of Nuclear Medicine

Guyot

Ferrara, 3M, 693(ab)Fettich, i, 319, 647(ab)Fields, AL, 658(ab)Fieschi, C, 633(ab)Fig,LM,640(ab)Filc-DeRicco, 5, 594(ab)Filmer, RB, 646(ab), 824Findley, DO, 684(ab)Fine, D, 658(ab)Fine,EJ,1393FIneman, D, 6l0(ab),

695(ab)F@ink,G, 688(ab)Finklestein, R, 643(ab)Finn, R, 722(ab), 852Finn, RD, 587(ab), 636(ab),

70l(ab)Fintel, D, 408(ab)Fioravanti, C, 676(ab)Fischer,E,1279Fischman, AJ, 119, 610(ab),

614(ab)Fish, LA, 704(ab)Fisher, R, 699(ab)Fisher, RS, 605(ab), 660(ab)Fisher, 5, 65 l(ab), 684(ab),7l5(ab)

Fishman, MC, 704(ab)Fissekis, JD, 650(ab)Fitzgerald, R, 55l(ab),

586(ab)Fitzgerald, RH, 927Flamm,E, 1251Flamm, 5, 609(ab), 650(ab),

67l(ab)Flatman,WD, 319,973Fleet,IR, 1187Fleiner, T, 408(ab), 410(ab)Fleming, JS, 372, 683(ab)Flint, E, 595(ab)floyd, CE, 566(ab), 577(ab),

661(ab), 678(ab), 696(ab),1584

Flynn, BM, 532Flynn, R, 564(ab)Fogelman, I, 253, 561(ab),

674(ab), 1229, 1820Fommei, E, 613(ab)Foon, KA, 281, 602(ab)Ford, E, 1604Ford, PV, 402, 590(ab),

664(ab)Fordham, EW, 564(ab)Forcll, BW, 684(ab)Formica, N, 1888Forster, AM, 191, 559(ab)Foster,J, 1911Foster,JE, 1536Foster, W, 526Fountos, A, 837Fowler, iS, 60, 624(ab), 1251Fox, KAA, 1322, 1563Fox,PT,646(ab)Frager, DH, 139Frances, B, 722(ab)Franceschi,D, 620(ab)Franchebois, P. 803Franck, 0, 702(ab)Frank, G, 452Frank, U, 723(ab)Frank, Tl@,620(ab), 630(ab)Franke, M, 705(ab)Frankel, AH, 613(ab)Franklin,P, 1911

Frazier, C, 663(ab)Freauff, Si, 68Freeman, LM, 139Freeman,ML, 667(ab)Freitas, JE, 575(ab), 640(ab)French, W, 598(ab)Frenkel, A, 733(ab)Frenkel, EP, 229Frey, P. 1554Friberg, H, 407(ab)Fridrich, L, 925Friedman,8.1,1453Friedman, JD, 561(ab),

589(ab), 597(ab)Friedman,iP, 1453Friedman, Y, 618(ab)Friend, LE, 577(ab)Frincke, 3M, 637(ab),

692(ab), 71 l(ab)Frinke, JM, 693(ab), 7l0(ab)Fiitzberg, AR, 656(ab),

691(ab),1180Froelicher, V, 631(ab)Frohman, iE, NlSlFroncisz,W, 1268Frost, ii, 600(ab), 6l2(ab),

635(ab), 699(ab), 700(ab),701(ab)

Fu, L, 672(ab)Fudo, T, 567(ab)Fujibayashi, Y, 724(ab)Fujii, H, 558(ab), 559(ab)Fujikawa, DO, 645(ab)Fujimi, K, 688(ab)Fujita, T, 559(ab), 569(*b),

623(ab), 699(ab)Fujiwara, T, 658(ab),

706(ab)Fukuda, H, 658(ab), 706(ab)Fukuda, N, 567(ab), 703(ab)Fukuda, T, 609(ab)Fukukita, H, 689(ab),

696(ab)Fukuyama, H, 569(ab),

623(ab)Fulton, RF, 1925Fumoleau, P. 1807Funke-VÃ¶lkers,R, 576(ab)Furukawa, T, 1027Furunishi, H, 639(ab)Furuta, T, 703(ab)Fuster,V,639(ab)

Gachon, P, 667(ab)Gal, R, 116, 254, 597(ab)Galante, M, 583(ab)Galey,WT, 615(ab)GaIt,JR.577(ab),1925Gambhir, SS, 588(ab),

653(ab)Gamson, J, 6l7(ab)Gan, MP, 562(ab)Gandsman, El, 585(ab),

664(ab)Gannon, S, 223Gansow,0,722(ab),1924Gansow, OA, 668(ab), 861Ganz, W. 674(ab)Garay, SM, 1107Garcia, E, 642(ab), 673(ab)Garcia,EV, 325,577(ab),

6l8(ab), 672(ab), 675(ab),1925

Garcia, FA, 405(ab)

Garrett,K,598(ab)Garrity,ST.73l(ab)Gaily, I, 632(ab)Garvin, PJ, 583(ab)Gastard, J, 688(ab), 707(ab)Gatenby,R,616(ab)Gatenby, PA, 709(ab)Gatley, Si. 66(ab), 624(ab),

635(ab)Geatti,0, 7l5(ab),1736Geckle, Wi, 630(ab)Gefter, WB, 685(ab)Gelbard, AS, 594(ab)Gelman, N, 703(ab)Geman, SA, 677(ab)Genant, HK, 565(ab)George,EA, 583(ab)Geoi@e, P, 574(ab)Georgiadis,A,652(ab)Gerich, B, 1441Germano, 0, 607(ab),

682(ab)GelTitsen, JG, 1892Gerson, MC, 670(ab)Gerson, R, 697(ab)Gerundini, P, 566(ab),

699(ab), 701(ab), 1870Getchcll,J, 1536Ghaed,N,544Ghione, S, 613(ab)Ghose, T, 258Ghosh, L, 552(ab)Giblcr, CD, 568(ab)Gibler, WB, 568(ab)Gibson, RE, 700(ab)Gibson, RW, 654(ab),

663(ab)Gilardi, MC, 566(ab),

701(ab)Gilbert, FW, 726(ab)Gilbert, S. 261(ab), 568(ab),

569(ab)Gilday, D, 62l(ab)Gilday,DL, 646(ab)Gildersleeve, DL, 624(ab),

724(ab), 726(ab)Gill, P, 638(ab),694(ab)Gilland, DR. 566(ab),

576(ab)Gingrass,D, 1268Gini,A,633(ab)Ginos, JZ, 600(ab), 1844Ginsberg,HN, 610(ab)Gionet, M, 712(ab), 7l4(ab)Giovannidllo, i, 410(ab)Girard, C, 685(ab)Girod, DA, 621(ab)Giuliano, A, 71 l(ab)Giuntini, C, 585(ab)Gjedde, A, 61 l(ab)Glissner, H, 573(ab)Glazer, G, 640(ab), 1401Gleason,WA,660(ab)Gleichmann, U, 567(ab),

670(ab)Glenn, Hi, 25Glick, Si, 630(ab), I 192Glickman, S, 564(ab),

653(ab)Glickman, SL, 629(ab)Glowniak, JV, 667(ab), 1625Go, RT, 718(ab)Gober, A, 589(ab), 642(ab),

674(ab)

Gobuty, AH, 596(ab)Godon, JP, 829Godtfredsen,J,1330Goeckeler, WF, 495Goedemans,WTh,1020Golas, DB, 1478Gold, HK, 76, 632(ab),

672(ab),718(ab),720(ab),1671

Goldenberg, DM, 615(ab),652(ab), 683(ab), 713(ab),723(ab), 1604

Goldenberg,0, 1657Goldenberg, H, 652(ab)Goldfarb,OR, 1230Goldfarb, H, 594(ab),

729(ab)Goldman, M, 639(ab)Goldman, MA, 704(ab)Goldman-Leiken, RE,

603(ab), 722(ab)Goldman-Leiken, RE,

, 553(ab)Goldachiager, N, 673(ab)Goldsmith, MS. 561(ab)Goldsmith,SJ,Nl48,

574(ab), 610(ab), 629(ab),639(ab), 664(ab), 689(ab),695(ab), 1637

Goldstein,L,1683Goldstein,RA, 1262Goldstein,S.1484Gomes,A, 1683Gomes, AS, 584(ab)Gon, J, 689(ab)Gonazlez,l@718(ab)Gonazlez,M, 669(ab)Gonzales, ET, 262(ab)Goodgold, HM, 580(ab),

7l6(ab)Goodman, MM, 571(ab),

720(ab),724(ab)Goodwin,DA, 561(ab),

722(ab),1358Gordon, I., 688(ab)Gore,J,632(ab)Goria, ML, 405(ab), 558(ab)Gorkin,J, 1393Gotfredsen,A@960Goto, Y, 670(ab)Gottesman, R, 704(ab)Gottschalk,A,573(ab)Goudonnet, A, 57l(ab)Gougeon,J-P,254Gould, KL, 668(ab), I 155,

1262Gould, L, 410(ab), 655(ab),

702(ab)Govanella, B, 704(ab)Graham, LS, 562(ab),

677(ab)Graham, MM, 406(ab), 929Oranowaka, M, 637(ab)Grant, LM, 725(ab)Gray, HW, 926Gray, JM, 683(ab)Gray, LL, 667(ab)Grecos,G, 734(ab)Grecos,GP, 1171Green,AM, 1419Green, MA, 407(ab), 722(ab)Green,MV, 557(ab),

607(ab), 631(ab), 67l(ab)Greenberg@D, 1338

Greenberg, HS, 645(ab)Greenberg, J, 633(ab), 1447Greenberg, JH, 570(ab)Greenber& M, 574(ab)Greene,JB, 1107Greene, R, 666(ab)Greenspan, B, 652(ab),

7l3(ab)Greenspan, 0, 596(ab)Greenwell, KL, 562(ab)Greer,DM, 582(ab),1745Greer, KL, 566(ab), 577(ab),

696(ab), 1584Gregor, A, 626(ab)Gregory. RR, 698(ab)Greif, PM, 561(ab)Grekin, Ri, 1401Gresch, A, 559(ab)Grierson,JR.1599Griffin, T, 7l2(ab)Griffith, BP, 6l6(ab)Griffith, MH, 617(ab)Griffiths, GL, 723(ab)GTIMthSI1,599(ab)Grimmond, AP, 732(ab)Grindheim,L,N1517Groch, MW, 564(ab),

590(ab)Grochowiki, F,,634(ab)Grochowski, EW, 682(ab)Gros1@ar,D, 733(ab)Gross,M, 733(ab)Gross, MD, 640(ab),685(ab),979,lOSS,1401

GTCSS,ML, 1171Grover-McKay, M, 631(ab),

682(ab)Green, OS, 664(ab)Oruenewald, SM, 510Grunbaum, Z, 68, 594(ab),

668(ab)Grund, FM, 575(ab),

603(ab)Guan, JH, 727(ab)Guess, W, 670(ab)Guillard, JM, 627(ab)Guillard, Y, 1807Guillaume, M, 702(ab)Guilloteau,D, 658(ab)Guimond, J, 803Gulenchyn, KY, 563(ab),1364

Gullberg, GT, 566(ab),570(ab),576(ab),66l(ab),677(ab),678(ab)

GUIIbeI'g,P,1037Gungon, R, 729(ab)Gungon, PA, 594(ab)GÃ¼nter,H-H, 58l(ab)Guo, Y-Z, 60l(ab), 725(ab),

1012Gupta, B, 733(ab),734(ab)Gupta,BK, 1171Gupta, NC, 586(ab)Gupta, S, 1920Gur, RC, 655(ab), 702(ab)Our, RE, 601(ab),655(ab),702(ab)

Guscar, T, 714(ab)Guscar,TIc 69l(ab)Gusella, J, 655(ab)Guth, B, 576(ab)Outh-Tougelides,B, 562(ab)Guyot, M, 627(ab), 685(ab)


Haber

Haber, E, 76, 668(ab), 1671Habibi, H, 643(ab), 669(ab)Hackett, M, 596(ab)Hadley, 5, 560(ab)Hadley, SW, 725(ab)Hagan, i, 705(ab)Hagan, PL, 637(ab), 692(ab),

71 l(ab), 712(ab), 7l4(ab)Hahn, Li, 566(ab),577(ab),

661(ab), 678(ab), 696(ab),1584

Hahn, M, 659(ab)Haindl, W, 637(ab)Haines, JE, 1826Hakim, AM, 633(ab),

699(ab)Hakim,TS, 1758Hakki, AH, 644(ab), 670(ab)Halama, JR, 577(ab)Hall, EW, 649(ab)Hall, P, 63l(ab)Hall, T, 615(ab)Halldin, C, 625(ab), 636(ab),

1037Halls, J, 69l(ab), 713(ab)Halpern, H, 682(ab)Halpern, SE, 596(ab),

637(ab), 692(ab), 71 l(ab),712(ab), 7l4(ab)

Ham, H, 686(ab)Ham, HR. 715(ab)Hamamoto, K, 628(ab)Hamilton, DR. l925Hamilton,HB, 1115Hammersley, PAG, 595(ab)Hamon,M, 1187Hanada, J, 383Hanein, LO, 604(ab)Hangen, D, 649(ab)Hann, IM, 626(ab)Hanna, M, 636(ab)Hanna, MG, Jr, 709(ab)Hansen, Hi, 6l5(ab),

652(ab)Hansen, L, 647(ab), 1180Hanson, B, N795, Nl087,

Nl248, N1513Hanson, RN, 728(ab)Harada, K, 569(ab), 623(ab)Harbors,D,658(ab)Harcke, HT, 249, 716(ab),1550,1688

Harkness, BA, 678(ab)Harper, P, 572(ab)Harpootlian, J, 669(ab)Harris, CC, 410(ab), 696(ab),

697(ab)Harris, SO, 1478Harris, W1@,263(ab)Harrison, JE, 703(ab)Harrison, RC, 559(ab)Harrison, RL, 696(ab)Hartling,0J, 1330Hartmann, A, 569(ab),

593(ab)Hartnell, 0, 646(ab)Hartshorne, MF, 260(ab),

26l(ab), 266(ab)Harwood, Si, 604(ab)Hasegawa, H, 660(ab)Hashimoto, K, 1006Hashimoto, 5, 626(ab)Hashimoto, T, 567(ab)Haspel,MV,636(ab),

709(ab)Hassan, IM, 676(ab)Hasselquist, BE, 576(ab)Hassenein, M, 579(ab)Hatano, K, 728(ab)Hatano, M, 579(ab),

672(ab), 673(ab)Hatfield, MK, 1831Hauner, R, 608(ab)Hattner, RS, 565(ab),

626(ab)Hauck, RM, 1279Haughton, V, 622(ab)Hausdorf, 0, 1839Hauser, M, 551(ab), 586(ab)Hawkins, LA, 647(ab)Hawkins, PA, 564(ab),

584(ab), 587(ab), 61 l(ab),629(ab), 631(ab), 653(ab),7ll(ab),1683

Hawman, EG, 576(ab), 1308Hayashi,H, 1061Hayashi, M, 590(ab), 1344Hayashida, K, 671(ab), 1344Hayashida, N, 579(ab)Haynie, TP, 130, 263(ab),

264(ab), 542, 648(ab),65l(ab)

Headington, i, 713(ab)Heal, A, 690(ab), 7l8(ab),

735(ab)Heap, RB, 1187Hebold, I, 612(ab), 645(ab)Hedges, JH, 568(ab)Hedrick, WR, 544, 1208Heiss, W-D, 612(ab), 645(ab)Heitner, D, 1771Hellman, RM, 1348Hellman, PS, 559(ab),

585(ab), 592(ab), 622(ab),665(ab), 1268

Hellstrom, I, 34Hellstrom, KE, 34Hellwig, D, 458Heminger, LA, 718(ab)Hendel, R, 632(ab)Henderson, BL, 648(ab)Hendry, GO, 697(ab)Henkin, RE, 577(ab),

6l6(ab)Henneman, PL, 574(ab)Henning, A, 576(ab)Henriksen, 0, 1330Henry, TD, 670(ab)Heo, J, 644(ab), 670(ab)Herbold, D, 606(ab)Herholz, K, 645(ab)Herman, iH, 698(ab)Hero, AO, 695(ab)Herre, J, 608(ab)Herry, iY, 637(ab), 688(ab),

707(ab)Herscovici, C, 6l8(ab)Hersh, EM, 25Herzog, H, 591(ab)Hestrin, L, 589(ab), 597(ab)Heyman, 5, 7l6(ab)Heyns, AdP, 402Hibi, 5, 293Hichwa, RD. 634(ab),

641(ab), 661(ab), 1695Hicken, P, 659(ab)Hiesiger,E, 1251Higa, T, 409(ab)

Higashi, 5, 558(ab), 559(ab),660(ab)

Higashi, Y, 409(ab)Higgins, D, 616(ab), 664(ab)Higgins, J, 733(ab)Hightower, D, 263(ab)Hijdra,A,178Hilditch, TE, 253Hill, ThC, 178Hill-Zobel, RL, 223Hilson, A, 613(ab)Hilson, AJW, 733(ab)Himi, T, 567(ab)Hind, A, 599(ab)Hines, ii, 617(ab)Hino, M, 627(ab), 688(ab)Hirano,T, 1901Hiraoka,T, 173Hirose, 5, 670(ab)Hirose, Y, 409(ab), 607(ab)Hirota, K, 1210Hirth, W, 1491,1870Hiruma, A, 697(ab)Hisada, K, 558(ab), 559(ab),

702(ab), 7l4(ab), 731(ab)Hise, HL, 618(ab), 675(ab)Hise,L, 642(ab)Hnatowich, DJ, 560(ab),

7l2(ab), 7l4(ab), 1294,1465, 1924

Hoebing, GC, 264(ab),265(ab)

Hoechst, AG, 693(ab)Hoeffel, JM, 894Hoefnagel, CA, 308Hoell,K, 591(ab)Hoffer, PB, 573(ab), 603(ab),

708(ab), 709(ab), 1303,1441

Hoffman, EJ, 558(ab),607(ab), 682(ab), 696(ab)

Hoffman, J, 655(ab)Hoffman, iM, 587(ab),61l(ab)

Hoffman, Ti, 679(ab),729(ab)

Hoffmann, RG, 559(ab),592(ab)

Hohn, DC, 708(ab)Holden, JE, 66(ab), 635(ab)Holloway, R, 608(ab)Holman, BL, 13, 354,

585(ab), 630(ab), 680(ab),N1381, 1775, Nl804

Holman, L, 623(ab)Holmes, RA, 191, 495, 505,

576(ab), 593(ab), 633(ab),679(ab), 708(ab), 709(ab),722(ab), 729(ab)

Holte, 5, 607(ab)Horn,i, 407(ab)Hornan, R, 570(ab)Hornan, RW, 408(ab)Hornrna, K, 927Hornrna,S,1531Honrna, H, 589(ab), 674(ab)Hoogmartens, M, 73l(ab)HÃ¶r,G, 706(ab)Horiuchi, K, 571(ab),

639(ab),1027Horiucht, K, 252Horne,C, 1853Home, T, 319, 973Horowitz, M, 281, 605(ab)

Horowitz, SF, 408(ab),676(ab),918

Hosain, F, 723(ab)Hosenpud, JD, 668(ab)Hoshi, K, 707(ab)Hosoi, 5, 342Hottenrou, C, 706(ab)Hotze, A, 592(ab), 659(ab)Houck, J, 627(ab)Houle, 5, 608(ab), 618(ab),

620(ab), 643(ab), 679(ab)Howman-Giles, R, 646(ab),

824Hricak, H, 598(ab)Hsieh, i, 576(ab)Hsu, DF, 622(ab)Hu, HB, 566(ab), 677(ab)Hu, HH, 622(ab)Huang, JC, 622(ab)Huang, Mi, 638(ab)Huang, 5, 655(ab)Huang, SC, 558(ab), 587(ab),61l(ab)

Huang, S-C, 587(ab)Huang, SC, 588(ab), 63l(ab),

653(ab), 682(ab)Huberty, J, 608(ab)Huberty, JP, 626(ab)Huchon, Gi, 894Huesrnan, RH, 587(ab),

608(ab), 682(ab)Hugel, EA, 634(ab)Hughes, A, 572(ab)Hurnphries, L, 816Hundeshagen, H, 58l(ab),

595(ab)Hung, CY, 593(ab)Hung, GL, 638(ab), 664(ab),

69l(ab), 694(ab), 7l3(ab)Hungerford, JL, 637(ab)Hunter,iV, 1229Hunter, R, 7l2(ab)Huntley, TE, 665(ab)Hupp, TH, 406(ab)Hurtig, HI, 431, 601(ab)Hurwitz, RA, 62l(ab)Hutchins, GD, 634(ab),

641(ab), 661(ab), 695(ab),1695

Hutchinson, R, 618(ab)Hutter, AM, 672(ab)Hutton, BF, 677(ab), 844,1925

Hutton, I, 609(ab),632(ab)Hwang, Ki, 91Hyde, iS, 1268Hyde, RW, 378Hylarides, M, 560(ab)Hyslop, P, 655(ab)

Ibuki,Y,688(ab)Ide, M, 609(ab), 670(ab)Ido, T, 658(ab), 706(ab),

723(ab), 727(ab), 728(ab)Igarashi, H, 569(ab)Igarashi, M, 579(ab)lida, H, 607(ab), 697(ab)linurna, T, 567(ab), 703(ab)ho, M, 19, 557(ab), 598(ab),

668(ab), 700(ab)Ikawa, T, 627(ab), 628(ab)Ikehira, H, 703(ab), 1006Ikekubo, K, 627(ab),

688(ab), 691(ab)

Ikeoka, N, 689(ab)Ikuno,Y, 1210Iles,SE, 1540Imai, K, 558(ab), 559(ab),

579(ab), 672(ab), 673(ab)Imanishi, M, 1780Imashuku, 5, 293Irnazeki, K, 648(ab)Inagaki, Y, 567(ab)Ingels, M, 570(ab)Ingvar, C, 7l0(ab)Inoue, M, 173Inoue,O, 1006Inoue, T, 637(ab)Installe, E, 669(ab)Intenzo, CM, 438Inuzuka, E, 697(ab)Irvine,A, 1230Irvine, P1, 563(ab)Isaka,Y,701(ab)Isawa,T, 1901Ishida,Y, 173Ishii, K, 569(ab)Ishikawa, M, 569(ab),

623(ab), 626(ab)Ishirnura, T, 1780Ishine, M, 628(ab)Ishiwata, K, 658(ab),

727(ab), 728(ab)Ishizaka, A, 649(ab)Isitrnan, AT, 585(ab),592(ab),1268

Iskandrian, AS, 644(ab),670(ab)

Isorn, OW, 918Ithakissios, DS, 1430Ito, H, 688(ab)Ito, M, 706(ab)Itoh, H, 587(ab), 628(ab),

69l(ab)Itoh, M, 598(ab), 658(ab)Itoh, T, 1006Iui,R,658(ab),716(ab)Iwal, K, 723(ab), 727(ab)Iwata, R, 658(ab), 723(ab),

727(ab), 728(ab)Iyo, M, 1006Izurni,M, 1115Izurni, Y, 697(ab)

Jackson, K, 41 l(ab)Jacobs, GI, 701(ab)Jacobson, AF, 606(ab), 1775Jacobson, K, 627(ab)Jacobson, R, 679(ab)Jacques, 5, Jr, 1620Jaffe, D, 613(ab), 1383Jafri, RA, 647(ab)Jagoda, E, 568(ab)Jahns, M, 263(ab)Jam, A, 579(ab)Jam, M, 643(ab)Jambaque, I, 592(ab)James, TL, 598(ab)Jarnieson, DO, 601(ab)iansen, HM, 659(ab)Janssen, 5, 734(ab)Jaques, 5, 639(ab)Jarden, i, 700(ab)iarritt, PH, 593(ab)iarvi, K, 442iass, iR, 637(ab)iaszczak, Ri, 566(ab),

577(ab), 661(ab), 678(ab),


Lange

696(ab), 1584ieandot, R, 627(ab)icavons, A, 1554iensen, KC, 1134Jeroudi, M, 654(ab)iesrnanowicz, A, 1268Jeweit, DM, 635(ab)Jhingram, SO, 265ihingran, 5, 260(ab)ihingran, SG, 560(ab)Jochelson, MS. 606(ab)Joensuu, H, 910, 1782Jofre, L, 675(ab)iohannes, RS, 679(ab),

680(ab)iohn, ER, 63 1(ab)iohns,iA, 1671Johnson, B, 627(ab)Johnson, D, 354Johnson, DA, 810Johnson, G, 735(ab)iohnson, i, 618(ab), 687(ab),

7l5(ab)iohnson, LL, 663(ab)Johnson, RF, Jr. 260(ab),

703(ab)Johnson, TK, 603(ab),

680(ab)Johnson, TR, 590(ab)Johnston, DL, 871iohnston, SA, 1447ionckheer, MH, 630(ab)Jones, AG, 13, 593(ab),

60l(ab), 602(ab), 728(ab)Jones, B, 62l(ab)Jones, D, 560(ab)iones, GS, 728(ab)Jones, i, 666(ab)iones, KW, 697(ab)Jones, MM, 262(ab)Jones, PL, 390, 573(ab)Jones, RF, 34Jones, RM, 655(ab)iones, T, 989Jonson, B, 1144JÃ¶nsson,P.E, 710(ab)Jorkasky, D, 733(ab)Jovkar, 5, 471Jubault, C, 658(ab)Juillard, G, 71 l(ab)Julien, P. 561(ab)iuma, N, 715(ab)iunck, L, 645(ab)Juni, JE, 6l9(ab), 659(ab),

707(ab)Juri, PN, 592(ab), 730(ab)

Jurisson, 55, 601(ab)

Kabalka, GW, 571(ab)Kabat, L, 1915Kagan, A, N942Kagaya,A, 567(ab)Kahane, SN, 679(ab),

680(ab)Kahen, HL, 552(ab), 694(ab)Kahn, CB, 664(ab)Kahn,D, 1768Kajubi,SK, 1366Karnada, T, 173, 70l(ab)Karnani, N, 1915Kamata, R, 579(ab),

672(ab), 673(ab)Karnath, P, 551(ab)Karnbara, H, 567(ab)

Kaminski, MS. 614(ab)Kan,SH, 1751Kang,H, 734(ab)Kanke, M, 584(ab), 718(ab),

720(ab), 1671Kanno, I, 409(ab), 607(ab)Kaplan, E, 667(ab), 1920Kaplan, NM, 623(ab)Kaplan, WD, 47, 562(ab),

606(ab), 693(ab)Karbus,JE,1064Karcher, G, 654(ab)Karesh, SM, 6l6(ab)Karirneddini, MK, 723(ab)Karp, iS, 565(ab), 607(ab),

64l(ab)Karvelis, K, 810Kasabali, B, 552(ab)Kashida,H,688(ab)Kashii, C, 1780Kashiwagi, T, 627(ab),

628(ab)Kasi, L, 263(ab), 648(ab),

1367Kasina, 5, 573(ab), 650(ab),

656(ab),69l(ab), I180Kassis, Al, 693(ab)Kath, G, 676(ab)Kato, K, 672(ab)Katoh, K, 643(ab), 707(ab)Katoh, Y, 69l(ab)Katz,I,161Katz, i, 260(ab), 406(ab)Katz, M, 58l(ab), 687(ab)Katz, P. 698(ab)Katzenellenbogen, iA,

, 56l(ab)Kaizenellenbogen, JA,

625(ab)Kaul, 5, 1531Kawabata, 5, 714(ab)Kawai, C, 567(ab)Kawai, K, 724(ab)Kawai, M, 598(ab)Kawamoto, S. 1115Kawarnura, M, 628(ab),

723(ab), 727(ab)Kawarnura, Y, 342, 568(ab),

712(ab), 7l9(ab), 720(ab),730(ab)

Kawashirna, K, 727(ab)Kaye, MP, 667(ab)Kazarn, E, 640(ab)Kazikiewicz, 3M, 553(ab),

603(ab)Kazikilewicz, JM, 722(ab)Keast, CM, 372Keech, F, 614(ab), 632(ab),

650(ab)Keeling, P. 551(ab)Keen, RE, 587(ab)Keen, RL, 544Keenan, AM, 42, 281Kelbaek,H, 1330Keller, AM, 102Kelley, EA, 615(ab)Kelly, JD, 574(ab), 648(ab)Kemeny, N, 41 l(ab)Kensett, Mi, 989Kereiakes, D, 568(ab)Ketchum, LE, NI, N 149,

N267, N278, N413, N426,N793, N799, N933,NllOO,N1371,Nl378,

Nl645Ketring, AR, 656(ab)Keyes, iW, Jr, 334, 678(ab)Keyeux,A, 610(ab)

Khafagi,F,526Ithaw, BA, 76, 572(ab),

584(ab), 610(ab), 614(ab),668(ab),695(ab),7l8(ab),720(ab), 1671

Kiat, H, 588(ab), 589(ab)Kiess, M, 254Kijewski, MF, 630(ab),

680(ab)Kilbourn, MR. 134,462,

582(ab), 727(ab)Kim, B-H, 173Kim, CK, 594(ab), 699(ab),

716(ab)Kim, EE, 548, 596(ab),

647(ab), 660(ab), 1052Kim, OH, 447Kim, R, 597(ab)Kimura, K, 173, 701(ab),707(ab)

Kimura, 5, 723(ab), 727(ab)King, MA, 565(ab), 6l9(ab),

630(ab), 677(ab), 732(ab),I192

King,W, 1683Kingswood, JC, 733(ab)Kinoshita, M, 609(ab)Kinsey, BM, 693(ab)Kinuya, S. 7l4(ab)Kirch, DL, 670(ab)Kirchner, PT, 209, 1134Kircos, LT, 334Kirkeeide, RL, 1262Kirkwood,J, 7ll(ab)Kirkwood, JM, 573(ab),

1441Kiwit, J, 59l(ab)Klappenbach, RS, 1679Klatte, EC, 714(ab)Klausrneyer, P, 701(ab)lace, 0, 55l(ab), 586(ab)Klein, HA, 616(ab), 622(ab)Klein, JL, 618(ab), 672(ab),

675(ab)Klein, L, 642(ab)Kleinhans, E, 620(ab)Klepser, C, 580(ab)Klippenstein, DL, 407(ab),722(ab)

Klopper, JF, 622(ab)Knabb, RM, 1563Knapp, FF, Jr. 57l(ab),

657(ab), 67l(ab), 720(ab),724(ab), 726(ab)

Knapp, WH, 567(ab),670(ab)

Kneeland, iB, 1268Knight, LC, 657(ab), 704(ab)Knittel, BL, 588(ab)Knust, Ei, 567(ab)Knust, E-J, 670(ab)Knutson, C, 707(ab)Kobayashi, K, 689(ab)Kobayashi, S, 609(ab)Koch, ER, 1290Koeppe, R, 702(ab)Koeppe, RA, 641(ab),

645(ab),66l(ab), 1695Koide, H, 567(ab)Koizumi, K, 714(ab),

73l(ab)Koizumi, M, 342, 568(ab),

712(ab), 7 19(ab), 720(ab),730(ab),1027

Koizumi, T, 627(ab),628(ab)

Koller, DW, 575(ab)Kollrnann,M,657(ab)Kolstad, KS, 723(ab)Kornaiko, M, 647(ab)Kornatani, A, 599(ab)Komori, H, 688(ab)Kong, C, 733(ab)Konishi, Y, 567(ab)Konka, 5, 580(ab)Konno, K, 1901Kopp, DT, 1232Koprowska, I, 575(ab)Koral, K, 687(ab)Koral, KF, 577(ab), 695(ab)KÃ¶rfer,R, 567(ab)Koritny, ES, 733(ab)Kornguth, ML, 635(ab)Kosaka, N, 557(ab), 668(ab)Koster, K, 557(ab)Kosuda, 5, 626(ab)Kotchon, T, 184Kothari, Pi, 636(ab)Kotoura, Y, 342Kottarnasu, SR. 244Kotze, HF, 402Kouris, K, 676(ab)Kozarek, PA, 604(ab)Kozuka, T, 173, 590(ab),

704(ab)Krajewski, NJ, 655(ab)Kramer, Av, 729(ab)Krarner,EL, 1107, 1506Krantz, D, 597(ab)Krasicky, GA, 244Krasnow, AZ, 585(ab), 1268Krawczynska, EG, 589(ab),

642(ab), 673(ab)Krebs, J, 260(ab)Kreiten, K, 600(ab)Krerner, M, 1807Krepshaw, J, 600(ab)Krepshaw, JD, 551(ab)Kressel, HY, 639(ab),

685(ab), 733(ab)Krevsky, B, 660(ab)Kriegel, H, 573(ab)Kiishnaiah, PR, 366,

622(ab), 735(ab)Krishnarnurthy, GT, 615(ab)Krishnarnurthy, S, 6l5(ab)Kriss, JP, 558(ab)Krivokapich, i, 558(ab),

588(ab), 598(ab)Krizan, Z, 25Krohn, K, 692(ab)Krohn, KA, 34, 68, 594(ab),

653(ab),668(ab),728(ab)Krohn, L 559(ab), 592(ab)Kronauge, iF, 13, 60l(ab),

602(ab)Kronke, C, 576(ab)Kroop, SA, 704(ab)Kropp, i, 592(ab), 671(ab),

1218Kruis, W, 688(ab)Krupey, i, 723(ab)Kruzyk, GC, 644(ab)Kuba, A, 1782

Kubo, A, 626(ab)Kubota, K, 658(ab), 733(ab)Kuczynski, BL, 674(ab)Kudo, M, 627(ab),688(ab)Kuhar, Mi, 600(ab)Kuhl,D, 655(ab)KuhI, DE, 645(ab)Kuhlrnann, L, 693(ab)Kulkarni, MV, 524Kulkarni, PV, 260(ab),

263(ab), 406(ab), 704(ab)Kulkarni MV, 1052Kurnar, AJ, 626(ab)Kumura, D, 966Kundel, H, 736(ab)Kung, H, 600(ab), 1484Kung, HF, 360, 57l(ab),

60l(ab),725(ab)KungHF, 1012Kuni, CC, 638(ab)Kunimatsu, M, 342, 568(ab),

7l2(ab), 7l9(ab), 720(ab),730(ab)

Kuniyasu, Y, 660(ab)Kuperus, JH, 574(ab)Kurai, 0, 689(ab)Kureishy, ZA, 7l9(ab)Kurimoto, K, 1780Kuroki, T, 689(ab)Kurthen, M, 592(ab), 1763Kuruc, A, 1338Kuschnir, E, 662(ab),

675(ab)Kushiro, H, 1780Kushner, M, 633(ab),

699(ab), 702(ab), 1667Kushner, Mi, 431Kusrnierek, J, 458Kutchrnan, R, 616(ab)Kuwert, T, 59l(ab)Kwai, AH, 562(ab), 606(ab)Kwong, K, 698(ab)Kyriakides, 0, 1383

Laarrnan, GJ, 579(ab)Lacy, JL, 401, 641(ab),

663(ab), 698(ab)Ladwi& EJ, 261(ab)Ladwig, EL, 265(ab)Laflarnme, L, 662(ab)LaFrance, N, 683(ab)LaFrance, ND, 575(ab),

615(ab), 645(ab), 663(ab),679(ab), 680(ab), 685(ab)

Lagunas-Solar, MC, 667(ab)Lai, HT, 717(ab)i@, iaÃ§ is@Laino, L, 65 l(ab), 684(ab)Lake, RR, 562(ab), 677(ab)[ama, P, 586(ab)Lamb, AC, 620(ab)Larnbert, B, 627(ab), 666(ab)Larnki, L 25Larnki, LM, 264(ab),

648(ab), 651(ab)Larnki,N,1511Larnoureux, F, 716(ab)Larnoureux, J, 7l6(ab)Lancaster,JL, 1232, 1725Landmeier, B, 1577Landry, Al, 260(ab)Lang, W, 1657Lange, L, 671(ab)Lange, PH, 603(ab), 651(ab)

AuthorIndexâ€¢1987 1937

Lang.n

Langen, K-J, 591(ab)Langfitt, T, 699(ab)LÃ£ngstrÃ¶rn,B, 636(ab), 1037Lantto,T, 442L.aragh, J, 735(ab)LaRaia, P, 666(ab)Larock, MP, 655(ab)Larson, BW, 575(ab)Larson, SM, 42, 53, 281,

557(ab), 572(ab), 587(ab),602(ab),614(ab),631(ab),636(ab), 65l(ab), 67l(ab),693(ab), 701(ab), 710(ab),722(ab)

Larsson,SA, 1861Lasher,JC, 1725LasHeras, C, 602(ab)Lassen, NA, 407(ab), 559(ab)Laude, JW, N15l7Lauenstein, L, 595(ab)Laufer, P, 6l2(ab)Lauffer, RB, 871Laughlin, IS, 640(ab)Lavender, JP, 574(ab),

646(ab), 648(ab), 694(ab)Layne, WW, 723(ab)lazarus, CR, 253, 561(ab),

1820I.e, TV, 629(ab)Leach, MO, 599(ab)Lear,JA, 1784Lear, JL, 218, 409(ab), 481,

559(ab)Lebesque, J, 659(ab)LeBlanc, A, 260(ab), 401LeBlanc, AD, 265(ab),

560(ab)Lechel, U, 616(ab)Lecklitner, ML, 108Leclerc, JR., 649(ab)I@eCloirec, J, 688(ab)Lee, B, 600(ab)Lee, CH, 687(ab)Lee, HB, 612(ab)LCC,HK, 1366Lee, KH, 713(ab)Lee, MC, 6l2(ab)Lee, ME, 604(ab)Lee, RE, 652(ab)Lce,VW, 1279, 1536, 1911Lee, W, 580(ab), 673(ab)Lee, YC, 721(ab)Lee, YS, 7l0(ab)Lefkowitz, C, 643(ab)Lcfort, 0, 685(ab)Leinbach,R, 632(ab)Leinbach, RC, 672(ab), 1671Lekic, MA, 590(ab)Lenen, N, 610(ab)Lentle, BC, 184, 1640I@enÃ±,OL, 699(ab), 701(ab)Leonard, JC, 264(ab),

265(ab)L4epanto,L, 586(ab),

649(ab), 1546Lepape, A, 658(ab)Leppo, J, 632(ab), 1058,

1419Leppo, JA, 405(ab), 620(ab),

878LeVeen, R, 736(ab)LÃ©veillÃ©,J, 662(ab)Lever,J,61l(ab)Lever, JR, 635(ab)

Lever, SZ, 594(ab), 729(ab),1065

Levin, H, 408(ab)Levine, A, 638(ab), 694(ab)Levison, DA, 973, 1907Levy, HA, 1275Levy, LM, 564(ab)Levy, R, 56l(ab), 692(ab)12w, AS, 325, 674(ab)Lewellen, 1'K, 696(ab)Lewington, V, 658(ab)Lewis, BJ, 708(ab)Lewis, CA, 733(ab)Lewis, M, 620(ab)Lewis, S, 650(ab)Lewitt, RM, 565(ab)Leysen, J, 570(ab)Li, QS, 620(ab)Liang, RI, 628(ab)Liberman, HA, 97, 589(ab),

591(ab),666(ab),674(ab)Libson, K, 626(ab), 1870Lichtenstein, M, 255, 1041Liebert, M, 610(ab), 65 l(ab),

684(ab), 706(ab), 713(ab),1736

Liehn, JC, 582(ab)Liehn, J-C, 254Liewendahl, K, 155Lightner, DJ, 603(ab)Lirn, AB, 402Lirn,KS,907, 1571Lirnburg, M, 178Lin, LC, 7l4(ab)Un, SN, 650(ab)Linde,R, 112Linder, K, 592(ab)Undo, C, 578(ab)Line, BR, 632(ab)Lingren, LE, 728(ab)Link, JM, 696(ab), 728(ab)Linke, D, 592(ab), 1763Links, J, 61 l(ab), 626(ab),

645(ab)Links, JM, 600(ab), 630(ab),

699(ab)Lipavsky, A, 894Lippo, F, 1888Lipszyc, H, 6l0(ab), 639(ab)Lisbona, R, 1758Lister-Jarnes,J, 13,593(ab),

601(ab), 728(ab)Liu, P. 608(ab), 6l8(ab),

620(ab),643(ab),871Liu, RS, 622(ab), 650(ab),

676(ab), 687(ab), 717(ab)Livaniou, E, 1430Livni, E, 632(ab), 727(ab),

728(ab)Uoyd, R, 979Locher, iT, 585(ab), 6l4(ab)Locke, E, 6l0(ab)Lockerrnan, Z, 660(ab)[email protected],J,1213Logan,J, 1251Logan, KW, 505, 576(ab),

633(ab)Logeais, Y, 637(ab)Lois,J, 1683Loken, MK, 342, 407(ab),

638(ab)Lob, CP, 710(ab), 71 l(ab)Loncaric,S, 662(ab)Long, SE, 26l(ab), 262(ab),

265(ab)Longenecker, BM, 7l2(ab)Longo, D, 636(ab)Lora, ME, 6l4(ab)Lorenz, M, 706(ab)Lotke, P. 584(ab)Lotke, PA, 565(ab)LÃ¶tter,MG, 402Lovegrove, Fr, 550(ab)Low,LR, 1171Lowe, BL, 264(ab)Lowenhjelrn, P, 581(ab)Lower, R, 586(ab)Lowinger, T, 678(ab)Lowry, PA, 596(ab), 647(ab),

660(ab)Lucignani, 0, 699(ab),

701(ab)Luckey,M,664(ab)Ludbrook, PA, 837Luft, Ch, 591(ab)Lui, B, 360Lui, D, 593(ab)Lui, WY, 687(ab)Lukash, F, 564(ab)Lukes, Si, 626(ab)Lund, JO, 399Luxen, A, 558(ab), 624(ab)Lyons,K, 631(ab)Lyons, KP, 627(ab), 688(ab)Lyster, D, 659(ab)

Mabus, J, 713(ab)Macapinlac, HA, 590(ab)MacEwen, GD, 1688MacGregor, RR, 60,

624(ab), 1251Machac, J, 408(ab), 639(ab),

676(ab)Machida, K, 19Machulla, Hi, 567(ab)Machulla, H-J, 670(ab)Maclas,ES,Nl5l9Maclntyre, WJ, 718(ab)Mack, E, 583(ab)Mackey, ST, 667(ab)Macklis, RM, 693(ab)MacLean, GD, 712(ab)MacMahon, H, 1831MacMathuna, P, 55l(ab)Maddahi, J, 325, 588(ab),

589(ab), 643(ab), 654(ab),674(ab)

Madsen, MT. 582(ab),680(ab),N15l5

Maeda, H, 689(ab), 734(ab),735(ab)

Magata, Y, 571(ab)Magee, 5, 68Maglaty, J, 676(ab)Magnuson, J, 551(ab),

586(ab)Magnuson, JE, 927Mahanta, B, 583(ab)Maher, KA, 604(ab), 690(ab)Mahrnarian, JJ, 578(ab),579(ab)

Mama, M, 619(ab)Maisey, MM, 253Maisey, MN, 561(ab),

674(ab), 1820Maklad, N, 647(ab)Makuuchi, M, 689(ab)Malbrain, S, 690(ab)

Malkinson, Ti, 717(ab)Malko, J, 642(ab)Mallette, 5, 6l8(ab), 1625Malloy, CR, 102Malrnborg, P, 1037Malrnud,LS,605(ab),

660(ab), 704(ab)Maloney, P, 651(ab),

693(ab), 7l0(ab)Maloney, PJ, 572(ab)MaltaiS, F, 650(ab)Maltese, A, 645(ab)Man,SFP,487Manaster, BJ, 606(ab)Mancini, M, 6l6(ab)Mandell, GA, 249, 716(ab),1550,1688

Maneval, D, 595(ab)Manglos, SH, 566(ab),

577(ab), 661(ab), 678(ab),696(ab), 1584

Mangner,TJ,1620,1625Mankoff,DA,607(ab),

64l(ab)Mann, 5, 735(ab)Mantha, 5, 705(ab)Manyari, DE, 717(ab)Maquet, P, 702(ab)Marabotti, C, 613(ab)Marchal, G, 633(ab)Marciano, D, 564(ab),

629(ab), 653(ab)Marcus, A, 676(ab)Marcus, C, 1064Marcus, CS, 574(ab),

581(ab)Marcuse, HR, 308, 659(ab)Margouleff, D, 596(ab),

704(ab)Maric, N, 603(ab), 708(ab),

709(ab),1303,1441Markesbery, WR, 1484Markham, C, 655(ab)Markos, J, 550(ab)Markowitz, i, 596(ab)Marriott,JA,191Marsch, 5, 644(ab)Marsh, W, 688(ab)Martin, GV, 668(ab)Martin, JA, 624(ab)Martin, NL, 553(ab)Martin, RH, 1540Martin, SE, 666(ab)Martin, W, 609(ab), 632(ab),

886Martin,WB, 1831Martin, WRW, 634(ab),

682(ab)Martinez, F, 699(ab)Maslack,MM, 133Masoli, D., 662(ab)Masoli, 0, 675(ab)Massin, CC, 624(ab)Masuda, K, 609(ab), 639(ab)Masuda, Y, 567(ab)Masuo, M, 19Mather, SJ, 1034Mathias, C, 462Mathias, Ci, 56l(ab),

657(ab), 722(ab), 1704Mathis, CA, 594(ab), 725(ab)Mathisen, ML, 603(ab)Matsubara, N, 173Matsuda, H, 471, 558(ab),

559(ab), 627(ab), 628(ab),643(ab), 702(ab)

Matsuoka, D, 710(ab)Matsuoka, Y, 568(ab)Matsuzawa, T, 658(ab)Matthay, KK, 626(ab)Mattis, JA, 714(ab)Maturnoto, T, 703(ab)Matushita, T, 735(ab)Matuzawa, T, 706(ab)Maublant,JC,667(ab),1199,1315

Maurer, A, 1363Maurer, AH, 563(ab),

605(ab), 657(ab), 660(ab),704(ab)

Mausher, LP, 596(ab)Mausner, LF, 72l(ab)Maussier, ML, 576(ab)Maxon, HR. 626(ab),

718(ab)Maxwell, R, 599(ab)Mayberg, HS, 600(ab),

699(ab)Mayer, JC, 654(ab)Mayfield, GP, 7l8(ab)Mazoyer, BM, 587(ab),682(ab)

Mazziotta, J, 655(ab)Mazziotta, JC, 587(ab),

61 l(ab), 645(ab), 646(ab)McArdle, CB, 1052McCabe, R, 636(ab)McCabe, RP, 709(ab)McCall, Mi, 83, 56l(ab),

722(ab)McCandless, B, 223McCarthy, M, 666(ab)McCartney, WH, 570(ab),

576(ab), 661(ab)McCauley, DI, 1107McClure, DE, 677(ab)McCready, VR, 595(ab),

599(ab), 1230McCullough, RW, 585(ab)McDeviu, PA, 1521McDougall, IR, 558(ab),

649(ab)McElroy, NL, N153McElvany, K, 647(ab)McEwan, AJ, 658(ab),

712(ab), 979McGhie, I, 609(ab), 632(ab)Mcllvain, HB, 657(ab)McKeever, P, 706(ab)McKenzie, EH, 729(ab)McKillop, JH, 926McLaughlin, PR, 608(ab)McLurkin, B, 563(ab),647(ab)

McManaway, M, 70l(ab)McManus, KT, 565(ab)McNeil, KG, 703(ab)McNeil, M, 1826McPhee, lB. 526McPherson, D, 1251McTigue, M, 561(ab),722(ab)

Meares, CF. 83, 56l(ab),722(ab)

Mears, DC, 664(ab)Mease, RC, 572(ab)Meekin, GK, 1679Meerdink, Di, 405(ab),

1938 TheJournalof NudearMedicine

Palmer

620(ab)Meese, R, 623(ab)Mehta, A, 596(ab), 605(ab)Mehta, RC, 583(ab), 665(ab)Meier,D, 664(ab)Meignan, M, 1228Meijer, 5, 734(ab)Meikle, SR. 1925Meinken, G, 596(ab)Meinken,GE,721(ab)Melin, J, 400, 610(ab)Melin, JA, 578(ab), 644(ab)Meller, i, 918Mena, I, 666(ab), 677(ab),

1315Mena, 10, 598(ab)Merchant, B, 264(ab)Merchant, EB, 692(ab),71l(ab),7l2(ab)

Merchie, G, 409(ab)Merhige, ME, 1262Merhiqe, ME, 668(ab)Merkel,KD,927Mertens,J, 570(ab)Men, R, 654(ab)Mesgarzadeh, M, 605(ab)Metier, EJ, 645(ab)Meyer, E, 234, 471, 633(ab),

699(ab), 1123Meyer, 0-i, 595(ab)Meyer, P. 638(ab), 694(ab)Meyerovitz, JS, 585(ab)Meyers, A, 829Meyers, L, 640(ab), 1625Miceli, A, 583(ab)Michel, C, 681(ab)Mickey, B, 59l(ab), 633(ab),

634(ab)Milanesi, L, 566(ab)Milavickas, LR, 1208Milewski, Y, 660(ab)Miller, BI, 670(ab)Miller, GA, 575(ab)Miller, JH, 966, 1412Miller, MI, 566(ab)Miller, R, 692(ab)Miller,SW,1616Miller, TR, 837Milletich, RS, 70l(ab)Mills, L, 620(ab)Mills, SL, 264(ab)Milne, N, 627(ab), 688(ab)Mm,CY, 572(ab),65l(ab)Minarni, M, 598(ab)Minardo, J, 669(ab)Miner, 0, 704(ab)Minnaar, PC, 402Mintun,MA,561(ab),1704Miraldi,F, 1577Misawa, T, 1344Mitchell, DO, 733(ab),

736(ab)Mitchell, G, 598(ab)Mitchell, JB, 617(ab)Mitsutani, N, 627(ab),

628(ab)Mitta, A, 662(ab), 675(ab)Mitta, AEA, 13Miura, 5, 607(ab)Miura, Y, 727(ab)Miyagishirna, B, 69l(ab)Miyauchi, 5, 628(ab)Mlcoch, AG, 1920Mock, B, 600(ab), 669(ab)

Mock, BH, 575(ab), 649(ab),1471

Mock, BM, 55 1(ab)Moeller, JR, 600(ab),

700(ab)Moerlein, SM, 717(ab)Mogarni, H, 628(ab)Moi, MK, 83Moingeon, P, 354Moms, N, 667(ab)Moisan, A, 688(ab)Mokka, R, 442Moldofsky, P, 6l6(ab)Moldofsky, PJ, 709(ab)MÃ˜ller,ML,399Molnar, M, 360Mornose, T, 19, 668(ab)Monna, T, 689(ab)Montgomery, AB, 894Montz, R, 1839Moore, EN, 670(ab)Moore, 0, 560(ab)Moore, J, 1204Moore, JO, 563(ab), 604(ab),1926

Moore, R, 76, 609(ab),650(ab),67l(ab),672(ab)

Moore, SC, 630(ab), 680(ab)Moore, W, 673(ab)Moore, WH, 261(ab),

262(ab), 265(ab), 1928Morayati, Si, 575(ab)Moretti, JL, 354, 623(ab),

654(ab), 667(ab)Morgan, AC, 6l5(ab),

69l(ab)Morgan, AC, Jr, 656(ab)Mori, A, 639(ab)Mon. H, 559(ab),702(ab)Morirnoto, I, 1115Moths, DC, 589(ab),

591(ab),674(ab)Moths, iF, 615(ab)Moths, JH, 47Moths, L, 673(ab)Morrison, MC, 1279Morrow, PE, 378Morse, D, 689(ab)Mortelrnans, L, 690(ab)Morton, DL, 562(ab)Morton, KA, 168Moseley, ME, 590(ab),

599(ab)Moseley, R, 603(ab)Moser, E, 688(ab)Moser, EA, 616(ab)Moskowitz, GW, 564(ab)Moskwa, JJ, 634(ab)Mossberg, K, 668(ab)Mossberg,KA, 1155Mountford, PJ, 1187Mountz, JM, 685(ab),

702(ab), 706(ab)Mourot, J, 563(ab)Mousa, SA, 619(ab),

620(ab), 1351Moyer, RA, 605(ab)Msaki, P, 1861Muehllehner, G, 565(ab),

607(ab), 641(ab), 1717Mueller, SP, 630(ab),

680(ab)Muggia, F, 599(ab)Mukai, T, 567(ab), 569(ab),

623(ab), 656(ab), 682(ab),699(ab)

Muiholland, OK, 624(ab),635(ab)

Mullan, BP, 550(ab)Mullani, N, 655(ab),

681(ab), 702(ab), 1155Mullani,NA, 1262Muller,Ch, 1657Muller, ST, 562(ab), 576(ab)Mulshine, JL, 42, 281Mulshine, iM, 602(ab)Munck,O, 1330Murakarni, T, 609(ab)Murase, K, 628(ab)Murata, H, 19, 643(ab)Murata, K, 587(ab)Murby, B, 1820Murphy, K, 606(ab),

6l3(ab), 706(ab)Murphy, PH, 139, 545,

N792, 922, 1221, 1929Murray, iF, 894Murray, JL, 25, 264(ab),

651(ab), 1063Murray, T, 626(ab)Murray, WR, 565(ab)Muschel, M, 663(ab)Musewe, N, 62l(ab)Myers, MJ, 646(ab)Myers, SI, 596(ab)MyllylÃ£,G, 155Mylraganam,R, 690(ab)

Nagataki,S,1115Nagel, JS, 585(ab), 1611Nagle, CE, 552(ab)NÃ¢gren,K, 1037Najrn, YC, 674(ab)Nakagawa, T, 568(ab),

689(ab),734(ab),735(ab)Nakai, H, 471Nakajirna, K, 73l(ab)Nakajirna, 5, 724(ab)Nakarnura, F, 672(ab)Nakarnura, K, 689(ab)Nakamura, M, 609(ab)Nakamura, T, 342Nakarnura, Y, 639(ab)Nakanishi, 5, 409(ab)Nakashirna, T, 342, 568(ab),

712(ab), 720(ab), 730(ab),1027

Nakatani, T, 590(ab),704(ab)

Nakazawa, K, 569(ab)Nalivaika, L, 632(ab)Nally, J, 733(ab), 734(ab)Nally,JV,Jr, 1171, 1501Narahara, KA, 1315Narra, RK, 674(ab), 729(ab)Naruki, Y, 693(ab), 710(ab)Narula, AS, 725(ab)Nason, T, 573(ab)Nasu, K, 688(ab)Natale, R, 7l3(ab)Navarro, D, 481Navia, B, 600(ab)Nawaz, K, 730(ab)Neckrnan, C, 589(ab)Nedelrnan, M, 6l0(ab),

614(ab), 695(ab)Neely, H, 261(ab), 568(ab),

569(ab)

Neely,JE, 1577Neff, KH, 724(ab)Negri, M, 1365Neirinckx,RD, 191,407(ab),

559(ab), 574(ab), 648(ab),1657

NeIp, W, 573(ab), 650(ab),692(ab)

Neip, WB, 34, 615(ab)Nelson, D, 1577Neumann, R, 71 l(ab)Neumann, RD, 573(ab)Neutze, JA, 686(ab)Newell, JB, 871Newman, E, 615(ab)Newman, ES, 652(ab)Ng,CK, 667(ab)Ng, MN, 7l7(ab)Nickles, RJ, 697(ab)Niederhuber, J, 713(ab)Niemeyer, MG, 579(ab)Nienaber, C, 558(ab)Nienaber, CA, 1839Nierhaus, A, 593(ab)Nieves, E, 594(ab)Niewoehner, CB, 575(ab)Nihill, MR, 262(ab)Niio, Y, 660(ab)Niknejad,G, 1771Nilas@L, 960Nimmon, CC, 647(ab), 1284Nishihira, T, 409(ab)Nishikawa, A, 1262Nishikawa, J, 19, 598(ab),

668(ab)Nishikimi, N, 717(ab)Nishikimi, T, 1210Nishimura, 5, 643(ab)Nishimura, T, 590(ab),

67l(ab), 704(ab), 1344Nishizawa, 5, 559(ab),

569(ab),623(ab),656(ab),682(ab), 699(ab)

Nitsch, J, 67l(ab)Nocera, M, 713(ab)Noda, H, 590(ab), 704(ab)Noever, T, 97, 642(ab),705(ab)

Norby, EH, 686(ab)Norrgren, K, 710(ab)Northover, JMA, 637(ab)Noska, MA, 601(ab)Nossif, N, 584(ab)NOSSIff, N, 668(ab), 718(ab),

720(ab)Noto, R, 694(ab)Notoharniprodjo, 0,

567(ab), 670(ab)Noujaim, AA, 487, 712(ab)Nowak, D, 97, 642(ab)Nowak, DJ, 564(ab), 642(ab)Nowak, JA, 603(ab)Nowotnik,DP, 191Nunn, AD, 592(ab), 674(ab),

729(ab), 730(ab)Nussbaum, M, 1230Nusynowitz, ML, 265(ab),

950

Oates, J, 97, 642(ab),666(ab),674(ab)

Oba,H, 558(ab),559(ab)Oba, K, 697(ab)Oberdorster, 0, 378

Oberle, PA, 729(ab)O'Brien,GM, 1571O'Brien, HA, 83O'Brodovich, H, 903, 1213Ochi, H, 689(ab), 1210O'Connell, JW, 565(ab)O'Connell,W, 583(ab),

608(ab), 669(ab), 673(ab)O'Connor,MK,551(ab)Oderman, P., 41 l(ab)O'Donnell, JK, 7l8(ab)Oehr, P. 7l2(ab)Oepen, 0, 406(ab)Ohi, M, 734(ab)Ohmomo, Y, 712(ab)Ohta,H, 252, 342Ohtake, T, 19, 557(ab),

668(ab)Okabe, A, 672(ab)Okada, RD. 871Okazaki, A, 637(ab)Okerlund, MD, 583(ab)Oku,H, 1210Olea, E, 734(ab)O'Leary, DH, 178Olofsson, S, 735(ab)Olsen, J, 595(ab)Olson, DO, 690(ab)Olson,RE,603(ab)Ongseng, F, 1230Oohama,K, 1061Orino, A, 688(ab)Orzel, JA, 387, 1335Oshima, M, 717(ab)Osman, 5, 574(ab), 648(ab),

694(ab)Oster, ZH, 680(ab), 710(ab),

73l(ab), 733(ab)Osti-zega, E, 589(ab), 674(ab)O'Sullivan, M, 718(ab)Oswald,B,55l(ab)Oswald, WM, 550(ab),

660(ab)Othman, 5, 6l3(ab)Otsuka, FL, 582(ab)O'Tuama, L, 645(ab)Overall, JE, 655(ab), 702(ab)Oyarnada, H, 689(ab),

696(ab)Ozawa, Y, 579(ab), 672(ab),673(ab)

Ozinsky, M, 719(ab)

Pabst, HW, 573(ab)Pace, L, 671(ab)Pacini, F, 1888Packard, AB, 730(ab), 907,

1571Pahl, J, 655(ab)Paidi, M, 6l0(ab)Paik, CH, 572(ab), 602(ab),

65 l(ab)Palac, RT, 667(ab)Palestro,C, 574(ab),639(ab),

689(ab), 695(ab)Palla, A, 585(ab)Palla, L, 6l3(ab)Palme, DF, 65l(ab)Palmer,A, 409(ab)Palmer, DW, 559(ab),

585(ab), 592(ab), 665(ab)Palmer,EL,119,1616Palmer, M, 634(ab)Palmer, MR. 682(ab)

1939Author Index â€¢1987

Prather,JL, 263(ab)Pratt, C, 578(ab)Press, 0, 692(ab)Pressman, BD, 658(ab)Preston, DF, 553(ab)Prezio, JA, 586(ab)Price, DC, 598(ab), 708(ab)Price, M, 632(ab)Pr,ce, RW, 600(ab)Prigent, F, 325, 589(ab),

674(ab)Prirnus, FJ, 615(ab)Prokop, EK, 719(ab)Pusey, E, 1683

Quackenbush, RC, 728(ab),1435

Quadri, SM, 572(ab),602(ab), 65l(ab)

Qualfe, MA, 1367Quardi, SM, 572(ab)

Rabito, CA, 602(ab)Radwanska, E, 628(ab)Raese, J, 570(ab)Raese, JD, 698(ab)Raffel, DR. 667(ab)Raffin, TA, 649(ab)Raftery, R, 264(ab)Raftery, RG, 264(ab)Rahier, J, 6l0(ab)Rahman, IU, 6l0(ab)Raichle, ME, 646(ab)Ram, CVS, 623(ab)Ram, 5, 625(ab)Rarnanna, L, 56l(ab),

563(ab), 647(ab), 658(ab),686(ab)

Rarnon, Y, 707(ab)Rarnos, EC, 590(ab)Rarnos-Gabafln, A, 685(ab)Ranney, DF, 704(ab)Rao, SA, 574(ab), 585(ab),

638(ab)Rao,TN, 656(ab)Raoul, JL, 707(ab)Rapaport, Fr, 731(ab)Rasey, is, 68, 594(ab),

668(ab)Rath, P. 707(ab)Raval, JK, 638(ab)Raval, U, 733(ab)Ravert, H, 61 1(ab), 645(ab),

663(ab)Ravefl, HT, 600(ab),

624(ab), 635(ab), 699(ab),726(ab)

Raylman,RR,634(ab)Raymond, F, 586(ab),

649(ab), 1546Raymond, P, 706(ab)Raynaud, C, 592(ab),

623(ab), 680(ab)Razavi, MS. 656(ab)Reasner, C, 685(ab)Reba, RC, 572(ab), 602(ab),

65 l(ab), 662(ab), 700(ab)Redies, C, 471Reed, K, 524Rehling, M, 399Reich, 0, 1554Reichmann, K, 569(ab),

592(ab), 593(ab), 67l(ab),1763

Reidel, 0, 573(ab)Reilly, RM, 715(ab)Reinhardt, U, 599(ab)Reisman, 5, 580(ab)Reitz, B, 615(ab), 663(ab)Reivich, M, 431, 570(ab),

594(ab), 601(ab), 633(ab),655(ab), 699(ab), 702(ab),1667

Rernbish, RA, 732(ab)Remley, K, 514Reno,J, 573(ab),650(ab)Reno,JM,656(ab),69l(ab)Reske, SN, 671(ab)Resnick, SM, 601(ab),

655(ab), 702(ab)Resser, K, 325, 588(ab),

647(ab)Restrepo, W, 7 l8(ab)Retik, A, 62l(ab)Reuter,BM, 1763Reynolds, J, 636(ab)Reynolds, iA, 281Reynolds, JC, 42, 572(ab),

602(ab), 614(ab), 651(ab),693(ab), 7l0(ab), 722(ab)

Rhodes,CG, 1144Ricard, 5, 592(ab)Ricci, AR, 558(ab)Rice, DE, 657(ab), 720(ab),724(ab)

Rice, K, 701(ab)Richard, MD, 657(ab),

720(ab)Richmond, B, 1055Richter, M, 616(ab)Riege, W, 655(ab)Riege, WH, 645(ab)Rifkin, RD. 597(ab)Riggs, K, 565(ab)Rigo, P, 655(ab), 829Rils, BJ, 960Rimland, A, 1037Rippin, R, 575(ab)Rittenhouse, HG, 603(ab)Rivera, i, 602(ab)Robbins, MS. 732(ab), 1881Robbins, W, 642(ab)Robbins, WL, 577(ab),

589(ab), 673(ab)Robert, A, 644(ab)Roberts, R, 578(ab), 579(ab),

663(ab)Robertson,JS,257Robeson,W, 596(ab)Robinson, D, 553(ab)Robinson, GD, 570(ab)Robinson, RC, 553(ab)Robinson, V, 717(ab)Robyn,C, 686(ab)Roche,J, 714(ab)Roddie, ME, 574(ab),

648(ab), 694(ab)Roden,TM, 1820Roe, D, 584(ab)Roedler,HD, 616(ab)Roger, P, 685(ab)Rogers, WL, 577(ab),

641(ab), 661(ab), 695(ab)Rohaigi, PK, 1508Rokey, R, 545Romrnel, F, 593(ab)Romyn,A, 1920Roos, JP, 567(ab)

Roosen,N, 591(ab)Rosarnond, TL, 1322Rosen, BR, 871Rosen, iM, 723(ab)Rosen, M, 60l(ab), 633(ab),

699(ab), 1667Rosen,PR, 1338Rosen, S. 575(ab)Rosen, ST, 553(ab), 603(ab),

722(ab)Rosenblum, MG, 25,

264(ab), 65 1(ab)Rosenfeld, T, 632(ab)Rosenspire, KC, 594(ab)Rosenthall,L, 586(ab),649(ab),9l5,1546

Ross, C, 61 1(ab)Ross,0, 319,973Rosseni, C, 70l(ab)Rota, E, 591(ab)Roth,B, 714(ab)Roth,DR. 262(ab)Rothendler, JA, 1419Rothley,JM, 1695Rothstein,R, 598(ab)Rouenberg, DA, 600(ab),

700(ab), 998, 1844Rowe,BR,583(ab)Rowland, R, 7l4(ab)Roy, L, 654(ab)Roy,LP,646(ab),824Roza, AM, 733(ab)Rozanski, A, 588(ab),

589(ab), 597(ab), 674(ab)Rozenberg, 5, 686(ab)Rozenblit, 0, 735(ab)Rubenstein, J, 616(ab)Rubenstein, JB, 1771Rubin, E, 690(ab)Rubin, RH, 572(ab),

614(ab), 695(ab)Ruddy,TD, 643(ab),669(ab)Rufini, V, 576(ab)Rumbaugh,CL,47Rumley, 5, 218Rusckowski, M, 560(ab),712(ab),714(ab),1294

Rush, C, 649(ab)Russell, CD, 663(ab)Ruth,TJ, 1599Ryan, DE, 1268Ryan,JW,1831Ryan, K, 637(ab)Ryan,TJ, 1419RydÃ©n,5, 1424Ryo, U, 648(ab), 1103Rypins, EB, 627(ab), 688(ab)Rzasa, PJ, 7l9(ab)

Saad, R, 652(ab)Saccavini, JC, 637(ab)Saccavini, J-C, 1807Sacchi, T, 580(ab)Sachs, 5, 564(ab)Sadek, 5, 730(ab)Sadzot, B, 701(ab), 702(ab)Saenger, EL, 1521Sahlstorn, K, 442Saild, Y, 688(ab)Saito, 5, 579(ab), 672(ab)Saito, T, 584(ab), 7 l8(ab),

720(ab)Saito, Y, 660(ab)Saitou, 5, 673(ab)

Palombo, C, 613(ab)Pan, S-J, 60l(ab)Pant, KD, 7l0(ab)Park, CH, 438, 582(ab),

1275Park, HM, 649(ab)Park, Y-D, 1344Parker, HG, 402Parker,TM,610(ab)Parkey, RW, 260(ab),

263(ab), 406(ab)Partain,CL, 1052, 1928Patchell, L, 524Pate, BD, 634(ab), 682(ab),

1599Patel, B, 583(ab)Patel, BS, 654(ab)Patel, D, 410(ab)Patel,K, 550(ab)Patlak, cs, 587(ab)Patrarca, B, 597(ab)Patterson, RE, 97, 589(ab),

591(ab),642(ab),666(ab),674(ab)

Patton,JA, 122, 1231Patton, R, 597(ab)Paul, R, 288Paulman, R, 570(ab)Paulman,RG,698(ab)Paurngartner, 0, 688(ab)Pauwels, EKJ, 675(ab)Pauwels, 5, 563(ab), 605(ab),

690(ab)Pavel,DO, 734(ab)Pawlik, 0, 6l2(ab), 645(ab)Payne, J, 599(ab)Pearison, 0, 61 l(ab)Pcarlstein, RM, 602(ab)Peck, DC, 585(ab)Pederson, K, 1599Peifer, JW, 675(ab)Pekrul, E, 697(ab)Pelizzari, CA, 682(ab)Peltier, P, 1807Pemberton, JH, 550(ab),

660(ab)Pena, A, 1506Pencke,M,696(ab)Peng, FK, 687(ab)Peng, NJ, 650(ab)Peng,TT,1279Penney,BC,565(ab),

630(ab), 1192Penney, HF, 184Pepping, P, 628(ab)Perani, D, 699(ab), 70l(ab)Perentesis,P, 281,602(ab),

636(ab), 722(ab)Peretz, A, 686(ab)Perez Balino, N, 662(ab),

675(ab)Perex-Balino, N, 13Perez-Stable, E, 1383Perkins, JV, 673(ab)Per-Lee, JP, 652(ab)Perlrnan, SB, 583(ab),

687(ab)Pernot, C, 654(ab)Perry, J, 660(ab)Perry, JR. 570(ab), 576(ab),

661(ab)Peshock, RM, 260(ab),

406(ab)Peters, AM, 574(ab),

646(ab), 648(ab), 694(ab)Peters,LC,709(ab)Peterson, RE, 261(ab)Pettigrew, R, 642(ab)Pettigrew, RI, 564(ab),

591(ab), 705(ab)Pezim, ME, 550(ab), 660(ab)Phaneuf, D, 662(ab)Phelps, M, 655(ab)Phelps, ME, 558(ab),

564(ab), 587(ab), 588(ab),598(ab), 61 l(ab), 612(ab),624(ab), 631(ab), 646(ab),653(ab)

Phillips, R, 639(ab)Phillips, 5, 55 l(ab)Picard, D., 803Picard, M, 654(ab), 662(ab),

803Pickering, T, 735(ab)Pickeit, RD, 191Piepsz, A, 715(ab)Piers, DA, 684(ab), 734(ab)Piers, DB, 584(ab)Pierson, R, 610(ab)Piko, CR, 715(ab)Pillay, M, 135Pinchera,A,1888Pinsky, 5, 648(ab), 1103Pinsky, SM, 552(ab)Piper,IM, 191Pircher,FJ, 1510Pisano, M, 734(ab)Pjura, GA, 547, 596(ab),

647(ab), 660(ab)Plager, CE, 25Plankey, M, 642(ab)Plehn,J, 1536Plotnick, J, 218PÃ¸denphant, J, 960Podreka, I, 1657Posgenburg, JK, 692(ab),71l(ab),7l2(ab)

Pojer, PM, 1041Politte, DO, 566(ab)Polla, BS, 203Pollack, H, 733(ab)Pollack, W, 733(ab)Pollock, JCS, 632(ab)Pornato,N, 709(ab)Pomper, MG, 625(ab)Ponto,JA,649(ab),684(ab),

1781Port, 5, 254, 597(ab)Port,SC, 116Porter,BA,690(ab)Porter-Fink, V, 677(ab)Ports, T, 580(ab)Post, NC, 603(ab)Poston, GJ, 265(ab)Potter, CS, 652(ab)Potvin, B, 733(ab)Potvin, WJ, 1171Pouleur,H, 6l0(ab)Pounds, BK, 262(ab),

265(ab)Pourcelot, L, 658(ab)Powe,J, 686(ab)Powe, JE, 694(ab)Powers, J, 584(ab), 668(ab),

718(ab), 720(ab)Powles, T, 599(ab)Pozzilli, P, 1365Prasad, R, 552(ab)


Palombo

Saji, H, 567(ab), 569(ab),57 l(ab), 623(ab), 656(ab),682(ab), 699(ab), 1027

Sakahara, H, 342, 7l2(ab),719(ab), 720(ab), 730(ab),1027

Sakai, F, 569(ab)Sakata, I, 724(ab)Sakki, 5, 442Sakota, 5, 609(ab)Sakuma, H, 689(ab)Sakuma, 5, 717(ab)Saleemi, K, 1393Salehi,N, 1041Saliken, JC, 1540Salimi, Z, 606(ab)Salk, RD, 58 l(ab)Sallinen, P, 442Salmon,E, 702(ab)Saltzgaber-Muller, J, 560(ab)Saizyman, L, 1536Samaan, NA, 263(ab)Sampson, WFD, 1461Samson, DS, 591(ab),

633(ab)Sarnuels, BI, 1401Sarnuels, LD, 580(ab),716(ab)

Sandler,MP, 122, 1231Sandmaier, B, 692(ab)Sands, H, 390, 560(ab),

573(ab), 1351Sanger,Ji, 1107, 1506Sapega, AA, 605(ab)Sarkar, 5, 640(ab), 735(ab)Sasaki, Y, 637(ab)Sass, KS, 710(ab)Sato,K, 1115Satoh, Y, 587(ab)Satoyoshi, E, 700(ab)Satyamurthy, N, 587(ab),

611(ab)Sauer, R, 599(ab)Sauter, R, 599(ab)SaVi,A,1870Sawaf, NW, 387Saxena, Vl@ 622(ab)Saxton, RE, 562(ab)Sazbon,A,733(ab)Schaefer, 5, 260(ab), 406(ab)Schaller,G, 1554Schauwecker, DS, 575(ab),

649(ab), 69l(ab)Scheffel, U, 594(ab), 624(ab),

729(ab)Scheibe, P0, 653(ab)Scheinin,B,6l5(ab)Schelbert, H, 682(ab)Schelbert, HR. 558(ab),

588(ab), 61 l(ab)Schenkenfelder, R, 62l(ab)Scheurlen, C, 688(ab)Schicha, H, 705(ab)Schick,EC, 1419Schiepers, CWJ, 632(ab)Schiff, RG, 564(ab), 1915Schlemper, EO, 601(ab)Schlom, J, 722(ab), 861Schlusselberg, DS, 619(ab)Schlyer, DJ, 60, 624(ab)Schrnidlin,P, 406(ab)Schmidt, DH, 597(ab)Schneck, CD, 1835Schneider, V, 260(ab)

Schober,0, 581(ab),595(ab),N 1795

Schoeps, K-D, 636(ab)SchÃ¶n,HR.924, 926Schreiber, MH, 703(ab)Schroff, R, 573(ab), 650(ab)Schroff,RW,281,602(ab),

6l5(ab)Schteingart, DE, 640(ab),

685(ab)Schubiger, PA, 585(ab),

614(ab)Schulrnan, DS, 578(ab)Schultz, KR, 577(ab)Schuning, F, 692(ab)Schuster, DP, 1704Schwaiger, M, 558(ab),

588(ab), 598(ab), 61 1(ab)Schwartz, A, 693(ab)Schwartz, AN, 406(ab),

710(ab)Schwarz, A, 721(ab)Schwarzrock, R, 58l(ab)Schwinger, RB, 565(ab),I192

Scott,JA, 119Scott, JW, 629(ab)Scott, 5, 606(ab)Seabold, JE, 562(ab),

649(ab)Sedvall, 0, 625(ab)Segal, JL, 688(ab)Segall,G, 558(ab)Segall, GM, 649(ab)Sehgal,E,918Seldin,DW,663(ab)Selin, CS, 558(ab)Selvaraj, 5, 712(ab)Selwyn, AP, 585(ab), 989Senda, M, 567(ab), 569(ab),

587(ab), 623(ab), 656(ab),682(ab), 691(ab), 699(ab)

Senekowitsch, R, 573(ab),706(ab)

Sennesael, i, 630(ab)Scrafini, AN, 590(ab)Sergent, A, 623(ab)Serizawa, T, 19Servis, KL, 599(ab)Sethi,SS, 1348Sethia, B, 886Seto, M, 731(ab)Seubert, J, 560(ab)Severson, AR, 665(ab)Sewall, 5, 1268Sewing, K-Fr, 595(ab)Seybold, K, 585(ab), 614(ab)Sfakianakis, ON, 6l3(ab),

735(ab), 1383Sgouros, 0, 6l7(ab), 653(ab)Shackford, H, 597(ab)Shafer, RB, 575(ab), 603(ab)Shaffer, P, 595(ab)Shah, PK, 674(ab)Shah, Y, 580(ab)Shanes, J, 666(ab)Shani, J, 595(ab)Shankland, EG, 594(ab)Shao, H-S, 7l0(ab)Shapiro, B, 315, 618(ab),

640(ab),685(ab),687(ab),979,1401,1625

Sharkey, C, 1550, 1688Sharkey, CA, 7l6(ab)

Sharkey, RM, 652(ab),683(ab), 713(ab), 1604

Sharma, SC, 597(ab)Sharp, P. 601(ab)Sharpc, J, 599(ab)Shaw,P, 560(ab)Shayne, P, 666(ab)Shea,MJ,989Shea, W, 666(ab)Sheahan,K,1911Shealy, D, 7l4(ab)Sheikh, KH, 670(ab)Shen,SW,315Shen,5-W, 1055Sherman, P. 7l5(ab), 1620,

1625Sherman, W., 918Shewman, DA, 646(ab)Shi, K-C, 697(ab)Shi, QX, 628(ab)Shiba, K, 559(ab), 702(ab)Shibahara, N, 696(ab)Shibata,T, 559(ab),569(ab),

623(ab), 656(ab), 682(ab),699(ab)

Shields,AF,690(ab),728(ab), 1435

Shields,JB, 606(ab)Shier, CK, 244Shih,i,725(ab)Shih, W-J, 816Shib, WJ, 1484Shikata, J, 660(ab)Shimoji, T, 409(ab)Shin,SY,572(ab),651(ab)Shinotoh, H, 703(ab), 1006Shiomi, 5, 689(ab)Shionoya, 5, 717(ab)Shiue,C-Y,60, 635(ab),1164

Shochat, D, 713(ab), 723(ab)Shonkoff,D, 589(ab),

642(ab), 674(ab)Shreve, P. 1736Shtern, F, 572(ab)Shuke, N, 714(ab)Shuler,5, 26l(ab), 568(ab),

569(ab)Shulgin, AT, 725(ab)Shulkin, B, 687(ab)Shulkin, BL, 315, 7l3(ab)Shurvell, B, 643(ab)Sia, STB, 13Siddhivarn,N, 1835Siddiqui, A, 669(ab)Sidtis, JJ, 600(ab), 700(ab)Siebecker, DA, 7l2(ab),

7l4(ab)Siegel,BA,56I(ab)Siegel, JA, 563(ab), 605(ab),

660(ab), 690(ab), 704(ab),1363

Siegel, M, 595(ab)Siegel, ME, 590(ab), 638(ab),

664(ab),691(ab),694(ab),713(ab)

Siegl, P, 676(ab)Signore, A, 1365Silberstein, EB, 708(ab)Silver, F, 633(ab)Silver, M, 599(ab)Silverman, ED, 810Silverstein, EA, 408(ab),

681(ab)

Simmons, B, 640(ab)Simmons, M, 524Simon, J, 495, 722(ab),

729(ab)Simon, JD, N150Simon, P, 560(ab)Simon, T, 570(ab)Simon, TR, 102, 229,619(ab),1232,1363

Simpson, DE, 861Sinatra,FR,966Singer, 5, 585(ab)Singh, A, 708(ab)Singh, M, 595(ab), 649(ab),

1853Sinha, AK, 593(ab)Sinni, BJ, 604(ab)Sirr, 5, 342Sisson, J, 6l8(ab), 687(ab)Sisson, JC, 315, 639(ab),979,1620,1625

Sjogren, HO, 710(ab)Skagen, K, 1330Skolnick, BE, 655(ab)Slatkin, DN, 697(ab)Slavin, JD, Jr. 1348Sledge, G, 714(ab)Slosrnan, DO, 203Small,OW,645(ab)Smallhorn, iF, 62l(ab)Smalling, RW, 1262Smith, ER, 7l7(ab)Smith, IE, 1230Smith, J, 636(ab)Smith, K, 663(ab)Smith, T., 240Smith, WH, 618(ab), 653(ab)Smith, WK, 6l9(ab)Smitherman, TC, 102, 1363Smolorz, J, 705(ab)Snyder,DL, 566(ab)Snyder, SH, 699(ab), 70l(ab)Sobel,BE, 1322,1563Sodoyez, JC, 583(ab)Sodoyez-Ooffaux, F, 583(ab)Solanki, K, 637(ab), 647(ab)Solin, L, 616(ab)Solis, E, 667(ab)Solomon, HF, 676(ab)Sorn, P, 680(ab), 710(ab)Sone, K, 697(ab)Sonnernaker, R, 26l(ab),

568(ab),569(ab)Sonnemaker, RE, 262(ab)Sood, VK, 651(ab)Sorenson,J, 1180Sorsdahl, 0, 673(ab)Sos, T, 735(ab)Sosa, JA, 632(ab)Soucy, JP, 7l6(ab)Soufer, R, 578(ab)Sournac,M, 1199Sowton, E, 674(ab)Specht, HD, 383, 1826Specker,BL, 1521Spencer, P, 669(ab)Spencer, PC, 643(ab)Spencer, RP, 723(ab),

732(ab), 1063, 1348Sperling, MI, 568(ab)Spicer, JA, 553(ab)Spicer, LD, 625(ab)Spielmann, RP, 1839Spies, SM, 408(ab), 553(ab),

603(ab), 605(ab), 68 1(ab),722(ab)

Spies, WG, 408(ab), 605(ab),681(ab)

Sporn, V, 13, 662(ab),675(ab)

Spraragen, 5, 597(ab)Spritzer, CE, 685(ab),

733(ab)Squicciarini, SA, 552(ab),

578(ab)Snnivasan, A, 573(ab),

650(ab), 656(ab), 691(ab)Srivastava, PC, 57l(ab),726(ab)

Snvastava, SC, N 143,596(ab), 721(ab)

Stabin,MG, 581(ab)Stadalnik, RC, 627(ab),

653(ab)Staffen, W, 645(ab)Stafford-Schuck, K, 702(ab),

706(ab)Stagg, RJ, 708(ab)Starkey, D, 61 l(ab)Starling, MR. 552(ab),578(ab),950,1725

Starnes, C, 561(ab)Starnes, HF, 693(ab)Starnes, HF, Jr. 640(ab)Staum, M, 736(ab)Stefen,H, 1763Stein, HL, 704(ab)Steiner, M, 1657Steinhaeusl, H, 59l(ab)Steinhardt, OF, 7l6(ab)5teinstri@8er,A, 693(ab),721(ab)

Steis, R, 636(ab)Steis, RO, 281, 602(ab)Steplewski, Z, 721(ab)Sterling, FH, 685(ab)Sterreu, G, 550(ab)Steves,A, 360Steves,AM,6l8(ab)Stirner, H, 600(ab), 620(ab)Stocklin, 0, 6l2(ab), 634(ab)Stoffer,SS, 1341Stokely, EM, 262(ab),

407(ab)Stomper, PC, 606(ab)Stone-Elander, 5, 625(ab),

636(ab)Storb, R, 692(ab)Stouffer, B, 568(ab)Stowers, 5, 673(ab)Strand, S-E, 58l(ab),

710(ab), 1424Strashun,A, 639(ab),

678(ab)Straub, RF, 721(ab)Strauss, A, 6l7(ab)Strauss, H, 666(ab)Strauss,HW,76, 572(ab),

584(ab), 609(ab), 6l0(ab),614(ab), 632(ab), 650(ab),662(ab), 668(ab), 671(ab),672(ab), 695(ab), 718(ab),720(ab), 727(ab), 728(ab),1671

Strauss,L,645(ab)Strauss, LG, 406(ab),

408(ab), 4l0(ab)Stringham, LM, 708(ab),


Stringham

Stritzke

722(ab), 729(ab)Stritzke, P, 619(ab), 732(ab)Strother, SC, 600(ab),

695(ab), 698(ab), 700(ab),1844

Stroup, SD, 603(ab)Stubbs, iB, 618(ab)Stutzman, M, 663(ab)Subrarnanian, G, 1643, 1784Subramanian, K, 735(ab)Subramanyan, V, 60l(ab)SuessE, 1657Sugai, Y, 599(ab)Sugarhara, M, 728(ab)Surniya, H, 558(ab), 559(ab)Summers, RW, 562(ab)Summerville, DA, 621(ab),

730(ab), 907Sun, J5, 360Sun, TT, 72l(ab)Sundberg, R, 1424Sundoro, BM, 723(ab)Suresh, MR. 7l2(ab)Surma, A, 568(ab)Suzuki, A, 609(ab), 67l(ab),

672(ab)Suzuki, K, 1006Suzuki, MN, 609(ab),

671(ab)Suzuki, T, 609(ab), 639(ab)Suzuki, Y, 609(ab), 670(ab)SvÃ£rd,H, 1037Swanson, N, 713(ab)Swayne,LC,1771Sweny, P. 613(ab)Swiniarski, JK, 572(ab)Sychra, JJ, 734(ab)Sykes, TR, 7l2(ab)Syijala, MT. 155Syrota, A, 592(ab)Szpunar, WE, 1341Szyjkowski, M, 703(ab)

Tabata, Y, 639(ab)Tada, M, 706(ab)Taegtmeyer, H, 668(ab),

1155Taha, B, 676(ab)Taher, MA, 1782Taillefer, R, 605(ab),

654(ab), 662(ab)Takada, H, 672(ab)Takada, T, 660(ab)Takahashi, K, 639(ab)Takahashi, T, 658(ab),

727(ab), 728(ab)Takamiya,M, 67l(ab)Takano, H, 590(ab), 704(ab)Takano, Y, 703(ab)Takao, N, 579(ab)Takayama, T, 731(ab)TaIceda,H, 173Takeda, K, 689(ab), 734(ab),

735(ab)Takeda,T, 1210Takehara, T, 627(ab),

628(ab)Takeuchi, K, 1210Taki, J, 609(ab), 650(ab),

671(ab), 672(ab)Takvorian, T, 47Tam, SW, 731(ab)Tamaki, N, 567(ab), 569(ab),

609(ab), 623(ab), 632(ab),

671(ab), 672(ab), 682(ab),699(ab)

Tamamoto, K, 699(ab)Tamas, MJ, 642(ab), 674(ab)Tamura, K, 626(ab)Tanada, 5, 559(ab), 6l2(ab),

624(ab)Tanagho, EA, 598(ab)Tanaka, H, 342Tanasescu, DE, 56l(ab),

563(ab), 647(ab), 658(ab),686(ab)

Tang, Y-N, 631(ab), 678(ab),697(ab)

Tangerman, R, 55 1(ab)Tarburton, P, 714(ab)Taren, JA, 706(ab)Tarr,RR, 1052Tashiro, T, 735(ab)Tate, Y, 703(ab)Tateno, Y, 567(ab), 1006Tauxe, WN, 366, 616(ab),

622(ab), 664(ab), 735(ab)Taylor, A, 613(ab), 642(ab),

647(ab)Taylor, A, Jr. 732(ab), 1180Taylor, AT, 168Tazaki, Y, 569(ab)Teates, CD, 6l6(ab),

618(ab), 653(ab)Teefey, 5, 7l0(ab)Teng, R-R, 635(ab), 1164Tennison, JR. 407(ab)Tepe,P0,366Terada, H, 558(ab), 559(ab)Terahara, A, 668(ab)Tereda, N, 735(ab)Terriere, D, 570(ab)Terui, 5, 689(ab), 696(ab)Teshima,T, 1901Thakur, ML, 438, 582(ab),

657(ab), 720(ab)Thedrez, P, 1807Thomas, B, 679(ab)Thomas, FD, 1062Thomas, KD, 582(ab), 1745Thomas, U, Jr. 566(ab)Thomas, SR. 626(ab)Thompson, 0, 677(ab),

698(ab), 699(ab), 1315Thompson, FD, 733(ab)Thompson, J, 690(ab)Thompson, JC, 265(ab)Thompson, NW, 979Thonoor, CM, 582(ab)Thorell, J-O, 636(ab)Thornback, JR. 602(ab)Thorne, DA, 514, 820Thornton, B, 578(ab)Thouvenot, P, 563(ab)Tikofsky, PS, 559(ab),

592(ab), 622(ab)Tilbury, RS, 140Timmons, JH, 266(ab)Tintner, R, 407(ab)Tiu,S, 1107Tobes, MC, 639(ab), 1620Tobin,M, 736(ab),1667Tochon-Danguy, Hi, 1554Todd,IP,637(ab)Todd-Pokropek, A, 660(ab)Todd-Pokropek,AE,652(ab)Todo, A, 627(ab), 688(ab)Todo, 5, 293

Togawa, T, 707(ab)Tornaczewski, J, 736(ab)Tornazewski, J, 733(ab)Tominaga, T, 1006Tornita, 5, 688(ab)Tonami, N, 714(ab), 731(ab)Toorongian, SA, 624(ab),

635(ab)Torizuka, K, 252, 342,

559(ab), 568(ab), 569(ab),571(ab), 587(ab), 623(ab),627(ab), 656(ab), 682(ab),688(ab), 699(ab), 7l2(ab),719(ab), 720(ab), 730(ab),1027

Toujas, L, 637(ab)Tourje, JE, 658(ab)Touya, JJ, 405(ab)Tow, DE, 596(ab), 1047Townsend, CM, 265(ab)Townsend, D, 1554Toyama, H, 19, 643(ab),

700(ab)Toyama, 5, 342, 7l2(ab)Toyoda, 5, 734(ab)Toyonaga, K, 409(ab)Trani, M, 636(ab)Trap-Jensen, i, 399Treher, E, 592(ab), 730(ab)Trembath, L, 585(ab)Trembath, LA, 574(ab),

638(ab)Treves, 5, 730(ab)Treves, ST. 532, 621(ab),652(ab),907,1338,1571

Troilo, A, 662(ab), 675(ab)Troncone, L, 576(ab)Troutner, DE, 60l(ab)Trowbridge, EA, 402Tsan, M-F, 223Tsay, HM, 568(ab)Tsuda, Y, 569(ab), 593(ab)Tsui, BMW, 566(ab),

570(ab), 576(ab), 577(ab),66l(ab), 677(ab)

Tsuji, 5, 558(ab), 559(ab),702(ab)

Tsujino, D, 637(ab)Tsuneoka,Y, 173Tu, J-I, 568(ab)Tuli, M, 669(ab)Tumeh, 55, 585(ab), 1611Tummon, I, 628(ab)Tune, L, 61 1(ab)Turbiner, E, 550(ab)Turgeman, Y, 632(ab)Turner, DA, 140Turner, FE, 667(ab)Turpin, TA, 656(ab)Tveter, D, 263(ab)Tweddel, AC, 609(ab),

632(ab)Tweedle, M, 705(ab)Tweedle, MF, 705(ab)Tyler, JL, 234, 699(ab), 1123Tzen, KY, 638(ab)

Uber, DC, 608(ab)Uchiyaina, K, 660(ab)Udelson, JE, 557(ab),

63l(ab)Uebis, R, 620(ab)Ueda, N, 639(ab), 724(ab)Uehara, A, 701(ab)

Uehara, T, 671(ab), 1344Uemura, K, 409(ab), 607(ab)Ueno, K, 1061Ueno, T, 672(ab)Ujiie, A, 727(ab), 728(ab)Unger, M, 264(ab), 65 l(ab),

71 l(ab)Unger, MW, 25, 710(ab)Uno, K, 648(ab)Unsworth,J, 1062Urbain, JL, 563(ab), 605(ab),

690(ab)Urbon, JA, 590(ab)Uren, R, 824Uren, RF, 646(ab)Utell, Mi, 378

Vahatalo, @,442Valenza, V, 576(ab)Valeyre, i, 254, 582(ab)Valind, SO, 1144Vallabhajosula, 5, 574(ab),

610(ab), 639(ab), 695(ab)Vallar, G, 699(ab)Valtonen, V, 155van der Hem, GK, 734(ab)Vanderheyden, JL, 656(ab)Vanderheyden, J-L, 656(ab),

1870vanderSchoot,JB, 178vanderWall,E, 135van Doom, T, 526VanDort, ME, 726(ab)van Giessen, JW, 1892Van Herle, AJ, 71 l(ab)van Lingen, A, 631(ab)Van Mechelen, H, 610(ab)Van Nostrand, D, 586(ab),

686(ab)van Rijk, PP, 1892van Rijswijk, MH, 734(ab)vanRoyen,EA, 178,1365Van Train, K, 588(ab),

643(ab)Van Train, KF, 589(ab),

654(ab), 674(ab)van Zyl, JM, 402Vaquer, R, 408(ab), 639(ab)Vaquer, RA, 678(ab)Varma, M, 57l(ab)Varma, 5K, 580(ab)Vas, W, 583(ab), 606(ab)Vasquez, TE, 596(ab)vd Schoot,JB,659(ab)Vea, HW, 406(ab)Veall, N, 240Velasco,EA,405(ab)Velchik, M, 584(ab)Velchik, MG, 565(ab),

639(ab), 685(ab), 686(ab),733(ab)

Vera, DR, 627(ab), 653(ab)Verani, MS, 401, 578(ab),

579(ab), 654(ab), 663(ab),698(ab)

Verani, R, 647(ab)Verbeeleen, D, 630(ab)Verbruggen, A, 690(ab),

731(ab)Vergara, M, 401Verreault, J, 716(ab)Verzijlbergen,JF, 579(ab),

584(ab)Vessella, RL, 603(ab),

651(ab), 680(ab)Veyre,A, 1199Vieras, F, 1508Viergever, MA, 1892Vigneron, DB, 598(ab)Villemagne, V, 61 l(ab),

626(ab), 645(ab)Villemure,J-G, 1123Vincent, MD, 1230Virzi, F, 560(ab), 1294Visser, FC, 567(ab)Vogel, M, 62l(ab)Volkert,W, 191Volkert, WA, 495, 505,

593(ab), 679(ab), 708(ab),709(ab), 722(ab), 729(ab)

Volkow, ND, 524, 655(ab),702(ab),1251

Von Moll, L, 979Vorne, M, 442Vossepoel, AM, 675(ab)Votaw, J, 697(ab)VoÃ¼te,PA, 308Vuletich, T, 608(ab)Vyska, K, 567(ab), 670(ab)Vyth,A, 178, 1365

Wackers, FJ, 557(ab)Wackers, FJTh, 945Wagner, HH, Jr. 700(ab),

70l(ab)Wagner, HN, Jr. 575(ab),

594(ab), 600(ab), 61 l(ab),612(ab), 615(ab), 620(ab),624(ab), 626(ab), 635(ab),645(ab), 662(ab), 663(ab),681(ab), 683(ab), 685(ab),699(ab), 726(ab), 729(ab),Nl235

WahI, RL, 610(ab), 614(ab),651(ab), 665(ab), 684(ab),713(ab), 715(ab), 1736

Wahner,HW, 1751Wakakura, M, 672(ab)WaId,A, 1926Waldbaum, RS, 704(ab)Waldman, DL, 378Walker, B, 570(ab)Walker, KA, 626(ab)Walker,PJ, 844Walker-Andrews, 5, 659(ab)WaIler, DO, 372Walovitch, RC, 731(ab)Walsh, PR, 622(ab)Walsh, RA, 950, 1725Waltzer, WC, 73l(ab)Wand, G, 626(ab)Wang, Si, 676(ab)Wang, TST, 723(ab)Wappenschmidt, J, 1763Waiter, SL, 659(ab), 707(ab)Ward, BG, 1034Warren, LP, 4l0(ab),

697(ab)Warren, R, 686(ab)Warren, RS, 640(ab)Washburn, LC, 721(ab)Wasserman, Hi, 622(ab)Watanabe, I, 579(ab),

673(ab)Watanabe, M, 697(ab)Watanabe, N, 7l4(ab)Watanabe, T, 557(ab),

668(ab)

1942 TheJournalofNudearMedicine

Yoshida

Watanabe, Y, 568(ab),7 12(ab), 7 l9(ab), 720(ab),730(ab)

Watanuki, 5, 658(ab)Waters, W, 705(ab)Watkins, GL, 726(ab)Watson, AD, 731(ab)Watson, DD, 580(ab),

618(ab), 653(ab), 1066Watson, EE, 581(ab)Watson, IA, 989Waxman, AD, 561(ab),

658(ab)Waxman, AW, 563(ab),

647(ab), 686(ab)Waxman, S, 658(ab)Webber, MM, 564(ab),584(ab)

Weber, DA, 548Weber, H, 599(ab)Webster, DA, 378Webster, EW, N423Wechter, DG, 710(ab)Wedeen, Vi, 871Wedeking, P, 705(ab)Wegst, AV, 553(ab)Weiland,FL,387,1335Weinberg, IN, 682(ab)Weiner, MF, 407(ab)Weiner, R, 669(ab), 714(ab)Weiner, RE, 575(ab),691(ab)

Weinrauch, M, 676(ab)Weinrauch, ML, 610(ab)Weinshenker, E, 568(ab)Weinstein, JN, 42Weinstein, R, 648(ab), 1103Weintraub, WS, 652(ab)Weisner, PS, 191Weissler, AM, 670(ab)Welch, Mi, 134, 462,

56l(ab), 582(ab), 625(ab),657(ab), 722(ab), 727(ab),1704

Wellrnan, H, 669(ab)Weliman, HN, 551(ab),

600(ab), 649(ab), 7l4(ab)Wells, SA, ir, 582(ab)Wendt, RE, III, 545, 547Wenger, HC, 676(ab)Wesolowski, CA, 1134Weasels, BW, 617(ab),651(ab)

Wessels, P, 402

West, MS. 675(ab)Westermann, CJJ, 584(ab)Wetzel, E, 408(ab), 4l0(ab)Wheatley, Di, 886Whelchel, JD, 673(ab)Wheldon, TE, 626(ab)White, DL, 590(ab), 599(ab)White,SR, 634(ab)Whitfield, HN, 1284Widding, A, 705(ab)Wieland, DM, 624(ab),

724(ab), 726(ab), 1620,1625

Wider, H, 591(ab)Wienhard, K, 612(ab),645(ab)

Wijns, W, 610(ab)Wikstrand, 0, 7l0(ab)Wilbur, DS, 68, 69l(ab),

725(ab)Wilbur,RS,Nl247Wilbur, 5, 560(ab)Wiles, HB, 262(ab), 663(ab)Wilkinson, R, 6l4(ab),

695(ab)Williams, A, 708(ab),

709(ab)Williams, BA, 558(ab)Williams, CC, 626(ab)Williams, CM, 582(ab), 1745Williams, J, 645(ab)Williams, KJ, 6l0(ab)Williams, LE, 684(ab)Williams, Si, 13, 619(ab),620(ab),731(ab),1351

Williams, W, 596(ab)Williams, WG, 62l(ab)Williams, WH, 1047Williamson, BRJ, 6l6(ab)Williamson, 5, 666(ab)Wilson, A, 61 l(ab), 645(ab)Wilson, AA, 624(ab),

635(ab), 699(ab), 726(ab)Wilson, B, 7 13(ab), 1736Wilson, CA, 133Wilson, CR, 665(ab)Wilson, D, 495Wilson, DO, 687(ab)Wilson, J, 714(ab)Wilson, MA, 583(ab),

665(ab), 687(ab), 1768Wilson, RA, 989Wilton, GP, 1401Windham,JP, 1171

Winkler, C, 569(ab), 1218Wintjen,M, 616(ab)Wirquin, E, 1228Witherspoon, L, 26l(ab),

568(ab), 569(ab)Woight, 0, 58l(ab)Wolf, AP, 60, 624(ab),635(ab),1164,1251

Wolf, F, 659(ab)Wolf, W, 595(ab), 599(ab)Wolfson, T, 649(ab)Wolfstein, I, 298Woilner, I, 707(ab)Wolverson, MK, 606(ab)Wong, C, 588(ab), 643(ab),

654(ab)Wong, D, 645(ab)Wong, DF, 594(ab), 61 l(ab),

626(ab), 726(ab)Wong, JYC, 684(ab)Wong, WH, 681(ab)Wong, WJ, 622(ab)Wood, RM, 1640Woodard, Di, 619(ab)Woodbury, MC, 685(ab)Woodhouse, C, 573(ab),

650(ab)Woolfenden, JM, 1643Wooten, W, 606(ab),

647(ab), 706(ab)Wooten, WW, 405(ab)Wortman, JA, 1447Wu, AM, 628(ab)Wu, LC, 650(ab), 676(ab),

687(ab)Wynchank, 5, 685(ab)

Yabuki, M, 720(ab), 730(ab)Yacoub, T, 730(ab)Yahata, T, 720(ab), 730(ab),

1027Yamada, ES, 562(ab)Yarnada, M, 579(ab)Yamada, Y, 590(ab), 704(ab)Yamaguchi, H, 688(ab)Yamaguchi, K, 599(ab),

658(ab), 706(ab)Yamaguchi, N, 568(ab),

689(ab), 735(ab)Yamaguti, N, 734(ab)Yamamoto, K, 569(ab),

623(ab), 682(ab), 69l(ab)Yamamoto, LY, 234Yamamoto, 5, 558(ab),

Yoshida, T, 568(ab)Yoshikawa, K, 598(ab),

648(ab)Yoshimoto, Y, 1115Yoshioka, H, 627(ab),628(ab)

Yoshizumi, M, 19Young, AB, 724(ab), 726(ab)Young, KA, 575(ab)Younis, LT, 578(ab)Yu, C.C, 601(ab)Yudd,AP,1447Yumikura, 5, 579(ab),

672(ab), 673(ab)

Zalutsky, MR. 603(ab),710(ab), 725(ab)

Zambelli, M, 690(ab)Zamora, P0, 7l0(ab)Zanelli, GD, 240Zanzi, I, 596(ab), 704(ab)Zanzonico, PB, 581(ab),

617(ab), 653(ab), 687(ab)Zaret, BL, 557(ab), 578(ab)Zaret, EC, 557(ab)Zecca,L,70l(ab)Zeeberg, BR, 662(ab),

68l(ab), 700(ab)Zerbi, M, 675(ab)Zhao, HY, 628(ab)Zhou, YG, 628(ab)Zhu, T, 628(ab)Zhu, YY, 580(ab), 673(ab)Zielonka, J, 663(ab)Ziessrnan, HA, 604(ab),

629(ab), 678(ab), 690(ab),1408,1679

Ziffling, P, 645(ab)Zimmer, AM, 408(ab),

553(ab), 603(ab), 681(ab),722(ab)

Zimmermann, RA, 431Zinreich, J, 626(ab)Zipes, D, 669(ab)Zito, F, 70l(ab)Zivanovic, MA, 683(ab)Zoghbi,5,71l(ab)Zoghbi, SS, 573(ab), 1441Zohrab, i, 659(ab)Zollars,LE, 1611Zolnierczyk, K, 734(ab)Zukerberg, BW, 53Zuzarte,J, 1907Zwas, ST, 161, 298, 452,

707(ab)Zwicke, D, 597(ab)Zwijnenburg, A, 659(ab)

607(ab)Yamamoto, Y, 1780Yamamoto, YL, 471, 1123,

1783Yamamuri, T, 342Yamamuro, T, 7l2(ab),

720(ab), 730(ab)Yarnane, T, 703(ab)Yamaoka, N, 697(ab)Yamaoki, K, 19Yamasaki, T, 567(ab), 1006Yamashina, A, 579(ab)Yamauchi, H, 724(ab)Yamazaki, 5, 689(ab)Yamazaki, T, 609(ab),

639(ab)Yanai, K, 624(ab)Yang, DC, 410(ab)Yang, JM, 676(ab)Yang, KP, 263(ab)Yang, KTA, 677(ab)Yang, W, 725(ab)Yano, Y, 594(ab), 649(ab),

7l7(ab), 725(ab)Yasuda, H, 660(ab)Yasuda, T, 76, 584{ab),

609(ab), 632(ab), 671(ab),672(ab), 7l8(ab), 720(ab),1671

Yasuhara, Y, 628(ab)Yee, W, 4l0(ab)Yeh, SH, 622(ab), 650(ab),

676(ab), 687(ab), 717(ab)Yen, TC, 622(ab), 687(ab)Yester, MV, 629(ab),

663(ab)Yip, K, 608(ab)Yip, T-CK, 6l8(ab)Yland, M, 73l(ab)Yokoi, F, 700(ab)Yokoyarna, A, 252, 571(ab),

639(ab), 7 l2(ab), 720(ab),724(ab), 730(ab), 1027

Yokoyama, K, 572(ab),65 l(ab), 7l4(ab), 722(ab)

Yomoda, I, 252Yoneda, 5, 701(ab)Yonekura, Y, 559(ab),

567(ab), 569(ab), 587(ab),623(ab), 656(ab), 682(ab),691(ab), 699(ab)

Yoosufani, Z, 1348Yorke, ED, 617(ab)Yoshida, K, 567(ab)


A

Abscessanti-inflammatory agent effects, In-lll IgG,

695(ab)detection,comparisonofln-lll Mercand

oxine, 438Tc-99m albumin colloid leukocytes, location of

infectious foci, 574(ab)Tc-99m HM-PAO, evaluation for leukocyte

labeling, 638(ab)AbscrptlOnietry

bone densitometry asserts clinical role despitelack ofreimbunement, N267

dual-photon. See Dual-photon absorptiometrysingle-photon. See Single-photon

absorptiometryAcademic Council, 5NM councils report at Winter

Meeting, N802Acetate, C-i 1 labeled, myocardial tricarboxylic

acid cycle tracer, 61 i(ab)Acquired immunodeficlency syndrome (AIDS)

ARC and, Ga-67 scintigraphy in, 1103chest scans, Oa-67, 1107children, Ga scanning in lymphoid interstitial

pneumonitis, 1915Ga-67 lung uptake in, l793(ab)Ga-67 scintigraphic patterns, 648(ab)Guidelines for radiation safety, AIDS

prevention, pose conifict, Nl806liver spleen scans in, 1792(ab)nuclear medicine role in, l790(ab)with PCP, In-l 11 1CUkOCYIeSand gafflum

imaging, 695(ab)AddactOr insertion avulsion syndrome, bone

scanningin, 1835Adenopathy, hilar and mediastinal, tumor vs@

sarcoidosis using 11-201, 561(ab)Adrenalglands

abnormal, Cushing's syndrome, 1-131 NP-59 in,640(ab)

localization ofl-l23 IMP in, 409(ab)nonhyperfunctioning mass, 1-131 NP-59 uptake,

640(ab)pheochromocytoma, dosimetry ofl-l31 MIBO,

687(ab)primary aldosteronism, Cushing's syndrome

and, iodocholesterol scintigraphy and CFin, 640(ab)

silent mass, functional and scintigraphicevaluation,1401

Adrenal medalla, normal, hypertension, 1-123MIBO uptake in, 319

Adrenergic nervous systemintegrity and function,

16201625

Adrenoleukodystrophy,imaging,524Adrsiiomedullarycells,1-125MIBO and

norepinephrine release, acetylcholinestimulated and basal, 639(ab)

Adult respiratory distress syndrome, acutely septicprimates, In-ill leukocyte migration in,649(ab)

Aging, dementia, brain, PET, 431AIDS-related complex (ARC)

AIDS and, Ga-67 scintigraphy in, 1103Ga-67 scintigraphy, 402(le)

A@convolution, uniform attenuation in SPECT

and,677(ab)reconstruction

Gibbs model for emission computedtomography, 677(ab)

SPEcr imagereconstruction,566(ab)Mpha-amlnolsobutyrlc add, Ga-67 citrate and, rat

sepsis model, 693(ab)Alzhehner'sdisease

C-l 1 pyruvate metabolism, cerebrum, 700(ab)functional mapping, FDO rate constants,

699(ab)Ambulatorycardiacmonitoringdevice

left ventricular dysfunction, chest pain and,CAD patients, 671(ab)

unstable angina, CAD and left ventriculardysfunction, 672(ab)

American Association ofPbyslclsts in Medicine(AAPM), AAPM explores antibodydosimetry, bone odsimetry, PET, Nl515

American Board of Nuclear Medicine (ABNM),ABNM adopts recertification policy, N280

American Collage ofNuclesr Physicians (ACNP),Quality Assurance and PracticeCertification Committee, 135(k)

Amides, chemistry and design implications,593(ab)

Amino nddsbiodistribution, acute sepsis and abscess

formation, 693(ab)methionine and leucine, incorporation in brain

tumors, 595(ab)uptake, tumor necrosis fuctor, 640(ab)

Amyl nitrite, thathum imaging and, detection ofCAD, 597(ab)

Anal canal, dynamic assessment, scintigraphicballoon proctography, 660(ab)

Angk@graphydigital subtraction, ventilation-perfusion scan

comparison, pulmonary emboli, 584(ab)left ventricular volume measurement, 40l(le)PET comparison, exercise ability and, 261(ab)

Augiography, radlomidlidearterial to total hepatic blood flow, 551(ab)automatic ventricular edge detection, 677(ab)biventricular ejection fraction, flow and volume

measurements,950first transit studies, reproducibility, 26l(ab)great vessels, congenitally corrected

transpositionof, 116hepatic hemangioma, differentiation from

hepatocellularcarcinoma, 688(ab)indices ofleft ventricular function, diagnosis of

CAD and, 671(ab)left-ventricular regional dyssne@gy,1725left ventricular volume calculation, assessment

ofEmax, 578(ab)renography and, renal artery flow defects,

6l3(ab)

reproducibility ofsequential rest and exercise,578(ab)

sequential torsion, appendix testis, 119subclavian vein obstruction, 11-201, 254(le)sublingual nifedipine effects, forearm venous

capacitance, 717(ab)Angioplasty

following thrombolysis, 11-201 scintigraphy,enhanced myocardial salvage, 674(ab)

percutaneous transluminal coronary, changes inmyocaqrdial perfusion reserve after, 1262

Angloscintigraphy, hepatic, portal venous hotspot, 689(ab)

Anorexia nervosagastric emptying studies with, 816stress fractures and reduced bone mineral

density,1506(k)And-antibody enhancement,

radioimmunodetection, experimental andclinical studies, 1604

AntibodiesSeealsospecifictypeFDA releases updated â€œpointsto considerâ€•for

antibody products, Nl520non-labeled, background reduction by

immunoscintigraphy, 712(ab)radiometallic labeling, reversal of sequence,

723(ab)Antidepressant drugs, distribution ofIMP and,

354Antigens, density, tumors, new in vitro method,

719(ab)Antlglobulins, responses, monoclonal antibody,

6l5(ab)AntI-inflammatory agents, radiolabeled

immunoglobulin scans, focal inflammation,695(ab)

AntI-monoclonal antibodies,radioimmunodetection, cancer, 652(ab)

Anti-marine antibodies, hama-murine antibodycomplexes and, 614(ab)

Anti-platelet antibodiesclot localization, experimental pulmonary

emboli, 7l8(ab)In-Ill and In-l25, behavior in experimental

pulmonary emboli, 720(ab)And-tumor antibodies, status report, l786(ab)Aorta, atherosclerotic lesions, experimental,

rabbit, 610(ab)Aortic root, perivascular abscess, Ga-67 and

NMR, 1616Arterial thrombus, detection with Ga-67 DD

fibrinogen,639(ab)Arterlography, total-body, intravenous

radionudlide, 4l0(ab)Arthrography, dual isotope, femoral component of

prosthetic hips, 565(ab)Arthro@ty

kneeasymptomatic, radiophosphate uptake in,

1546postoperative bleeding, Tc-99m RBC, 565(ab)radiophosphate uptake in, 586(ab)

Page numbers followed by (ab) indicate abstracts.Page numbers followed by (le) indicate letters.N preceding a page number indicates an article appearing in

Newsline.

1944

SubjectIndexâ€”I 987

TheJournalof NudearMedicine

Bone

image, decrease in Tl-20l specificity, SPECT,672(ab)

motion, prevention on dual isotope subtractionparathyroid scintigraphy, 1335

rotational, phase imaging ofcardiac scans, 1536Asian and Oceanic Society of Nuclear Medicine,

SNM Asia tours, two international nuclearmedicine conferences in China, N 1806

Astrocytomas, cisplatin studies, drug metabolism,595(ab)

Atherosclerotic lesions, experimental, aorta,rabbit, 610(ab)

Atrial natriuretic factor, Tc-99m DTPArenography and, Goldblatt hypertension,734(ab)

Attenuation correctionabsolute quantification, tumor activity, 577(ab)accuracy ofSPEC1', simultaneous transmission

and emission tomography, 677(ab)direct determination, radionuclide volume

measurements, 1363(le)high-resolution PET, heart, 696(ab)improved SPECT, simultaneous emission and

transmission tomography, 844non-isotropic

compensation in SPECT, 66l(ab)SPECT, 1584

nonuniform, correction improvement inSPECT, 661(ab)

SPECT, l925(le)convolution algorithm that compensates for,677(ab)

Tc-99m emissions, water, 678(ab)Automated edge detection technique

intracoronary thrombolysis, 135(le)leftventricularvolumes,ejectionfractionsand,

radioisotope angiography, 677(ab)Autoradiography

cerebral blood flow tracers, Tl-201 and 1-123IMP, 481

difference images used in, 631(ab)digital

comparison of measurements, 409(ab)solid-state image analyzer, 218

quantitative, microcomputer image analysissystem, 679(ab)

triple label digital, Tc-99m HM-PAO as a tracerfor cerebral blood flow, 559(ab)

whole-body, colonic cancer localization withmonoclonal antibodies, 683(ab)

Avascular necrosis, magnetic resonance imagingin diagnosis, potential pitfalls, 1052

Avidinbinding, radioiodinated biotin derivatives, 1430imaging applications, 1294, 560(ab)

AVIdID-bIOtInchelate system, imaging tumors,722(ab)

B

Back pain, evaluation and improvement, SPECT,564(ab)

Bacterial growth, radiometric assay, 209Benzazepine, up-regulation ofcardiac beta

receptors, cardiomyopathy, 666(ab)Beazoates, 4-1000-, protein labeling, 725(ab)Benzodlazepine

derivatives, F-l8 fluoroethylation, 727(ab)receptor-bindingligands, iodinated peripheral,

726(ab)Billary stream, cholescintigraphy value in, 7l6(ab)Billary obstruction, transient, sequential

hepatobiliary scintigraphy, 1775Billary tract, operative reconstruction, 01 dual

radionuclide method, 660(ab)

thallium and rubidium uptake, 878portal, Tc-99m pertechnetate per-rectal portal

scintigraphy, 689(ab)pulmonary, normal regional distribution,

SPEC!', 1758renal

first-passanalysis using aorta, 405(ab)non-invasive measurement, Tc-99m DTPA,

646(ab)transit times, technetium-radiolabeled

chelates, 1134skeletal muscle

C-l 1 MB, starvation effects, 650(ab)Rb-82, glucose, insulin, and exercise effects,1155

splenic artery and vein resection, pancreas organdonation, 638(ab)

11-201 uptake and, heart, 399(le), 400(le)workload effects, myocardial uptake of Tc-99m

RP-30 and 11-201, 666(ab)Blood-pool Imaging

cardiac, cost-effective, PC-based system, 669(ab)experimental frostbite, intravenous

streptokinase, rabbit, 606(ab)gated cardiac, regurgitant fraction of left

ventricle, 19hepatic hemangiomas, 1683ionic and nonionic contrast agent effects, Tc

99m RBC, 574(ab)mechanical left ventricular assistance,

myocardial infarction, 886nuclear angiograms, sequential rest and exercise,

reproducibility of, 578(ab)portal hypertension, portosystemic collaterals in,

627(ab)Rb-82 cardiac studies, PET-acquired input

functions, validation of, 682(ab)regional left ventricular relaxation, myocardial

perfusion, impairment with rightventricular pacing, 672(ab)

sublingual nifedipine effects, forearm venouscapacitance, 717(ab)

subtractions, intracardiac thrombosis, In-l 11,639(ab)

Tc-99m DTPA, pare-axial neurofibromatosis,1688

Blood pressure, systolic, light exercise inmyocardial ischemia, 672(ab)

Blood volume, end-systolic, light exercise inmyocardial ischemia, 672(ab)

Blue Cross/Blue ShIeld, bone densitometry assertsclinical role despite lack of reimbursement,N267

Bonebiopsy, guided aspiration, 550(ab)bone densitometry asserts clinical role despite

lack ofreimbursement, N267colddefects,In-i11leukocyteimaging,820dual-photon absorptiometry, spine, 665(ab)dynamic scanning, diabetic osteoarthropathy,

664(ab)ectopic, uptake ofTc-99m MDP, rats, 665(ab)femoral component, prosthetic hips, dual

isotope arthrography, 565(ab)femoral head

aseptic necrosis, SPED' and MRI, 564(ab)following acetabular fracture, 664(ab)

fluoride, detection by NMR, 703(ab)graft, SPED' bone scintigraphy, 564(ab)growth plates, surgical closure, scintigraphy,

7l6(ab)high dose methotrexate and Tc-99m MDP,

diffuse hepatic uptake, 532infections

Biopsyfine needle aspiration, thyroid nodules, 575(ab)guided aspiration, bone, 550(ab)

Blotinimaging applications, 1294, 560(ab)radioiodinated derivatives, radioassays, 1430

Bladder, GFR, intravesical pressure effects,716(ab)

Bloodflowbone, increased extremity uptake in scanning

and, 108cerebral

abnormalities following subarachnoidhemorrhage, 634(ab)

arterial blood dispersion effects, PET, 656(ab)compartmental model with Tc-99m HM

PAO, 559(ab)copper radiopharmaceuticals for PET,

722(ab)C-I 1 pyruvate metabolism, Alzheimer's

disease, 700(ab)defects in chronic cocaine users, 655(ab)1-123 1MB distribution, cognitive challenge

and, 592(ab)1-123 iodoamphetamine SPECT, 6l9(ab)1-125 IMP binding and subcellular

distribution, 702(ab)infarct hyperemia, Tc-99m HM-PAO, 633(ab)Kanno-Lassen algorithm for, 262(ab)local studies in PET, 1695measurements with SPECT, schizophrenia,

698(ab)noninvasive quantitative assessment, 558(ab)PET measurement techniques, 587(ab)potential agents for measurement, PET,

l34(le)prazosin treatment, elderly patients, 623(ab)pre-operative mapping of function, PET,

646(ab)quantitative assessment with Tc-99m HM

PAO, 559(ab)single-photon tomographic study, 633(ab)SPECT, cerebrovasculardisease, 600(ab)SPECT measurements, arteriovenous

malformations, 59l(ab)SPECF with xenon-133 and 1-123, 570(ab)SQ 32,097, 592(ab)stroboscopic stimulation, 702(ab)subcortical stroke, SPECT, 699(ab)Tc-99m DADT, 594(ab), 73l(ab)Tc-99m HM-PAO, 191, 407(ab), 701(ab)Tc-99m HM-PAO SPECF, Wade test and,

592(ab)Tc-99m SQ 32,097 synthesis, 592(ab)Tc-99m triaminedithiol complex, 1064(le)11-201 DDC imaging, 178unstimulated 14 minute period, PET, 700(ab)

coronary stenosis, Tl-20l SPED'determination, 666(ab)

hepaticnew measurement method, 628(ab)portosystemic shunts in portal hypertension,

628(ab)radionuclide angiography, SSl(ab)Tc-99m pertechnetate per-rectal portal

scintigraphy, 689(ab)Kanno-Lassen algorithm for estimating,

tomographic diffusible tracer clearancecurves, 407(ab)

myocardialhypertrophic cardiomyopathy, N-13

ammonia measurement, 567(ab)RB-82 tissue kinetics and compartmental

model, 558(ab)

1945Subject Index â€¢1987

diagnosis by radioimmunoscintigraphy,585(ab)

In-l 11 WBC vs. other methods, 586(ab)infraction of second metatarsal, scintigraphic

manifestation, 249In-l 11 leukocytes and, culture proven acute

osteomyelitis, 694(ab)malignant disease, samarium-153 EDTMP and,

505metastatic pain, treatment with Strontium-89,

553(ab)mineral density

caucasian female volunteers, 664(ab)comparison in both hips, 629(ab)dual-photon absorptiometry, 629(ab)endometriosis, 628(ab)errors in longitudinal measurements, dual

photon absorptiometry, 1751femoral, ROl size and angulation effects,1793(ab)

gamma camera measurement, 629(ab)medullary thyroid carcinoma, 685(ab)prolonged maintenance hemodialysis effects,

630(ab)regional differences in lumbar spine, 663(ab)spinal, loss with inactivity, 260(ab)stress fracture with prior anorexia nervosa,

1506(le)trabecular and cortical contents, 686(ab)xenon multiwire proportional counter,

64l(ab)mineral loss, femur, spinal cord injured patients,

l792(ab)multiphase scanning, postprandial blush in,

1550non-infected closed fractures, In-i 11 WBC

uptake, 586(ab)primary cancer, Sm-153-EDTMP as a

radiotherapeutic agent, 709(ab)quantitative scintigraphy, hyperparathyroidism,

458regional measurements, osteoporotic fractures of

spine and distal forarm, 960scanning

adductor insertion avulsion syndrome, 1835bacterial lumbar spondylitis, 254(le)delta sign in, l229(le)increased extremity uptake, ischemia and,108

pathophysiology, 585(ab)rheumatic disorders, 262(ab)

scan/positive findings, breast cancer, 606(ab)scintigraphy

comparison with NMR, spinal lesions,590(ab)

insufficiency fractures and, 605(ab)patellar tendonitis, 1768

skeletal tuberculosis, resembling metastaticdisease, l507(le)

sternal lesions, breast cancer, 606(ab)stress fractures,interpretation of scintigraphic

findings, 452Tc-99m DTPA uptake, blood clearance and,

1461tertiaro syphilis involving, radionuclide imaging

in, 1047therapeutic agents, Sm-l53, 495three-phase scintigraphy, osteochondritis

dissecans, 605(ab)trauma, Tc-99m phosphonate imaging,

glucocorticoid effects, 606(ab)triple phase scan

simultaneous In-i 11 WBC, neuropathic footdisease, 649(ab)

tissue viability in frostbite injury, 665(ab)upright spine, scintigraphy, 664(ab)

Bone densitometrybone densitometry asserts clinical role despite

lack of reimbursement, N267OHTA advises HCFA to deny Medicare

coverage for SPA, DPA, N 1656Bone marrow

investigation, Tc-99m microcolloid and MRI,malignant lymphom disease, 705(ab)

involvement in hairy cell leukemia, NMR,690(ab)

In-111 WBC as an imaging agent, 574(ab)metastases

detection, examination of liver withradiocolloid and, 184

liver examination with radiocolloid, l640(le)transplantation, 1-131 antimyeloid monoclonal

antibodies, 692(ab)Book reviews

BoneScanningin ClinicalPractice,1643CardiacImaging:New Technologiesand

ClinicalApplications,929EssentialsofNuclearMedicineScience,1511Immunoscintigraphy,258Introductionto RadiologicalPhysicsand

RadiationDosimetry,1066MagneticResonanceImagingandSpectroscopy,

1367MagneticResonanceImagingofthe Central

NervousSystem,1232MagneticResonanceImaging:Principlesand

Applications,140MagneticResonanceofthe Musculoskeletal

System,1511NCRP Report91:RecommendationsonLimits

for Exposureto IonizingRadiation, 1929NMR in Medicine:TheInstrumentationand

ClinicalApplications.AAPM MonographNo.14,1232

NuclearCardiacImaging:PrinciplesandApplications,1066

NuclearMagneticResonanceImaging inMedicineand Biology,1928

NuclearMedicinein ClinicalOncology,548NuclearMedicinein UrologyandNephrology,

929

NuclearMedicineTherapy,1233NuclearPharmacy,1784NuclearTechniquesin DiagnosticMedicine,

1511NumericalRecipies:TheArt of Scientific

Computing,547PatientIrradiation in DiagnosticNuclear

Medicine,1985,257PET and NMR: New Perspective in Neuro

Imagingand in ClinicalNeurochemistry,1784

Physicsand EngineeringofMedical Imaging,1784

Physicsin Medicineand BiologyEncyclopedia,139

Physicsin NuclearMedicine,930Progressin Radiopharmacy,1368RadiationRisksto theDevelopingNervous

System,1233RadioactiveWasteâ€”Proceedingsofthe Twenty

FirstAnnualMeetingofthe NationalCouncilonRadiationProtectionandMeasurements,258

RadionuclideImagingofthe GI Tract, 1928RadionuclideImaging Techniques,1367Radiopharmacyand Radiopharmacology

Yearbook,257

SPECTSingle-PhotonEmissionComputedTomography:A Primer, 548

TableofRadioactiveIsotopes,140Technetiumin Chemistryand Nuclear

Medicine, 1643TheNuclearWastePrimerâ€”AHandbookfor

Citizens,2581986 YearbookofDiagnosticRadiology,1391986 YearBookofNuclearMedicine,547

Boundary determination, organ, SPED'visualization, 334

Bowel disease, inflammatory, isotopic index ofdisease activity, 688(ab)

Brainabnormal PET, early Alzheimer's disease,

645(ab)acute infarction, Tc-99m HM-PAO SPED',

622(ab)aging and dementia, PET, 431astrocytoma, Tl-201, 706(ab)blood flow. See Blood flow, cerebralblood flow tracers, Tl-201 DDC and 1-123 IMP,

481

blood perfusion, Tc-99m HM-PAO, 191caudate D2 dopamine receptor density, PET,

700(ab)cerebral extraction efficiency, Tc-99m oxine

complexes, 729(ab)cerebrovascular disease, Tc-99m HM-PAO and

RBC SPED', 600(ab)C-i 1 eticlopride synthesis, PET, 625(ab)C-i 1 L-methionine accumulation, PET, 645(ab)C-i 1 pyrilamine, synthesis and biodistribution,

624(ab)comparative imaging, 1-123 amphetamines and

Tc-99m HM-PAO, 569(ab)complex partial seizure foci, SPED' 1-123

HIPDM imaging, 600(ab)cortical and subcortical metabolism, anxiety

effects, normals and schizophrenics,655(ab)

cryptogenic West syndrome, Xe-l33 SPED' in,592(ab)

D2 dopamine receptorsF-18 fluoroalkylated spiperones, 612(ab)manic-depressive patients, 61 l(ab)primates, 61 l(ab)

deanol removal, C-i 1 choline, 136(le)delayed scan, 1-123 IMP SPED', 559(ab)demented patients, Xe-133 inhalation SPED',

599(ab)dopamine and serotonin receptors, equilibrium

binding kinetics, 61l(ab)fluorodeoxyglucose metabolism, deoxyglucose

tissue concentration with F-19 NMR andF-18 PET, 655(ab)

gliomas, PET evaluation of, I 123glucose metabolism

aging, systemic health factors in, 60l(ab)F- 18 deoxyglucose studies, 53, 1667schizophrenia on and offmedication, 702(ab)

glucose transport, 1-123 IBG SPED' studies,57 l(ab)

high resolution SPED' imagingastigmatic collimator, 576(ab)cone beam collimator, 577(ab)fan beam collimator, 576(ab)1-123HIPDM, with fan beamcollimation,

570(ab)Huntington's disease, glucose metabolism and

DNA polymorphism studies, 655(ab)IBZM and NMSP in, D-2 dopamine receptor

binding of, l930(ab)1-123 HEAT, radiation dosimetry of, 1745

1946

Bone densitometry

The Journalof NuclearMedicine

Cerebrovascular disease

1-123 HIPDM, radioactive iodine exchangereaction, 360

1-1231MB distribution,cognitivechallengeand,592(ab)

1-125 IMPbinding and subcellular distribution, 702(ab)diagnosis ofischemia vs. infarction, 409(ab)distribution, temporal changes in, 623(ab)images, Metz filters for processing, 677(ab)

imaging1-125 IPPA preparation and biodistribution,

57 l(ab)SPED' 1-123IMP,aphasicsvs. normals,

559(ab)intracranial hemorrhage, CK-BB levels,

premature infant, 7l8(ab)lead-203 DDC, perfusion agent, mice, 723(ab)local, quantitative visualization, 698(ab)lumped constant, deoxyglucose model, 471MAO-B activity, C-i 1 DMPEA kinetics, 1006N-nitrosourea synthesis, tumor, 625(ab)perfusion imaging, 1364(le)perfusion imaging agents, SPED', 1012perfusion SPED', Tc-99m HM-PAO, 569(ab)PET

C-l 1 deprenyl, baboon, 624(ab)copper radiopharmaceuticals, 407(ab)

prazosin treatment, elderly patients, 623(ab)radioligand-neuroreceptor interaction, four

compartment model, 681(ab)refractory neonatal seizures, PET in surgical

selection, 646(ab)â€œslicesoflife,â€•scientific highlights, SNM 34th

Annual Meeting, 1987, Nl235structures on O-15-H20 PET scans, NMR and

stereotactic method comparison, 702(ab)study of two behavior states, PET/FDG

procedure, 852synthesis, radiopharmaceuticals, 635(ab)Tc-99m HM-PAO

decomposition, aqueous media, 593(ab)kinetics, first minutes after injection, baboon,593(ab)

vs. 11-201 DDC, subcellular distribution,593(ab)

Tc-99m HM-PAO SPED'epileptic patients before and during Wade

test, 1763initial experience with, 1657

Tc-99m scintigraphy, 1787(ab)11-201 scintigraphy, increasing specificity,

658(ab)tomoscintigraphy, subacute strokes, Tc-99m

HM-PAO and 1-123 IMP, 623(ab)tumors

characterization by parametric imaging ofblood volume, FDG and metabolism,645(ab)

F-18 FDG grading system, 594(ab)methionine and leucine incorporation,595(ab)

primary, Tc-99m HM-PAO SPED', 59l(ab)Tl-201 imaging, 47

xenon-133 and 1-123 SPED', comparison,570(ab)

Brain death, scintigraphic evaluation, 1279Brake radiation, Y-90, anthropomorphic

phantom, 684(ab)Breast

cancerscan positive/radiograph negative bone

findings, 606(ab)sternal lesions in, 606(ab)

carcinoma

assessment of estrogen receptors, 56l(ab)1-131 monoclonal antibody

radioimmunotherapy, 573(ab)internal mammary grafts, Xe-l33, 632(ab)milk, suppression ofTc-99m pertechnetate by

perchlorate, 1187P-3l spectroscopy, 599(ab)tumors, radiolabeled bacterial

immunomodulator, 658(ab)Bromine-BOrn, labeled estrogen receptors, synthesis

and biodistribution, 572(ab)Bronchial asthma, remission, clearance of

radioaerosols by bronchodilation, 1901Bronchodilation, deposition and clearance of

radioaerosols, bronchial asthma inremission, 1901

Brucer, Marshall, Marshall Brucer still full ofacerb wit 30 years after serving as SNMpresident, fight against societal radiationphobia, Nl645

BUdd-ChI*rI syndrome, typical and atypicalscintigraphic aspects, 803

C

Cakitoninradiolabeled monoclonal antibody to,

localization in meduliary thryoidcarcinoma, 263(ab)

stability, commercial radioimmunoassay kit,718(ab)

Calcium-45, Tc-99m MDP uptake and, ectopicbone, rats, 665(ab)

Calibrator, dose, varying geometry effects, 1478Cal Bad Forum, Cal Rad Forum, workshop, low

level radioactive waste, Nl382Canada

Commentary: rationale for â€œSNMin Canadaâ€•,NlO

Etienne LeBel recognized for leadership inCanadian nuclear medicine, N791

Cancer, hepatic indwelling, drainage patterns,hepatobiliary imaging, 1055

Captoprilradionuclide renal studies, renovascular

hypertension, 1789(ab)renography, 733(ab)

Goldblatthypertension,1171renal baseline function and, 6l2(ab)renovascular hypertension, 613(ab), 735(ab)

scintigraphic test, renovascular hypertension,613(ab)

single-dose, renovascular hypertension, 1383Tc-99m DTPA studies enhanced by,

renovascular disease, 613(ab)Carbohydrates, IgG residues, alteration by

radioiodination and radiochelation, 560(ab)Carbon-li

brain pH measurement, PET, 698(ab)thymidine labeled with, dosimetry estimates for

PET studies, 683(ab)Carbon-il MB, starvation effects, skeletal muscle,

650(ab)Carbon-il BMHDE

saturated and unsaturated, structure localizationrelations, 727(ab)

synthesis, biological evaluation and, 728(ab)Carbon-li carbon dioxide, preparation from C-li

cyanide, 636(ab)Carbon-il-carboxyl-labeled L-dopa, routine

synthesis, 1599Carbon-li choline, deanol removal, 136(le)Carbon 11 deprenyl, PET, brain, baboon, 624(ab)Carbon-li diprenorphine, PET, studies of opiate

receptors, 635(ab)

Carbon-li DMPEA, kinetics, brain MAO-Bactivity, 1006

Carbon-il eticlopride, synthesis, PET, 625(ab)Carbon-li IBZ, synthesis, D2 dopamine receptor

imaging, 726(ab)Carbon-il leuclne, cerebral protein synthesis,

PET, 587(ab)Carbon-il methionine, primary lung cancer

relations, PET, 658(ab)Carbon-il methyl benzazepine, synthesis,

reductive carboxylation approach, 625(ab)Carbon-li methyl iodide, synthesis, 1037

origin ofcarrier in, 728(ab)Carbon-il methylketanserin, PET and,

localization of serotonin-2 receptors,600(ab)

Carbon-il nitromethane, radiolabeing precursor,636(ab)

Carbon-il pyruvate, metabolism, cerebrum,Alzheimer's disease, PET, 700(ab)

Carbon-il SCOP, radiosynthesis of, from C-liformaldehyde, 635(ab)

Carbon-li thymidine, development, PET imagingagent, 728(ab)

Carbon-l4 amino acids, parathyroid glandautoradiography, 1447

Carbon dioxide, labeling blood cells, 1020Carclnoembryonlc antigen (CEA)

anti-monoclonal antibodies,radioimmunodetection ofcancer, 652(ab)

false-positive, anti-murine antibody withmonoclonal antibodies, 615(ab)

In-li 1, radioimmaging oftumors, 637(ab)kinetics ofmonoclonal antibodies, 693(ab)Tc-99m monoclonal antibody, labeling of

proteins, 721(ab)uptake, colorectal cancer, 637(ab)

Carcinoid syndrome, 1-131 MIBG diagnosis,658(ab)

Carcinoma, medullary, thyroid, Tc-99m DMSA,561(ab)

Cardiac monitoringambulatory device, left ventricular dysfunction

in CAD, 609(ab)left ventricular, dual cadmium telluride

detectors, 609Cardiac output, first-passradionuclide

determination, gamma camera, 1330Cardlomyopathy, hypertrophic, myocardial blood

flow measurement using N-13 ammonia,567(ab)

Cardiopulmonary blood volume, venous pumped,staged maximal exercise and, 650(ab)

Cardiovascular Council, SNM councils report atWinter Meeting, N802

Cardiovascular disease, SPED', 1-123iodoamphetamine, 622(ab)

Carotid artery, 1-131 monocional antibodyadministered through, glioma, 603(ab)

Carotid atherosclerosis, antithrombotic drugeffects, platelet deposition, In-i 11 plateletsand Tc-99m HSA, 701(ab)

Cations,heart,chemistryof, 1351Cerebellum, glucose metabolism, fluorine-18 FDG

and PET, 1667Cerebral infarction, focal hyperemia in,

demonstration with 1-123 IMP, 1920Cerebral lschemia

clinicaloutcome,metabolicand structuralabnormalities and, 633(ab)

1-123 IMP, Tc-99m HM-PAO SPED' and,623(ab)

study ofregional blood flow, SPED', 633(ab)Cerebrovascular disease, 1-123 1MB and Tc-99m

1947SubjectIndexâ€¢1987

Colon, transit, dietary fiber effects, colonic transitscintigraphy, 660(ab)

Coionk ca@nomamonoclonal antibody localization, tumor

seeking agents, 709(ab)monoclonal anti-colon/ovarian antibody,

potential imaging agent, 710(ab)Colonic transit scintigraphy, colonic transit,

dietary fiber effects, 660(ab)Colorectal cancer, uptake ofln-l 11 anti-CEA,

biological factors, 637(ab)Colorectal carcinoma

colorectal, detection with 1-131 anti-CEA,708(ab)

intra-arterial chemotherapy, Tc-99m MAAhepatic arterial perfusion pattern in,708(ab)

Commercial Services Council, SNM petitions fornew councils: NMR and CommercialServices, N801

Committee on Nuclear and RadiOCheinIstry,Committee on Nuclear and Radiochemistryexplores nuclear medicine issues, trainingrequirements for nuclear medicinechemists, N1519

Communication systems, picture archival and,1786(ab)

Computed tomographyadrenoleukodystrophy, 524attenuation, scatter and PSF correction,

elimination ofnon-stationary effect,660(ab)

three dimensionalcorrelations,PET and MRI,682(ab)

Computer CouncilSNM Computer Council plans buyers' guide,

N154SNM councils report at Winter Meeting, N802

Computerization, SNM Instrumentation Councilpromotes electronic mail, N 1656

Computersartificial intelligence comes to the clinic,

1788(ab)deconvolution dynamic scintigraphic studies,

functional images and partition blood flow,619(ab)

endocardial motion, myocardial thickening and,gated perfusion imaging, 618(ab)

expert systems concepts, 680(ab)gamma variate formation, 680(ab)gated blood-pool analysis, 618hough-like transformation, detection of partially

visible contours, 675(ab)lung index, Ga-67, interstitial pneumonitis,

1826lung scans, UCLA data base, 584(ab)optimal collimator resolution, complex

estimation, 680(ab)recent advances, 1786(ab)regional cerebral blood flow, 1-123

iodoamphetamine SPED', 6l9(ab)regional counting statistics, scintigraphic image

differences, 619(ab)11-201 SPED' imaging, feature extraction in,

6l8(ab)Computers, software

algorithm reconstruction, SPED', 566(ab)cardiac clinical database, archiving nuclear

imaging data, 652(ab)compartmental model, antibody dosimetry,

617(ab)cost-effective PC-based system, bedside cardiac

blood-pool processing, 669(ab)cross-correlation function, patient motion

during SPED' imaging, 97data collection methods, error-free, PA@S,

652(ab)3D display ofarterial structure, myocardial

perfusion distribution, 675(ab)diastolic shape deformity, equilibrium

radionuclide angiography, 557(ab)digital autoradiography, solid-state image

analyzer,218expert system shells, MS-DOS based

microcomputers, 679(ab)factor analysis and condensed image,

interpretation of lymphoscintigraphy,716(ab)

gamma camera, bone mineral measurement,629(ab)

gastric emptyingliquid and solid, equivalence, 563(ab)new math for an old test, 563(ab)

generalized dosimetry schema, tumor uptake ofmonoclonal antibodies, 680(ab)

high resolution PET, stationary-sampling,607(ab)

image analysis system, quantitativeautoradiography, 679(ab)

interactive visual optimization, SPED', 1192linear and nonlinear compartmental models,

techniques, 653(ab)mapping of FDG rate constants, myocardium,

682(ab)modified Iowa heart phantom, SPED' defect

detectability, 643(ab)multivariate segmental pattern recognition,

coronary artery disease, 676(ab)noise power spectrum, SPED', 630(ab)nuclear cardiac imaging, IBM PC, 679(ab)pressure-volume loop determinations, left

ventricular function, 676(ab)radionuclide gastric emptying studies, anorexia

nervosaand, 816regional wall motion, probabilistic image,

676(ab)resolution recovery, SPED', 566(ab)systems approach, information collection,

PA@S,652(ab)T4/5 functional image, derivation and

properties of, 676(ab)three-dimensionalspatially-variantpointspread

function, SPED', 662(ab)treatment ofaxial data, three-dimensional PET,

1717ventilation studies, Xe-l33, 616(ab)ventricular wall motion simulation, finite

element method, 557(ab)Concanavalln-A, molecular presentation of

immunoglobulins, radiolabeling effects on,560(ab)

Cone beam detector system, SPED', estimatingparameters of, 661(ab)

Continuous ambulatory peritoneal dialysis, Tc-SCintraperitoneal scan in, 1930(ab)

Copper, PET measurement and, cerebral bloodflow, 722(ab)

Coronary artery bypass surgery, myocardialfunction and, 1791(ab)

Coronary artery disease (CAD)amyl nitrite inhalation, thallium imaging and,

597(ab)automated edge detection technique, 135(le)blood flow,sublingualnifedipineeffects,

609(ab)cardiac free fatty acid metabolism, after

submaximal exercise, 671(ab)combined perfusion-function imaging, 597(ab)

HM-PAO distribution, early and lateSPED', 591(ab)

Cedificadon, ABNM adopts recertification policy,N280

Charged particle camera, high resolution charged,stable isotopes in cells and tissues, 697(ab)

Chelating agentsavidin-biotin system, imaging tumors, 722(ab)bifunctional

In-il 1 bimane potential for, 657(ab)In-i 11 entrapment in liver, 657(ab)In-i 11 fragment El, 657(ab)

CE-DTS, localization ofTc-99m in tumorxenografts, 720(ab), 730(ab)

In-i 11 monoclonal antibodies, humanneutrophils, 720(ab)

selective bifunctional, antibody modification,Ga-67(ab)723(ab)

Chemotherapy, malignant brain tumors,assessment with cisplatin PET, 1844

ChernobylChernobyl, decontaminate world threatened by

fallout, risk misperception, N933Chernobyl, physicians' role examined in

planning response to nuclear accidents,N413

Commentary: Chernobyl predictions and theChinese contribution, long-term healtheffects, N423

lessons from, l790(ab)thyroid screening oftravelers after, 1-131, 535

China, SNM Asia tours, two international nuclearmedicine conferences in China, N 1806

Cholecystitis, cholescintigraphic diagnosis,morphine in, 596(ab)

Cholecystokinin, analogues, comparison by RIAand RRA, 568(ab)

Cholesclntlgraphycholecystokinin,fundaladenomyomatosis,1771reliability,biliaryatresia,716(ab)rim sign in, 1679

Cborlogonadotropln, immunoassay for, discordantinter-kit results, 719(ab)

Chromatography, lectin affinity, detection ofradiolabeled igG carbohydrateperturbations, 265(ab)

PET, chemotherapy assessment, malignant braintumors, 1844

Cobait-57, dose calibrator response, varyinggeometry effects, 1478

Cocaine, chronic users, cerebral blood flow defectsin, 655(ab)

Coincidence timing, improved, estimation theory,695(ab)

Collimatorastigmatic, high resolution SPED', brain,

576(ab)cone beam

3-D SPED' images, variance distribution in,678(ab)

high resolution SPED', brain, 577(ab)fanbeam

high resolution 1-123 HIPDM SPED', brain,570(ab)

high resolution SPED', brain, 576(ab)In-i 11 SPED', development of, 696(ab)optimal resolution, complex estimation, 680(ab)pinhole

metastasis, fracture, and infections of thespine, 447

transverse SPED', 678(ab)slant and parallel hole, measurement, SPED',

1592COHOIdshift, following trauma, 1366(le)


Certification

comparative assessment, exerciseelectrocardiography and ventriculography,589(ab)

3D display ofarterial structure, myocardialperfusion distribution, 675(ab)

detection, analysis of ventricular filling, 837diabetics,dypyridamolethalliumscintigraphy,

l780(ie)dipyridamole

peripheral hemodynamic response, 580(ab)TI myocardial SPED' following, 408(ab)

dipyridamole thallium studies, improved criteriafor interpretation, 580(ab)

evaluation ofextent, Tc-99m MIBI, 655(ab)exercise thallium scintigraphy, antianginal

medication effects, 644(ab)factoranalysisassessment,radionucide

ventriculography, 666(ab)first-pass radionuclide angiography, gamma

camera and Ta-l78, 663(ab)following myocardial infarction, Tl-201

rotational tomography, 674(ab)indices of left ventricular function, combined

diagnosis, 671(ab)left ventricular diastolic function, age-related

changes, 670(ab)left ventricular dysfunction

ambulatory cardiac monitoring device,609(ab)

chestpainrelations,671(ab)patients with unstable angina, 672(ab)

left ventricular functional recovery, afterexercise, 579(ab)

mental stress and, ventriculography, 597(ab)multivariate segmental pattern recognition,

gated blood-pool studies, 676(ab)myocardial perfusion reserve, changes after

PTCA, 1262normal Tl-20l images, strongly positive exercise

ECO and, prognosis, 643(ab)prediction ofdeath and myocardial infarction,

exercise ECG and 11-201 scintigraphy,644(ab)

thallium scan defects, small localized, 643(ab)Tl-20l imaging

alternatives to dynamic exercise for, 1788(ab)emission tomography, oral dipyridamole,

579(ab)lung/heart ration of, 1531planar studies, new approach to

interpretation, 588(ab)11-201 and Tc-99m MIBI, quantitative

comparison, 654(ab)Coronary heart disease, Tc-99m RP-30, 11-201

comparison, 620(ab)Coronary reperfusion, imaging with Tc-99m MIBI,

comparison with microspheres, 620(ab)Corrections

appendixtoarticleon 1393, 1927extrapulmonary radioactivity in lung

permeability measurements, 1509figuresmislabledon 1471, 1783figureson 526,1065metoclopramide misspelled, 1640table ofcontents, April issue, 928, 1065

Cortical perfusion Index, evaluation of coldstorage and immunosuppression, renalallografts, 73l(ab)

Council of Medical Specialty Societies (CMSS),organized medicine in a destabilized era,Nl247

Counting stathtics, regional, scintigraphic imagedifferences and, 619(ab)

C-reactive proteins, In-i 11granulocyte

scintigraphy, 155Creatine phosphokinase-MB, screening test,

myocardial infarction, 568(ab)Creutzfeldt-Jakob disease, 1-123 HIPDM brain

imaging, 1484Crohn's disease, deal dysfunction in, 75-SeHCAT

test for diagnosis, 688(ab)Cystography, nuclear, 264(ab)

D

Deconvolution analysisapplication to dynamic Tc-99m DTPA, 734(ab),

735(ab)hepatobiliary SPED', 689(ab)

Delta sign, bone scan, 1229(le)Dementia

abnormalPET,earlyAlzheimer'sdisease,645(ab)

aging and, brain, PET, 431AIDS complex, FDG/PET correlates of

neuropsychological test scores, 600(ab)SPED', Xe-133 inhalation, 599(ab)vasoreactivity in, 407(ab)

Densitometry, bone, trabecular and corticalcontents, 686(ab)

2-Deoxy-D-glucose, PET studies, cerebralmalignancy, 1251

Department of Energy (DOE)Los Alamos, conflict between radioisotopes and

neutrinos resolved, Nl378physics experiment may cloud future of Los

Alamos nuclear medicine program,proposals for dedicated radionuclideproduction facility, N1371

SNM testifies in Congress on DOE researchfunding, DOE offers grants forepidemiologic studies, N1249

Detectorscontinuous two-dimensional position-sensitive,

high count rate performance of, 607(ab)semiconductor, left ventricular monitoring,

609(ab)Dextran 110, MRI tumor-enhancing agent,

melanomas in nude mice, 704(ab)Diabetes, insulin immunized patients,

abnormalitiesofl-123 insulinbiodistribution, 583(ab)

Diagnosis-related groups (DRGs). See ProspectivePayment System (PPS)

Diagnostic centers, free-standing, 1789(ab)Diethylpyrocarbonate, labeling blood cells, 1020Digital image filtering

SPED'interactive visual optimization, 1192Mets restoration filter, 565(ab)

Digoxin, assay, renal failure, newborns, andinfants, 261(ab)

Dipyridamoleexercise and, 11-201 uptake, myocardial

ischemia, 580(ab)infusion

changes with and without exercise, 579(ab)peripheral hemodynamic response, 580(ab)11-201 and, improved criteria for

interpretation, 580(ab)intravenous administration

elderly patients, 670(ab)thallium in conjunctionwith,children,

262(ab)oral, 11-201 emission tomography and, CAD,

579(ab)thallium scintigraphy, CAD in diabetics,

l780(le)11-201SPED'

coronary disease diagnosis, 642(ab)silent myocardial ischemia in, 580(ab)

Diuresis, volume expansion renal scan, urinarytract obstruction, 824

DObutainlie enoximone comparison, ventricularvolume, 669(ab)

Dopainine ID1Iantagonist, C-l 1 labeled, reductivecarboxylation approach, 625(ab)

Dopamine receptors

imaging, IBZM and NMSP in rat brain,1930(ab)

pituitary tumors, 626(ab)dynamic PET studies, F-i8, 587(ab)equilibrium binding kinetics, brain, 6l1(ab)measurement, manic-depressive patients,

61 l(ab)Do@

antibody, compartmental model of kinetics,617(ab)

blood radiation, acute toxicity oftherapeutic I-131 MIBO, 618(ab)

brake radiation dose, anthropomorphicphantom, 684(ab)

generalized schema, tumor uptake ofmonoclonal antibodies, 680(ab)

1-131 MIBO, pheochromocytoma, 687(ab)linear and nonlinear compartmental models,

computer simulations, 653(ab)photons/RAD ratios, tracer labels, 683(ab)quantitative autoradiography, micro-TLD

measurements and, 6l7(ab)radiation

brain distribution and, 1-125 HEAT, 582(ab)calculations ofsamarium-l53 EDTMP, 505ethiodol, treatment of teratoma, 582(ab)fetal, maternally administered I-131, 581(ab)1-123 excretion, breast milk, 544(le)1-123 HEAT, 1745, 1793(ab)1-131, hyperthryoid patients, 581(ab)1-131 thyroid screening, after Chernobyl

accident, 535lymphocyte radiolabeing, 1228(le)thyroid cancer, hematologic long-term

hazards, 58i(ab)SR-89, between patient variation in strontium,

683(ab)Tc-99m RBC, Criticalorgan, 684(ab)

DTPA complex, attachment of, protectivecomplex to prevent loss of In-I 11 fragmentEl activity, 657(ab)

Dual-photon absorptlometry (DPA)SeealsoAbsorptiometrybone den@tometry,trabecularand cortical

contents, 686(ab)bone densitometry asserts clinical role despite

lackofreimbursement,N267bonemineraldensity

caucasian female volunteers, 664(ab)comparisonin bothhips,629(ab)errors in longitudinal measurements, 1751femoral, ROI size and angulation effects,

1793(ab)healthy white and black females, 629(ab)prolonged maintenance hemodialysis, 630(ab)proximal femur, 629(ab)regional differences in lumbar spine, 663(ab)

OHTA advises HCFA to deny Medicarecoverage for SPA, DPA, N 1656

quality control techniques and artifacts, 550(ab)spine, scintillation camera, 665(ab)

Duodenogastric refiux, Ru-97 DISIDA and Tc99m sulfur colloid evaluation, 596(ab)


Duodenogastricreflux

hepatobiiary imaging, 660(ab)Environmental Protection Agency (EPA)

nuclear medicine community responds to EPAguidelines for indoor radon levels, cost/benefit analysis, epidemiologic studies,N1087

radon gas, radon daughters, pose potentialenvironmental hazard, linked to lungcancer, N 1095

Epilepsycomplex partial, comparative investigation,

702(ab)partial complex, vasoreactivity in, 408(ab)temporal lobe, regional opiate receptors and

glucose utilization, PET, 699(ab)unilateral hemispheric anesthesia, Tc-99m HM

PAO brain SPED' before and during, 1763Eplnephrlne, intra-arterial, hepatic tumor blood

flow, SPED', 659(ab)Epiphysiodesis, surgical closure ofgrowth plate,

scintigraphy, 716(ab)Esophageal emptying, radionudide studies,

oculopharyngeal muscular dystrophy,605(ab)

Esophagushepatobiiary imaging,scleroderma,387metaclopramide stimulation, progressive

systemic sclerosis, 810Ester bond, chemical modification with, antibody

tumor targeting by, 572(ab)Estimation theory, improved coincidence timing

through, 695(ab)Estradlol, gastric emptying and, 1204Estrogen receptors

Br-80m labeled, synthesis and biodistribution,572(ab)

F-l8 estradiol, breast carcinoma, 56l(ab)gastric function and, menstruating and

postmenopausai women, 604(ab)Ethlodol, radioiabeled, dosimetry of, teratoma

treatment, 582(ab)European Nuclear Medicine Congress 1987

European Nuclear Medicine Congress 1987,Budapest,Hungary,Ni 102

scientific highlights, European NuclearMedicineCongress 1987, Nl795

Exercisecapacity, noninvasive parameters for prediction,

congestive heart failure, 578(ab)dipyridamole infusion and, hemodynamic

changes, 579(ab)Expert system, 680(ab)Extracorporeal shock wave lithotripsy

pre- and post-, renal calculi, 1284renal function and hypertension after, 179l(ab)

F

Factor analysis, radiopharmaceuticals, 680(ab)Fats, gastrointestinal transit, 1-123 study of,

563(ab)Fatty acids

cardiac, metabolism, after submaximal exercise,CAD, 671(ab)

myocardialextraction, cardiomyopathy, 670(ab)extraction,hypertensiveheart disease,567(ab)

thallium imaging and, myocardial infarctionandischemia,632(ab)

Femoral headaseptic necrosis, SPED' and MRI evaluation,

564(ab)following acetabular fracture, avascular necrosis

vs. segmental impaction, 664(ab)Femur, mineral density, dual-photon

absorptiometry, 629(ab)Fever

In-ill granulocytescintigraphyin, 155undetermined origin, autologous In-l 11

leukocyte imaging in, 263(ab)unknown origin, oncology patient, In-I 11

leukocytesin, 648(ab)Fibrosis, interstitial, In-ill leukocyte diagnosis,

616(ab)First pass extraction, efficiency, scintigraphic

determination, 627(ab)Fluoride, bone, detection by NMR, 703(ab)Fluorlne-18

fluoroalkylatedspiperones,D2andS@receptorbinding, 612(ab)

lumped constant, deoxyglucose model, 471Fluorine-iS CF, naloxone preloading effects, PET,

701(ab)Fluorlne-18 deoxyglucose

cerebral glucose metabolism, test-retest studies,53

hexokinase and, no carrier added radiotracers,624(ab)

leukocyte accumulation, after reperfusion ofischemic myocardium, 6l0(ab)

PET, myocardial glucose uptake, dopamineeffects, 668(ab)

Fluodne-18 DGAL, PET, hepatocellularcarcinoma, 706(ab)

Fluorine-lB FESP, PET studies, primatedopamine-D2 neuroreceptor system,587(ab)

Fluorine-18 fluoride, no carrier added reactions,supporting salts for, 635(ab)

Fluorine-IS fluorocarboxylic acid ester, chemistry,634(ab)

Fluorine-lB fluorodeoxyglucosebrain metabolism, deoxyglucose tissue and,

655(ab)brain tumors, new grading system, 594(ab)functional imaging, head trauma, cerebellar

hypometabolismafter,699(ab)functional mapping of rate constants,

Alzheimer's disease, 699(ab)Ga-67 citrate comparison, lymphoma detection,

288glucose metabolism and polymorphism studies,

Huntington's disease, 655(ab)imaging ofmetastases, thyroid carcinoma, 910PET

cerebellar glucose consumption, 1667malignant gliomas, 645(ab)refractory neonatal seizures, 646(ab)

rate constants, PET mapping in myocardium,682(ab)

single PET procedure, study oftwo behaviorstates, 852

Fluorlne-18 fluorodopa, synthesis, regioselectivefluorodemercuration, 624(ab)

Fluorine 18 fluoroethylation, benzodiazepinederivatives, 727(ab)

Fluorine-iS fluorometaraminol, regioselectivesynthesis of, 624(ab)

Fluorine-iS fluoromlsonldazole, tumor hypoxia,594(ab)

Fluorine-iS fluoroprednisone, synthesis, neuroPET studies, 998

Fluorine-18 fluoropyridoxal, synthesis, 636(ab)Fluorlne-l8-N-methylspiroperidol, high dose

levels, radiolytic decomposition and, 60Fluorlne-18 progestin, synthesis and distribution,

animal studies, 625(ab)Fluorine-iS protein, reactions, 462Fluorlne-l8 receptor ligands, labeling agent,

E

Echocardiography, stress, postexercise wallmotion, 598(ab)

Edge detection, two-dimensional, filteredbackprojection image reconstruction,682(ab)

EditorialsPharmacokineticsandantibodies,1358Quantitative emission tomography, 922Renal scintigraphy in the evaluation of

renovascular hypertension: A note ofoptimism yet caution, 1501

Thallium washout analysis: Fact or fiction?,1058

The form and substance of science in ourjournals: With gratitude to the guardians,130

Thereadersspeakandtheeditorresponds:1986readership survey, 542

Education & Research FoundationE&R Foundation, student fellowships, N1250E&R Foundation plans permanent endowment,

N80lE@on fraedon

ageeffects,maximaluprightexercise,578(ab)ambulatory cardiac monitoring device, left

ventricular dysfunction in CAD, 609(ab)automated edge detection technique,

intracoronary thrombolysis, 135(le)biventricular, first-pass anger camera

radiocardiography, 950dobutamine infusion, pediatric patients, 621(ab)dual cadmium telluride detectors, left

ventricular monitoring, 609(ab)first-pass radionucide angiography, gamma

camera and Ta-l78, 663(ab)left ventricular, computer derived, gated

myocardial images, 662(ab)ventricular function, valvar regurgitation and,

aortic or mitral valve lesions, 621(ab)Electrocardlogram(EOG) gatlng, left ventricular

functional recovery, after exercise, CAD,579(ab)

Electrocardiography, exercise, T wavenormalization, 673(ab)

Electronic mail, SNM Instrumentation Councilpromotes electronic mail, N1656

Emergency department, chest pain, diagnosis ofmyocardial infarction, 598(ab)

Emission computed tomographyexercise, silent ischemia in, 589(ab)Gibbs model for, reconstruction algorithms

based on, 677(ab)maximum-likelihood reconstruction, noise and

edge artifacts, 566(ab)Mets restoration filter, image-dependent,

565(ab)segmental perfusion lung anatomy, 585(ab)sinograms, missing data, 565(ab)stress N-13 ammonia, 11-201 comparison,

myocardial ischemia, 567(ab)systematic errors in, selecting contrast

phantoms, 698(ab)Encephalopathy, subacute spongiform, 1-123

HIPDM brain imaging, 1484Endocardlum, motion, gated perfusion imaging,

6l8(ab)Endomefflosis, bone mineral density in, 628(ab)Energy weighted acquisition, 11-201 SPED'

imaging, myocardial, 577(ab)Englemann's disease, Ribbing's disease

comparison, 245Enoximone, ventricular volume and, 669(ab)Enterotest string, neonatal cholestasis, nuclear


Echocardiography

synthesis ofradiopharmaceuticals, 635(ab)Fluoromlsonldazole, uptake, ischemic

myocardium, 668(ab)N-(@'FIfluoropropyl)spiroperidoi, no-carder

added, biodistribution, 11645-Fluorouracil, F-i9 NMR studies with, drug

metabolism, 599(ab)Food and Drug Administration (FDA)

Commentary: Lines from the presidentradiodiagnostics, drugs, and the FDA,N 1804

FDA, separate centers for drugs and biologics,N 1806

FDA efforts to reduce radiopharmaceuticalreview time, advisory committee discussesregulation ofPET products, NI

FDA releases updated â€œpointsto considerâ€•forantibody products, N 1520

New members on FDA RadiopharmaceuticalDrugs Advisory Committee, N 1520

osmium-191/iridium-191m generator awardedorphan product grant, Nl54

quality assurance manual for scintillationcamera, Ni54

radiation committee terminated by FDA, N12Fosinopril, In-125 radioimmunoassay, human

serum, 568(ab)Friedenberg's disease, scintigraphic

manifestations, 249Frostbite, tissue viability in, triple phase bone

scan, 665(ab)

C

Gadoliniumphosphonate complexes

myocardial MRI and, 260(ab)NMR ofmyocardium, 406(ab)

Gadolinium-153bone densitometry asserts clinical role despite

lack ofreimbursement, N267chelates, mouse tumors, 705(ab)

Gadollnium-DTPAenhancement in early detection, acute

myocardial infarction, 704(ab)Mn-54 DTPA comparison, biodistribution, 349perfusion agent, myocardial, 871polymeric T70, MRI agent for melanomas in

nude mice, 704(ab)Gadolinium-159 EDTMP, localization, damaged

rat myocardium, 722(ab), 729(ab)Gallbladder

cholescintigraphy results, via morphineadministration, 595(ab)

differential contractility, fundaladenomyomatosis, cholecystokinincholescinitgraphy, 1771

motility, spinal cord injury, 596(ab)rim sign, cholescintigraphy, 1679

Galliumfollow-up, hepatocellular carcinoma, 1792(ab)lymphoid interstitial pneumonitis, children with

AIDS, 1915Gaillum-67

AIDSandARC, 1103AIDS-related lymphoma. 694(ab)antibody modification and radiolabeling,

bifunctional chelating agent in, 723(ab)chest scans, patients with AIDS, 1107citrate imaging, painful prosthesis, 926(le)emission tomography, asbestosis, 718(ab)high-resolution MRI, SPED' bone scintigraphy

comparison, temporomandibular joint,1268

In-i 11 chloride and WBC comparison, canine

osteomyeiitis model, 575(ab)inhibition of uptake, anti-human transferrin

receptor monoclonal antibody, melanoma,1303

lesion detectability, thresholds, 706(ab)lung uptake, AIDS patients, 1793(ab)MRI and, aortic root abscess, 1616radiophosphate visualization, total knee

prosthesis, 915relapsing Hodgkin's disease, non-Hodgkin

lymphoma and, 1611sarcoidosis, childhood, 716(ab)scintigraphy

AIDS, 648(ab)correlation with D' scanning, AIDS-related

lymphoma, 638(ab)thymic localization of, lymphoid and

nonlymphoid tumors, pediatric patients,293

11-201 uptake ratio, pulmonary neopiasms,707(ab)

total body, AIDS related complex, 402(le)uptake

chest, previous thoracic surgeryeffects, 1831inhibition by anti-human transferrin receptor

monoclonal antibody, melanoma, 603(ab)vs. In-l 11 DTPA, detection of metastatic

melanoma, 573(ab)Gallium-67 citrate

alpha-aminoisobutyric acid and, rat sepsismodel, 693(ab)

comparison with Tc-99m glucoheptonate,pulmonary malignancies, 442

F-18 FDG comparison, lymphoma detection,288

I-I 31 monoclonal antibody comparison,lymphoma detection, 7 13(ab)

lung index computerization, interstitialpneumonitis, 1826

primary pericardial mesothelioma detected by,1210

scintigraphy, renal disease and, 732(ab)vs. In-l I 1 porphyrin, detection of human

melanoma in athymic mice, 708(ab)Gallium-67 DD-fibrlnogen, arterial thrombus

detection, 639(ab)Galiium-67 -DFO-DAS-fibrinogen, prevention of

thrombus, following myocardial infarction,left ventricle, 609(ab)

Gallium-67 FIB, thrombus, left atrium, 691(ab)Gallium-67 Ifl000ClOflalantibodies

coupling agents, tumor targeting and, 7 i2(ab)versus In-i 11 monoclonal antibodies, human

melanoma detection, 1441Gallium-67 TPPS4, chemistry and distribution,

rabbits, 649(ab)Galiium-68 transferrin, PET, measurement of

pulmonary vascular permeability, 1704Gamma cameras

acceptance testing, quality control and, 1221bone mineral assessment

physical parameters of, 629(ab)planar and tomographic, 641(ab)

first-pass radionuclide determination, cardiacoutput, 1330

gastric emptying, liquid and solid, 563(ab)nodular thyroid disease, MR/RN correlation,

685(ab)SPED' systems based on, noise characteristics,

696(ab)Ta-178 and, first-passradionuclideangiography,

663(ab)xenon multiwire, improved scatter rejection,

698(ab)

Gamma variate function, simplified formulation,680(ab)

Ganglioside Gm monoclonal antibody, targeting toneuroblastoma, 1577

Gastric functionemptying

anorexia nervosa and, 816diabetic autonomic neuropathy and, 605(ab)Garren-Edwards Gastric Bubble effects,

604(ab)gender-relateddifferences, 1204lag phase, confirmation, 563(ab)liquid and solid, equivalence, 563(ab)liquid and solid, Tc-99m measurement,563(ab)

menstruating and postmenopausal women,604(ab)

morbid obesity, 690(ab)new math for an old test, 563(ab)proximal and distal stomach, normal

volunteers, 605(ab)reproducibility, 562(ab)reproducibility ofparameters, 690(ab)Ru-97 DISIDA and Tc-99m sulfur colloid

evaluation, 596(ab)sex and menopausal status of studies, 1926(le)systemic sclerosis, metoclopramide effects,

688(ab)transit of fats, 563(ab)

gastroesophageal reflux, retrospective study inchildren, 7 15(ab)

inflammatory bowel disease, In-i 11 leukocyteestimation of, 659(ab)

Gastroduodenal ulcer, detection, Tc-99msucralfate, 521

Gastroesophageal reflux, retrospective study,children, 7 15(ab)

Gastrointestinal bleeding, bleeding rates necessaryfor detection, Tc-99m red blood cells, 514

Gated blood-pool studiesdiastolic shape deformity, equilibrium

radionuclide angiography, 557(ab)dobutamine infusion, pediatric patients, 621(ab)integrated ECG analysis, list mode processing

system and, 6l8(ab)ischemia, exercise electrocardiography and

ventriculography, 589(ab)multivariate segmental pattern recognition,

coronary arterydisease, 676(ab)nuclear angiograms, sequential rest and exercise,

reproducibility of, 578(ab)nuclear cardiac imaging, IBM PC, 679(ab)pericardial effusions, 1419regional ventricular contraction, 558(ab)rotational artifact, 1536SPED', adult congenital heart disease, 608(ab)T4/5 functional image, derivation and

properties of, 676(ab)thrombolytic therapy, nuclear cardiology

techniques, 632(ab)time domain analysis, regional diastolic

functionventricular function, valvar regurgitation and,

aortic or mitral valve lesions, 621(ab)Gated heart studies

age effects, maximal upright exercise, 578(ab)blood-pool scanning, SPED', 668(ab)determination of attenuation coefficient,

1363(le)intracoronary thrombolysis, I35(le)left ventricular ejection fraction, automated

computer derived, 662(ab)left ventricular pseudoaneurysm, 918left ventricular volume studies, 401(le)

1951

Gated heart studies

SubjectIndexâ€¢1987

mechanical left ventricular assistance,myocardial infarction, 886

perfusion imaging, endocardial motion andmyocardial thickening, 618(ab)

pressure-volume loop determinations, leftventricular function, 676(ab)

radionuclidefollowing thrombolytic therapy, 632(ab)volume measurements, attenuation coefficient

for, 102regurgitant fraction ofleft ventricle, 19right and left ventricular function, spontaneous

respiration effects, 173Tc-99m MIBI, assessment offunction, 674(ab)time domain analysis, regional diastolic

functionventricular scans, xenon, 261(ab)

Generatorsosmium-191/iridium-l9lm radionudlide,

oxaiato osmate parent complex, 1571tungsten-l88/rhenium-188, radiotherapeutics,

656(ab), 657(ab)Geos@de Heresy Nuclear Medicine Pioneer

Award Cltatlouiâ€”1986,Rosalyn S. Yalowand Solomon A. Berson, 1637

Germanium detector, scatter corection and,SPED',1853

Glioma1-131 monoclonal antibody, administered

through carotid artery, 603(ab)subcutaneous and intracranial, 1-131

monodlonal antibodies, 710Glomerviar filtration rate (GFR)

determination, calculated ofinjected dose in,264(ab)

estimation1-123, 1-125, and 1-131 diatrizoate, 366Tc-99mDTPA,372

intravesical pressure effects, 716(ab)measurement, Tc-99m DTPA renography,

399(le)radionuclide determination, children, 262(ab)three-hourvolumeofdistribution method, 510

Glucocorticoida, Tc-99m phosophonate and, boneimaging for trauma, 606(ab)

Glucoheptonate, Tc-99m, pancreatic allogralt,583(ab)

GlucoseC-14, radiometric assay ofbacterial growth, 209cerebral metabolism

aging, systemic health factors in, 601(ab)schizophrenia, 702(ab)

transport, cerebral, 1-123 IBO SPED' studies,57l(ab)

L-Glutamate, metabolic fate of, transplantabletumors, 594(ab)

Grasulocytes, infiltration, drug effects on, 667(ab)Gravity, pulmonary circulation and, SPED', 1758Great vessels, congenitally corrected transposition

of, radionudlideangiography,116Grover-McKay, Maleah, Maleab Grover-McKay

receives Tetalman Memorial Award,Ni 100

Growth plate, surgical closure of, scintigraphy,716(ab)

H

Head, trauma, cerebellar hypometabolism,699(ab)

Heartallografts, rejection, anti-IL2 receptor

monoclonal antibody to, 610(ab)attenuation correction, high-resolution PET,

696(ab)

automaticventricularedgedetection,ejectionfractions and, radioisotope angiography,677(ab)

blood-pool imaging, rotational artifact in, 1536blood-pool scanning, regurgitant fraction of left

ventricle, 19cardiomyopathy, up-regulation ofcardiac beta

receptors, 666(ab)3D display ofarterial structure, myocardial

perfusion distribution, 675(ab)dipyridamole administration, intravenous,

elderly patients, 670(ab)fatty acid metabolism, 1-123 HA, 924-926(le)fatty acid uptake, 1-125 dimethyl fatty acids,

724(ab)first-pass radionudide angiography, gamma

cameraandTa-178,663(ab)glucose uptake, dopamine effects, F-18 PET,

668(ab)idiopathic congestive cardiomyopathy, 1-123

MIBO imaging, 667(ab)leftventricularmass,11-201SPED', 1315left ventricular pseudoaneurysm, vena caval

obstruction and effusive-constrictivepericarditis, 918

lipid metabolism, 3-methyl-branching effects,720(ab), 724(ab)

NMR images, functional display, 705(ab)

nuclear magnetic resonance, geometrical andfunctional, 590(ab)

perfusion agents, compared biodistribution,654(ab)

perfusion imaging, Tc-99m MIBI, intervalsbetween rest and stress, 662(ab)

pericardial effusion, 1-131 accumulation, 133(le)PET, copper radiopharmaceuticals, 407(ab)primary pericardial mesothelioma, Ga-67

citrate,1210radionuclide volume measurements, attenuation

coefficient for, 102regional ventricular contraction, contribution of

parametric images to interpretation,558(ab)

right and left ventricular function, spontaneousrespiration effects, radionuclideventriculography, 173

risk stratification, elderly patients, 644(ab)RP-30 retention, cytosolic protein and, 619â€œslicesoflife,â€•scientific highlights, SND 34th

Annual Meeting, 1986, N1235SPED' imaging, cross-correlation function to

detect motion, 97subclavianveinobstruction,11-201,254(le)Tc-99m isonitrile transport, hypoxia and,

620(ab)technetium oxime complex comparison,

730(ab)thallium redistribution, 588(ab)11-201uptake,bloodflowrelations,399(le),

400(le)transplant rejection, cyclosporin-treated, In-li 1

AMAb, 663(ab)uptake and clearance ofDMIPP analogues,

geminal dimethyl-substitution and, 571(ab)ventricular ejection fraction, first-pass anger

camera radiocardiography, 950xenon multiwire camera, improved scatter

rejection, 698(ab)Heart disease

congenital, gated blood-pool SPED' in, 608(ab)hypertensive, myocardial free fatty acid

extraction, 567(ab)Tc-99m isonitrile, myocardial perfusion

imaging, 675(ab)

valvular, pre- and postoperative right ventricularfunction, 671(ab)

Heart failure, congestive, exercise capacity,noninvasive parameters, 578(ab)

Hemangloma, Tc-99m RBC evaluation, infantsandchildren, 1412

Heparin, 1-125 fibrinogen and, lung transplants,615(ab)

Hepatobillary ini.glugbiliary atresia, cholescintigraphy in, 716(ab)carcinoma, Ga in, l792(ab)cholecystitis, morphine in diagnosis, 596(ab)detection ofbile leaks, 552(ab)differential gallbladder contractility, fundal

adenomyomatosis, 1771drainage patterns, indwelling hepatic cancer,

1055false-positive, neonatal jaundice, 966gallbladder motility, spinal cord injury, 596(ab)GI dual radionuclide method, operative

reconstruction ofbiliary tract, 660(ab)hepatic functional reserve, Tc-99m NGA in

estimation of, 627(ab)In-i 11, bowel via the intestinal wall, i787(ab)1-125 PHT, hepatoma and, 628(ab)kinetic function analyses, MRI, 703(ab)neonatal cholestasis, enterotest string in, 660(ab)new radiopharmaceuticals, 1790(ab)radionucides, radiation dose from, l794(ab)results ofcholescintigraphy, via morphine

administration, 595(ab)scleroderma, gastroesophageal reflux, 387sequential scintigraphy, apparent transient

biliary obstruction, 1775Tc-99m PMT, hepatoceilular carcinoma,

689(ab)Hepatocellularcarcinoma

delayed imaging, Tc-99m PMT, 689(ab)F-i8 DOALPET,706(ab)gallium follow-up, l792(ab)

Hepatocyte, localization, native and DTPAconjugated monoclonal antibodies, 552(ab)

Hepatoma, treatment, 1-131 lipiodol, 707(ab)HIDA studies, liver transplants, tracer-kinetic

modeling,653(ab)High density avalanche chamber (HIDAC),

positron camera, 1554Hodgkin's disease

galliumscanningin, 1611with hypercalcemia, 11-201 scintigraphy, 112

Horton, Barlmra L, SNM Technologist Sectionnames Barbara Horton as distinguishedhonoree, National Council holds strategicplanning session, Nl652

Huntington's disease, Tc-99m brain scintigraphyusing SPED', 406(ab)

Hydrooephrosls, hemodynamic changes in, Tc99m DMSA and MRI, pig, 598(ab)

Hypercalcemla, Hodgkin's disease with, 11-201scintigraphy, 112

Hypercholesterolemla, low-density lipoproteincatabolism, 1-123 LDL, 717(ab)

Hyperemla, demonstration in acute cerebralinfarction, 1-123 IMP, 1920

Hyperpamthyroidlam, quantitative bonescintigraphy, 458

Hypertensioncaptopril

renography and, 612(ab), 613(ab), 733(ab)scintigraphic test, 6i3(ab)Tc-99m DTPA studies enhanced by, 6i3(ab)

complication ofextracorporeal shock wavelithotripsy, 1791(ab)

Goldblatt, ANF effects on Tc-99m DTPA


Generators

autologous imaging, fever, 263(ab)bone scans and, culture proven acute

osteomyelitis, 694(ab)cold bone defects, 820comparative efficacy, osteomyeitis, 193l(ab)diagnosis and staging, idiopathic pulmonary

fibrosis, 616(ab)fever of unknown origin, oncology patient,

648(ab)gathum imaging and, AIDS with PCP, 695(ab)inflammatory bowel disease, extent and activity

estimation, 659(ab)migration, acutely septic primates, adult

respiratory distress syndrome, 649(ab)osteomyelitis, axial skeleton, 694(ab)simultaneous 3-phase bone scan, neuropathic

foot disease, 649(ab)Indium-ill Uganda, labeling blood cells, 1020Indium-ill Mere, comparison with oxine, abscess

detection,438Indium-Ill monoclonal antibodies

antifibrin, deep venous thrombi detection,1930(ab)

athymic mice, bearing human colon caricnomaxenografts, 861

biodistribution,722(ab),1924(le)chelating agents for labeling, human

neutrophils, 720(ab)chronic lymphocytic leukemia with,

radioimmunoscintigraphy, 602(ab)differential localization, melanoma, 709(ab)1-131 comparison, cutaneous T-cell lymphoma

imaging, 281intratumoral injection, nude mouse-human

tumor model, 712(ab)localization, melanoma, 65i(ab)lymphomaafter, immunoiymphoscintigraphy,

42melanoma detection, 1063(le)osteogenic sarcoma xenografts, 342SPED', new collimator for, 696(ab)versus Ga.67 monoclonal antibodies, human

melanoma detection, 1441Indium-ill oxine

comparison with Mere, abscess detection, 438leukocyte labeling, 1789(ab)platelet imaging, right atrial thrombus

associated with constrictive Peridcarditis,1344

Indium-ill oxine ontropolone, Tc-99m HM-PAOlabeled leukocytes, inflammatory imaging,648(ab)

Indium-ill plateletsdetection ofintracardiac thrombosis, blood-pool

subtraction, 639(ab)diagnostic imaging, 1789(ab)scintigraphy, deep vein thrombophlebitis,

649(ab)Tc-99mHSA,antithromboticdrugeffectson

platelet deposition, carotid atherosclerosis,701(ab)

Indium-Ill porphyrinsynthetic, tumor imaging agents, 724(ab)vs@Ga-67 citrate, detection of human

melanoma in athymic mice, 708(ab)Indium-ill tropolone, low density lipoprotein

receptors, uptake in liposome tissue,610(ab)

Indium-ill white blood cellsbone marrow imaging agent, 574(ab)comparative efficacy ofTc-99m MDP,

osteomyeitis, 586(ab)comparison with Tc-99m HM-PAO, imaging

inflammation, 574(ab)

subcutaneously administered, lymphatickinetics, 715(ab)

toxicity lymphocytes, i365(le)radiolabeled lymphocyte, 229

Indium-Ill antibodiescomparison oftumor size, melanoma, 71 l(ab)imaging applications, 560(ab)longtermfate,BALB-Cmice,692(ab)non-specific Fc receptor binding, tumor

detection with, 572(ab)Indium-ill an@A

localization, lung cancer, 6l5(ab)monoclonal antibody imaging

abdominal colorectal cancer, SPED', 604colorectal carcinoma, 7l0(ab)radioimmaging oftumors with, 637(ab)

uptake, colorectal cancer, 637(ab)Indium-ill a@

comparison with In-Ill antimyosin imaging,acute myocardial infarction, 590(ab)

DTPA and, 668(ab)heart transplant rejection, cyclosporin-treated,

663(ab)new cardiac imaging agent, l790(ab)

Indium-Ill aatlmyosln fabmyocardial damage, 76myocardial infarct imaging, 1671

Indium-ill bimane, potential as bifunctionalchelating agent, 657(ab)

Indium-ill catious, ionophoric transport, lipidbilayer membrane, 91

Indium-ill chelates, platelet labeling and, 223Indium-ill chloride

Ga-67 and In-ill WBC comparison, canineosteomyeitis model, 575(ab)

infected prostheses, 255(le)In-l 11 WBC comparison, adult osteomyelitis,

1540Indium-ill DTPA

antibody tumor targeting, chemicalmodification with ester bond, 572(ab)

conjugates with different linkages, comparison,572(ab)

entrapment in liver, proteins labeled usingbifunctional chelates, 657(ab)

GI dual radionuclide method, operativereconstruction ofbiliary tract, 660(ab)

non-platelet bound antibody, clot localization,experimental pulmonary emboli, 7l8(ab)

vs. Ga-67, detection of metastatic melanoma,573(ab)

Indium-Ill fab, renal uptake, reduction of,714(ab)

Indium-Ill f(ab')2, distribution, normal mice,692(ab)

Indium-ill fragment El, loss of functionalactivity, protective complex duringattachment ofDTPA groups, 657(ab)

Indium-ill gran@diagnostic significance, febrile patients, 155localizationmechanism,dog model,69i(ab)methyl-prednisolone, ibuprofen and vitamin E

effects,perfusedbeatingheart, 667(ab)splenic activity, inflammatory bowel disease,

688(ab)Indium-ill hapten

monoclonal antibody, radioimmunodetection ofcolon tumor model, 7i1(ab)

radioimmunodetection, normal mice, 692(ab)Indium-ill IgG, anti-inflammatory agent effects,

focal inflammation, 695(ab)Indium-ill leukocytes

accumulation, after reperfusion of ischemicmyocardium, 610(ab)

renography, 734(ab)Goldblatt two kidney and one kidney, captopril

renographyin, 1171normaladrenalmedulla,1-123MIBOuptakein,

319renal, exchangeable sodium and body fluid

spaces, 733(ab)renovascular

captopril and radionucide renal studies,l789(ab)

captopril renography in, 735(ab)renal scintigraphy in evaluation of, 1501revascularization therapy in, 406(ab)single-dose captopril in diagnosis, 1383

11-201 distribution alterations, SPED', 673(ab)Hyperthyroldism

feline,treatmentwithsodiumiodide1-131,263(ab)

radiation dosimetry for 1-131 administration,581(ab)

Hypocalcemla, postoperative, parathyroidlocalization scans and, 583(ab)

HypOmetabOllsm, cerebellar, after head trauma,699(ab)

Hypothyroidism, congenital, thyroid scintigraphyin, 687(ab)

Hypoxiaimaging, misonidazole for, 6811-201kinetics and, myocardial cells, 1453

Image processing, digital, autoradiography, 218ImagereconstructIon,axialdata,three

dimensional PET, 1717Image subtraction, parathyroid scintigraphy,

582(ab)Image transmIssion, digital, 68i(ab)Immunoassay

â€œCr-RBCmethod,evaluationof monoclonalantibody procedure, 7l8(ab)

radioassay and nonisotopic, l788(ab)Immunoglobulla, IgG, polyclonal, detection of

focal inflammation, 614(ab)linmunolymphosclntlgraphy, In-i 11-labeled TlOi

monoclonal antibodies, lymphoma after, 42Immunomodulator, radiolabeled bacterial, tumor

imaging, 658(ab)Immimoradlotherapy, 1-131 monoclonal antibody,

renal cell carcinoma xenografts, 65i(ab)Immunosdatlgraphy

background reduction by, non-labeledantibodies, 712(ab)

clinical assessment, tumor-seeking agents,637(ab)

coloncancer,1-13128A32imaging,636(ab)monoclonal antibodies, targeting

radiopharmaceuticals, 56l(ab)pre-targeted, chimeric antibodies, 561(ab)recurrences ofgynecologic carcinomas, 1807

Immunotherapy, radioimmunotherapycomparison, animal model, 691(ab)

Incubation media, chelates, with In-i I 1, plateletlabeling and, 223

Indium-illbowel activity, via the intestinal wall, l787(ab)differencesin metabolism,693(ab)lesion detectability, thresholds, 706(ab)liver uptake, 264(ab)mouse antimeianoma monoclonal antibody

ZME-0i8, optimal tumor localization of,25

platelet kinetics, mathematical model, 402(le)radioimmunodetection, testicular cancer

xenograft, 714(ab)

1953

Indium-Ill white blood cells


false positive, imaging in malignancy, 562(ab)In-l I I chloride and Ga-67 comparison, canine

osteomyelitis model, 575(ab)In-i 11 chloride comparison, adult osteomyelitis,

1540

orthopedic prosthesis infection, comparisonwith other methods, 586(ab)

suspected orthopedic prosthesis infection,55 l(ab)

uptake, non-infected closed fractures, 586(ab)Indium-li 1 ZCE-025, pharmacokinetics and

tissue distribution, 179l(ab)Infectionimaging,Ga-67andIn-iII,1788(ab)Inflammatory bowel disease, In-I I 1 SPED',

computed tomographic correlation, 659(ab)In memorlam

Jack W. Smith, RT (X)(N) AART, 137Norman H. Horwitz, Ph.D., 137Samuel R. Lerner, Ph.D., 1510

Institute of Medicine (lOM)IOM Council on Health Care Technology,

N154Michel Ter-Pogossian elected to lOM, N1520

Instrumentationequipment purchasing decisions, based on

clinical needs and facility design, transitionfrom planar to SPED', PET, N278

used nuclear medicine equipment needed indeveloping countries, N944

Instrumentation CouncilSNM councils report at Winter Meeting, N802SNM Instrumentation Council promotes

electronic mail, N 1656Insulin, 1-123 labeled, abnormalities, insulin

immunized diabetics, 583(ab)lodination, high efficiency, monocional antibodies

for radiotherapy, 1034Iodine-123

3-methyl-branching, myocardial lipidmetabolism, 720(ab), 724(ab)

myocardial blood flow agents, 725(ab)Iodlne-123 amphetamines, brain imaging,

comparative, Tc-99m HM-PAO and,569(ab)

Iodlne-123 antl-granulocyte antibodies, infectiouslesions, radioimmunodetection of, 614(ab)

Iodlne-l23 diatrizoate, glomerular filtration rate,children, 366

Iodlnc-123 HA, fatty acid metabolism,myocardium, 924-.926(le)

Iodlne-l23 HEATbiodistribution and radiation dosimetry,

1793(ab)radiation dosimetry of, 1745

Iodlne-123 heptadecanOic acid, free fatty acidscintigraphy, heart, 567(Ã b)

Iodlne-123 HIPDMbrain imaging, subacute spongiform

encephaJopathy, 1484complex partial seizure foci, brain, 600(ab)radioactive iodine exchange reaction, 360response ofvisual cortex, 551(ab)

.â€” Iodine-123 hlppuran, comparison with Tc-99m

MAG-3, renal work, 647(ab)Iodlne-123 IBG, glucose transport, cerebral,

571(ab)Iodlne-123 1MB

distribution, brain undergoing cognitivechallenge, 592(ab)

early and late SPED', distribution incerebrovascular disease, 591(ab)

Iodlne-l23 IMPacute cerebral infarction, focal hyperemia in,

1920

adrenal gland, 409(ab)autoracliographic comparison, cerebral blood

flow tracers, 481brain imaging

cerebral blood flow tracer, 570(ab)Metz fifters for processing, 677(ab)

brain scintigraphy, diagnosis ofischemia vs.infarction, 409(ab)

cerebral blood flow, noninvasive quantitativeassessment, 558(ab)

distribution, temporal changes, brain, 623(ab)malignant melanoma, 562(ab)Rb-82 tissue kinetics, measurement of regional

myocardial blood flow, 558(ab)SPED'

chronic aphasics vs. normals, 559(ab)delayed scan in brain, 559(ab)

Tc-99mHM-PAOSPED' and,subacutestrokes, 623(ab)

tracer kinetics, measurement of cerebral bloodflow, SPED', 569(ab)

Iodlne-123 insulin, abnormalities, insulinimmunized diabetics, 583(ab)

Iodine-l23 iodoamphetamlneportal hypertension, evaluation of portosystemic

shunts in, 628(ab)SPED'

cardiovascular disease, 622(ab)regional cerebral blood flow, 619(ab)

Iodine-123-iodobeptadecanoic acid, gastrointestinaltransit, fats, 563(ab)

Iodlne-123 IPPAmyocardial extraction, cardiomyopathy, 670(ab)11-201 comparison, coronary artery disease,

669(ab)Iodlne-123 LDL, comparison for imaging sites,

low-density lipoprotein catabolism, 717(ab)Iodbie-l23 MISC

adrenergic nerous system mapping, 1625carcinoid tumor imaging, 1907imaging, idiopathic congestive cardiomyopathy,

667(ab)regional washout, myocardial, sympathetic

innervation and, 608(ab)SPED', after transmural myocardial infarction,

dog model, 669(ab)uptake

hypertensionand,normaladrenalmedulla,319

pheochromocytomas, parangangliomas, andneuroblastomas, 973

Iodine-l23 monlodo-D-tyroslne, artificial aminoacid,membranetransportmeasurement,724(ab)

Iodlne-123 sodium iodide, breast milk excretion,radiation dosimetry, 544(le)

Iodlne-123 spiperone, high-yield labeling, SPED',animal studies, 570(ab)

Iodine-125, chimeric monoclonal antibody, tumorspecific genetically engineered, 560(ab)

Iodine-125 antibody, localization, human coloncarcinoma, 709(ab)

Iodine-125 AZIDO-IPAPP, serotonin receptoragonist, irreversible,CNS, 725(ab)

Iodine-125 diatrizoate, glomerular filtration rate,children, 366

Iodine-125 dlmethyl fatty acidmyocardial uptake and clearance kinetics

DMIPP analogues, 571(ab)measurement of myocardial fatty acid uptake,

724(ab)Iodine-125 fibrinogen, lung transplants, hepatin

effects, 615(ab)Iodine-125 HEAT, brain distribution, radiation

dosimetry and, 582(ab)Iodine-125 IBZ, synthesis, D2 dopamine receptor

imaging, 726(ab)Iodine-l25 IHDA, kinetic evaluation, isolated rat

heart, 667(ab)Iodine-125 IMP, binding and subcellular

distribution, brain, 702(ab)Iodine-125 iodotelluraoctadecenoic acid, heart,

iodoalkene and tellurium position effects,571(ab)

Iodlne-125 1PM, design and synthesis, antibodylabeling kit, 726(ab)

Iodine-i25 IPPA, preparation and biodistribution,brainimaging,57l(ab)

Iodlne-125 MISCadrenergic nervous system integrity, 1620norepinephrine and, adrenomedullary cells,

639(ab)Iodine-125 Pm', hepatobiliary imaging, hepatoma

and,628(ab)Iodine-125 PKlll9S, high specific activity, novel

synthesis of, 724(ab)Iodine-131

accumulation, pericardial effusion, 133(le)In-I 11 comparison, cutaneous T-cell lymphoma

imaging, 281low vs. high dose, thyroid remnant ablation,

686(ab)maternally administered, fetal radiation

dosimetry, 581(ab)neuroendocrinetumors,979radiation dosimetry for, hyperthyroid patients,

58l(ab)radioactive therapy, parotid oncocytoma,

626(ab)sodium iodide, treatment of feline

hyperthyroidism, 263(ab)therapeutic dose, undiagnosed metastases in

thyroid cancer, 1881therapy, monitoring radioactivity after, l064(le)thyroglobulin assays and, correlation with TI

201, follow-up with thyroid cancer, 686(ab)thyroid screening, Chernobyl accident, 535total body scan, differentiated thyroid

carcinoma, 685(ab)whole-body thyroid scans, hepatic visualization,

1408Iodine-13l Anti-CEA

anti-antibody enhancement, experimental andclinical studies, 1604

polyclonal, detection of metastatic colorectaland other carcinoma, 708(ab)

Iodlne-l31 anti-Ia, autologous bone marrowtransplantand,B-celllymphoma,692(ab)

Iodlne-131 diatrizoate, glomerular filtration rate,children, 366

Iodlne-131 HIPDMlung uptake

model,203single-pass multiple indicator dilution

technique,rabbitmodel,487Iodlne-131 hippuran

captopril renography, 733(ab)split renal function, renovascular hypertension

or urinary obstruction, 731(ab)Iodlne-131 lodomethylnorcholesterol, localization

ofovarian dysfunction, 685(ab)Iodine-i31 lipiodol, hepatoma treatment, 707(ab)Iodine-13l MISC

carcinoid syndrome, 658(ab)correlations with D' and MRI, detection of

pheochromocytoma, 639(ab)failure, small cell lung carcinoma, 1230(le)familial malignant nonfunctional

1954 TheJournalofNuclearMedicine

Indium-ill ZCE-025

Uver

paraganglioma, 528medullary carcinoma, thyroid, 576(ab), 1820metastatic pheochromocytoma and

neuroblastoma, extremities, 315mouseneuroblastoma,255(le)neural crest tumors, l787(ab)

diagnosis and therapy, 308pheochromocytoma and neuroblastoma

treatment, 627(ab)safety oftherapy, advanced neurobiastoma,

626(ab)therapeutic,acutetoxicityof, bloodradiation

dosimetry, 618(ab)uptake, medullary thyroid carcinoma, 265(ab)uptake and dosimetry of, pheochromocytoma,

687(ab)Iodlne-l31 monoclonal antibodies

against synthetic carbohydrate antigens, cancerimmunoscintigraphy, 712(ab)

biodistribution, 722(ab)clinical assessment, immunoscintigraphy,

637(ab)cutaneous T-cell lymphoma, retreatment,

603(ab)distribution, carotid artery administration,

glioma and, 603(ab)Ga-67 citrate comparison, lymphoma detection,

7l3(ab)gliomas, subcutaneous and intracranial, 710(ab)high activity, pharmacokinetics of, 553(ab)immunoradiotherapy,renalcellcarcinoma

xenografts, 65i(ab)immunoreactive fraction, altering labeling

parameter effects, 722(ab)lymphoscintigraphy, malignant melanoma, 34preparative regimen, bone marrow transplant,

692(ab)radioimmunotherapy with, mammary

carcinoma xenografts, 573(ab)recurrences ofgynecoiogic carcinomas, 1807renal cell carcinoma, phase I-Il trials, 603(ab)

Iodlne-131 NP-59Cushing's syndrome, abnormal adrenals in,

640(ab)silentadrenalmass,1401uptake, nonhyperfunctioning adrenal mass,

640(ab)Iodlne-131 OIH, renal plasma flow measurement,

1393Iodine-l31 toluldine blue, superimposed,

preoperative parathyroid localization by,298

lodoalkene, effects ofposition, 1-125 uptake and,heart, 571(ab)

lodoamphetamine, myocardial blood flow agents,725(ab)

lodocholesterol, scintigraphy, primaryaldosteronism and Cushing's syndrome,640(ab)

lodophenyl, conjugates, protein labeling, 560(ab)lodophenyl fatty adds, metabolic and kinetic

evaluation, isolated rat heart, 667(ab)Irldium-l9im, osmium-l9l/iridium-i9im

generator awarded orphan product grant,Ni54

Ischenilaextremity uptake and, bone scanning, 108transient, left ventricular wall motion induced

by, radionuclide angiography, 1725N-Isopropyl p-lodoamphetamlne, biodistribution,

antidepressantandnarcolepticdrugeffects,354

Isotopes, stable, cells and tissues, nuclear reactionsandchargedparticlecamera,697(ab)

J

Joint, infections, diagnosis byradioimmunoscintigraphy, 585(ab)

Joint prosthesis, femoral component ofhip, dualisotope arthrography,565(ab)

K

Kaano-Lassen algsdthmcerebral blood flow, 262(ab)estimation ofcerebral blood flow, from

tomographic diffusible tracer clearancecurves, 407(ab)

Kate, Sadatake, Sadatake Kato honored withservice award from RadiopharmaccuticalScience Council, NiSO

Kawasaki disease, children, tomographicmyocardial perfusion scintigraphy, 1839

Kidneyallcgrafts,evaluationofcold-storageand

immunosuppression, cortical perfusionindex, 731(ab)

amyloidosis, Tc-99m DMSA in, 734(ab)arteriovenous transit times, technetium

radiolabeled chelates, 1134artery stenosis, MRI, angiography, and nuclear

medicine, 736(ab)baseline function, renographic response to

captopril and, 612(ab)blood clearance, Tc-99m DTPA uptake in bone

and, 1461blood flow. See Blood flowcell line,diphosphonatesandpolyphosphateson

phosphate transport, 602(ab)depth determination, Tonnessen formula vs.

ultrasound, 647(ab)differential function, rapid method for

measurement, 829disease

captopril effects on renography, 6l3(ab)effective renal plasma flow, 622(nb)Ga-67 scintigraphy in, 732(ab)Tc-99m and captopril studies, 613(ab)

dynamic DTPA scan, evaluation of renalexcretion, 733(ab)

failure, Tc-99m MAG-3 kit formulation,647(ab)

functionearly and late changes, after ncphrectomy,

735(ab)renovascular hypertension or urinary

obstruction, 1-131 hippuran evaluation,731(ab)

Tc-99m DTPA, aluminemic disturbance, 383functional oncocytomas, dual tracer

scintigraphy, 1911glomeruiar filtration rate, three-hour volume of

distribution method, 510hypertension, exchangeable sodium and body

fluid spaces, 733(ab)In-ill F(ab')2 distribution, normal mice,

692(ab)In-III Fabuptake,reductionof, 714(ab)intravesical pressure effects, GFR, 716(ab)kinetic function analysis, MRI, 703(ab)plasma flow, 1-131 OIH measurement of, 1393potential imaging agent, Tc-99m MAG@,1180prolonged maintenance heinOdialysis,bone

mineral content determination, 630(ab)quantitative regional functional imaging,

732(ab)routinework,Tc-99mMAG-3and1-131

comparison, 647(ab)silent damage, vesicoureteral reflux, siblings,

62i(ab)

studies, factor analysis of, 734(ab)Tc-99m MAG3

biological characterization, 732(ab)1-131 comparison, 647(ab)physiologic factor effects, 732(ab)

Tc-99mPAHIDAclearance,907transplants

bolusfirstpassdataappliedto, 406(ab)MRI/RN correlation, 733(ab)rejection, nuclear scan and duplex

sonographic findings, 647(ab)urinary obstruction, volume expansion diuretic

renalscan,646(ab)volumeexpansiondiureticscan,urinarytract

obstruction, 824Kinetic models, receptor-binding

radiopharmaceuticals, 653(ab)K/KYYPtOIIX,no carrier added reactions, F-i8

fluoride, 635(ab)Knee

arthropiastyasymptomatic, radiophosphate uptake in,

1546postoperative bleeding, Tc-99m RBC, 565(ab)radiophosphate uptake in, 586(ab)

prosthesis, radiophosphate visualization offoreign body reaction, 915

Kwashlorkor, hepatic steatosis in, Xe-l33 uptake,622(ab)

L

Lactate, infusion, myocardial ischemia, labeledfree fatty acid scintigraphy, 567(ab)

IAplaclaa-of-the-Gausslan, edge detection, imagereconstruction, 682(ab)

Lead-203, labeling, preliminary results, 721(ab)Lead-203 DDC, preparation, brain perfusion,

mice,723(ab)LaSe@ Etienne, Etienne LeBel recognized for

leadership in Canadian nuclear medicine,N791

Left bundle branch block, LAD disease with, 11-201 SPED' in, 589(ab)

Lesions, space-occupying, calculations in featureextraction, 927(le)

Leukemia, hairy cell, marrow involvement in,NMR, 690(ab)

albumin coiloid, Tc-99m, characteristics,574(ab)

labeling, Tc-99m tin coiloids, 1471Liability, Commentary: How the malpractice

crisis effects nuclear medicine Physicians,Nl517

Lipophilicity, cerebral retention and, 729(ab)Lipoprotela, metabolism, I-l23-LDL, 717(ab)U@ein rece@

lowdensityactivity with Tc-99m LDL, liver, 610(ab)uptake in liposome tissue, In-l 11 tropolone

and, 610(ab)Uposomea, In-I I I cations, ionophoric transport,

91Liver

angioscintigraphy,portalvenoushotspot,689(ab)

arterial perfusion chemotherapy, Tc-99m MAAperfusion imaging, 41 l(ab)

blood flow. See Blood flowBudd-Chiari syndrome, typical and atypical

scintigraphic aspects, 803Fc-receptor function, pie- and post-treatment,

690(ab)functional reserve, estimation with Tc-99m


NGA,627(ab)hemangioma

MRI and Tc-99m RBC evaluation, 1683Tc-99m RBC evaluation, infants and

children, 1412hemangioma and carcinoma, differentiation by

SPED', 688(ab)hepatobiliary SPED', deconvolution analysis,

689(ab)hepatoma

1-131 lipiodol treatment, 707(ab)1-125 PHT, 628(ab)

indwelling cancer, drainage patterns,hepatobiliary imaging, 1055

In-i II entrapment,proteinslabeledusingbifunctional chelates, 657(ab)

In-i11uptake,264(ab)localizationofln-lil, melanoma,65l(ab)metastases, regional chemotherapy and

immunoscintigraphy, 706(ab)parenchymal and nonparenchymal cells,

radiolabeled monoclonal antibody uptake,573(ab)

portal hypertension, portosystemic collaterals,blood-pool emission D', 627(ab)

radiocoiloid examination, detection of bonemarrow metastases and, 184, 1640(le)

radiolabeled monoclonal antibody metabolism,methods for study, 390

ratioofTc-99m sulfurcolloid,transaxialSPED' images, 675(ab)

septo-optic dysplasia, neonatal jaundice, 966steatosis,kwashiorkor,Xe-133uptakeand,

622(ab)tertiary syphilis involving, radionucide imaging

in,1047transplant, HIDA studies, tracer-kinetic

modeling,653(ab)tumor blood flow, intro-arterial epinephrine,

SPED', 659(ab)tumor necrosis factor, radiolabeled metabolic

probes in, 640(ab)tumors, Y-90, 708(ab)visualization, 1-131 whole-body thyroid scans,

1408Liver-spleen scans, AIDS patients, l792(ab)L4$lgitudlnal emission tomography, two devices

for,thyroid,1892Los Alamos National Laboratory

Los Alamos, conflict between radioisotopes andneutrinos resolved, N1378

physics experiment may cloud future of LosAlamos nuclear medicine program,proposals for dedicated radionuclideproduction facility, Ni37l

Lumped constant, deoxyglucose model, estimate,471

asbestosis, Ga-67 emission tomography, 7l8(ab)asymptomatic pulmonary embolism, following

knee replacement, 584(ab)cancer

In-i I1anti-CEAlocalization,615(ab)soft-tissue accumulation of bone agent in,

1275Ga-67 chest scans, AIDS, I 107heart transplant and, tracheobronchial chary

function in, 6i6(ab)idiopathic fibrosis, In-I I 1 leukocyte diagnosis,

6l6(ab)1-131 HIPDM uptake

model,203single-pass multiple indicator dilution

technique, rabbit model, 487

imaging, Tc-99m PYP and DTPA aerosolcomparison, 585(ab)

index computerization, Ga-67, interstitialpneumonitis, 1826

malignancies, Ga-67 citrate and Tc-99mglucoheptonate comparison, 442

permeability measurements, extrapulmonaryradioactivity, 903

primary cancer, C-I 1 methionine uptake and,658(ab)

quantitative scans, post-radiotherapy pulmonaryfunction, 616(ab)

radiation-induceddamage,earlydetectionwithSPED', 659(ab)

resection, respiratory function following,pulmonary scintigraphy in, 550(ab)

routinescintigraphy,detectionof venousthrombosys by xenon-133, 1792(ab)

scan criteria, computer assistance, 584(ab)scans, cost-effectiveness and beneflthsk, 1521small cell carcinoma, failure ofl-131 MISC in,

1230(le)squamous cell carcinoma, immunoscintigraphy,

637(ab)transplants,hepatineffectson 1-125fibrinogen,

6l5(ab)ventilation studies, Xe-I33, 616(ab)

LymphocytesIn-I 11 toxicity on, l365(le)radiolabeled, l228(le)

In-I11toxicityon, 229Lymphoma

AIDS-relatedgalliumscintigraphyin, 694(ab)Ga-67 scintigraphy and D' scanning

correlation, 638(ab)cutaneous T-cell

In-iI1monocionalantibodyand1-131comparison, 281

radioimmunotherapy pretreatment of,603(ab)

detection, Ga-67 citrate and 1-131 monocionalantibody comparison, 713(ab)

F-18FDG,G-67citratecomparison,288non-Hodgkin, gallium scanning in, 1611T-cdll, cutaneous, radioimmunotherapy

treatment, 553(ab)Lymphom disease, magnetic, Tc-99m and MRI

bonemarrowinvestigation,705(ab)cervical, submucosal cheek injection of Tc-99m

rhenium-sulfid-colloid, 707(ab)In-il I IgGand1gM,monoclonalantibodies,

715(ab)interpretation, factor analysis and condensed

image in, 716(ab)interstitiallyadministeredmonoclonal

antibodiesfor, 1736melanoma, monoclonal antibody cocktail,

713(ab)monoclonal antibody, malignant melanoma, 34Tc-99m HES, preparation as an agent, 730(ab)

M

Maclntyre, William J., William J. Maclntyrereceives Aebersold Award for outstandingachievementin basicscienceappliedtonuclear medicine, N795

Magnetic resonance imaging. See Nuclearmagnetic resonance

Maguetopharmaceufical, kinetic function analyses,MRI, 703(ab)

Malpractice Insurance, Commentary How themalpractice crisis effects nuclear medicinephysicians, Ni517

Manganese-54 DTPA, Gd-153 DTPAcomparison, biodistribution, 349

Manic-depressive illness, D2 dopamine receptorsin, 61 l(ab)

Marketingadvanced techniques, 1786(ab)Nuclear Medicine Week, how it was observed in

1986,plansfor1987,N4i8Medical economics, current and future trends,

1787(ab)Medicare

bonedensitometryassertsclinicalroledespitelack ofreimbursement, N267

OHTA advises HCFA to deny Medicarecoverage for SPA, DPA, N 1656

MedUIIary carcinomathyroid

1-131 MISC imaging, 576(ab), 18201-131MISCusein, 576(ab)spinal bone mineral density in, 685(ab)

Melanin, PET, development oftracers for, 701(ab)Melanoma

detectionGa-67 versus In-i 11 monoclonal antibody,

1441In-I 11 monocional antibody, 1063(le)

Ga-67 uptakeanti-humantransferrinreceptormonoclonal

antibody effects, 603(ab)inhibitionbyanti-humantransferring

receptor monoclonal antibody, 1303lymphoscintigraphy, monoclonal antibody

cocktail, 713(ab)malignant

augmented splenic radiocolloid uptake in,262(ab)

1-123 IMP, 562(ab)nude rat transplanted with, radiolabeled

monocional antibodies, 7l0(ab)metastatic

imaging with Tc-99m antibody, 573(ab)In-i11monoclonalantibodylocalization,

65i(ab)Tc-99m monoclonal antibody imaging,

650(ab)monoclonal antibody lymphoscintigraphy, 34ocular, radioimmunoscintigraphy, 637(ab)radiolabeled monoclonal antibodies in,

differential localization, 709(ab)MetaiOdObenzylguanIdine

adrenergic nervous system integrity, 1620adrenergic nervous system mapping, 1625

Metastatic disease, skeletal tuberculosisresembling, 1507(le)

Methotrexate, high dose, Tc-99m MDT and,diffuse hepatic uptake, 532

H3-N-Methylspiperone, binding, serotonin-2receptors, monoamine oxidase inhibitorsand, 700(ab)

Metoclopramideesophageal stimulation, progressive systemic

sclerosis, 810gastric emptying, systemic sclerosis, 688(ab)misspelling, l640(le)

Micrometastases, radioimmunotherapy, tumorspheroid model, 626(ab)

MIsadmInIstratIOns, clarifying newmisadministration reporting rules, N153

MISOnIdaZOIe,imaging ofhypoxia, 68MOdeling

compartmentalantibody dosimetry, 617(ab)linear and nonlinear, computer simulations,

653(ab)

1956

Uver-spleenscans

TheJournalofNudearMedicine

deoxygiucose, estimate lumped constant in,l782(le)

four-compartment, radioligand-neuroreceptorinteraction, 681(ab)

mathematical, local cerebral blood flow studiesinPET, 1695

radioimmunoassay, compared withmathematical, 719(ab)

Monoamine oxidase lnhibkors, H3-N-methyispiperone binding, serotonin-2receptors, 700(ab)

Monoclonalantibodiesanti-CEA, localization, lung cancer, 6l5(ab)antiglobulinresponsesto, 6i5(ab)anti-human transferrin receptor, Ga-67 uptake

in melanoma and, 603(ab), 1303anti-idiotype, comparative radiolabeling and

binding,614(ab)anti-lU receptor,rejectingcardiacallografts,

610(ab)anti-melanoma,Tc-99m,preclinicalevaluation,

69l(ab)anti-munne antibody and, false-positive

carcinoembryonic antigen and, 615(ab)anti-platelets, detection ofpulmonary emboli,

584(ab)biokinetics, radiation dose from

radioimmunoscintigraphy,6l6(ab)chimeric

immunoscintigraphy with, 56l(ab)tumorspecific,characterizationby 1-125,

560(ab)cocktail, lymphoscintigraphy in melanoma, 713coloncancer,imagingwith1-13128A32,

636(ab)colon/ovarian, imaging agent for colon

carcinoma, 7i0(ab)detection ofCAl25 antigen, sensitive IRMA

for,568(ab)FDA releases updated â€œpointsto considerâ€•for

antibody products, N 1520F-18 labelIng ofproteins, 462Ga-67 labeled tumor imaging, 7l2(ab)hama-murine antibody complexes and, 6l4(ab)heart transplant rejection, cyciosporin-treated,

663(ab)high efficiency iodination, for radiotherapy,

10341gM, testicular cancer xenograft,

radioimmunodetection,714(ab)1-131-labeled, mammary carcinoma xenografts,

573(ab)immunoreactive, radiolabeled anti-p97 Fab

fragment, 651(ab)immunoscintigraphy, continuous regional

chemotherapyand,livermetastases,706(ab)

In-I11anti-CEA,colorectalcarcinoma,710(ab)In-i1I bimane,potentialas bifunctional

chelatingagent,657(ab)In-l I1IgGand1gM,lymphatickineticsof,

7l5(ab)interstitially administered, lymphoscintigraphy,

1736IP vs. IV delivery of, intraperitoneal ovarian

carcinoma,651(ab)kinetics, influence oflabeling, 693(ab)labeling with lead-203, preliminary results,

72l(ab)native and DTPA conjugated, localization by

hepatocyte, 552(ab)newly developed, thyroid cancer, 714(ab)parathyroid specific fragments, evaluation,

582(ab)

pharmacokinetics oftumor-seeking agents,cancer patients, 7l4(ab)

procedure for GI blood loss, compared to 51CrRBC method, 7I8(ab)

radioiodinatedimmunoreactive fraction, altering labeling

parameter effects, 722(ab)protein labeling, 560(ab)

radiolabeledintraperitoneal delivery of, 715(ab)metabolism by liver and tumor, 390nude rat transplanted with malignant

melanoma, 7i0(ab)preserved immunoreactivity and high in vivo

stability, 1027quality assurance, 264(ab)toxicityof, 684(ab)uptake by liver parenchymal and

nonparenchymal cells, 573(ab)recognizing colon cancer, initial

radioimmunodetection studies, 713(ab)relative tumor uptake of, systemic perfusion,

715(ab)review ofinternational NATO meeting, July,

1986,Italy,coverscancerdetectionandtherapy,clinicaltrials,labeling,dosimetry,N143

squamous cell carcinoma, immunoscintigraphy,637(ab)

targetingto neuroblastoma,1577tumor-seeking agents, targeting

radiopharmaceuticals, 561(ab)unlabeled, Y-90, purification method and

coinjection, 721(ab)uptake, tumor oxygenation and, 709(ab)Y-90 labeled TiOl, malignant T-cell line,

7l0(ab)Morphine

cholescintigraphyclarification ofresults, 595(ab)diagnosis ofcholecystitis, 596(ab)

MUCOcIIIarytransport system, clearance of Tc99m MAA aerosol, scintigraphicmonitoringof, 161

MuscleC-I I AIB transport, starvation effects, 650(ab)leg

perfusion, TL-20i SPED', 717(ab)peripheral arterial disease, 11-201 SPED',

717(ab)Myocardlal cells, 11-201 kinetics, hypoxia effects,

1453Myocardial Infarction

coronary occlusion and myocardial salvage, Tc9%@MIBI, 654(ab)

diagnosis in emergency room, 598(ab)diastolic shape deformity, equilibrium

radionuclide angiography, 557(ab)enhancement in early detection, gadolinium

DTPA contrast, 704(ab)evaluation ofheart disease following, 11-201

rotational tomography, 674(ab)imaging with Tc-99m MIBI, comparison with

microspheres, 620(ab)1-123 MISC SPED' after, dog model, 669(ab)In-i11monoclonalantimyosinfab,detectionof

necrosis, 1671ischemiaand,fattyacidandthalliumimaging

rolein,632(ab)left ventricular pseudoaneurysm, 918leukocyte accumulation after reperfusion, F-i8

andIn-III leukocytes,6i0(ab)mechanical left ventricular assistance, pled

blood-pool imaging in, 886

mortality risk indicator after, ventricularasynergy, 670(ab)

nuclear magnetic resonance, comparison withIn-Ill antimyosinimaging,590(ab)

quantifying methods, 11-201 SPED', 325radionuclideventriculography,following

thrombolytic therapy, 632(ab)recombinant tissue plasminogen activator,

NMR assessment, 59l(ab)screening test, myoglobin and creatine

phosphokinase-MB, 568(ab)Tc-99m PYP biodistribution in, NMR, 704(ab)thrombolytic therapy, nuclear cardiology

techniques, 632(ab)11-201, fast washout from area, 945

Myocardlal Inchemlaanimal model, RP-30 regional distribution,

620(ab)assessment of perfusion, isoproterenol infusion,

621(ab)C-li BMHDE, structure localization relations,

727(ab)coronary angioplasty following thrombolysis,

11-201 scintigraphy, 674(ab)dipyridamole infusion, peripheral hemodynamic

response, 580(ab)fluoromisonidazole uptake in, 668(ab)free fatty acid scintigraphy, 1-123, 567(ab)1-123 IPPA, 11-201 comparison, 669(ab)infarction and

fatty acid and thallium imaging role in,632(ab)

11-201 and MRI combined characterization,703(ab)

light exercise, systolic blood pressure/endsystolic volume during, 672(ab)

mental stress and, assessment with radionuclideventriculography, 597(ab)

multivessel PTCA outcomeaccurate identification, 63l(ab)functional assessment and quantitation,632(ab)

perfusion imaging, Tc-99m isonitrile, 675(ab)pharmacokinetics ofimaging agents, SQ 30,214

comparedwithSQ30,217,674(ab)Planar SQ 30,217 scans, localization of

perfusion defects, 663(ab)positive exercise electrocardiograms, normal TI

201scintigramsand,643(ab)prediction ofdeath, exercise ECO and 11-201

SPED', 644(ab)radiolabeled palmitate, metabolic fate of, 1322regional left ventricular relaxation and,

impairment with right ventricular pacing,672(ab)

@entdipyridamole 11-201 infusion, 580(ab)exercise electrocardiography and

ventriculography, 589(ab)exercise SPED' 11-201, 589(ab)

stress-induced, 11-201 SPED', 642(ab)stress N-13 ammonia PET imaging, 11-201

comparison, 567(ab)Tc-99mRP-30perfusiontomography,dogs,

620(ab)thallium studies, l791(ab)11-201 SPED'

exercise scintigraphy, 673(ab)followingexerciseanddipyridamoleinfusion,

580(ab)physiological significance, 666(ab)stereo view method, 643(ab)

Myocardial perfusionimaging, Tc-99m MIBI, 654(ab)

1957

Myocardlal perfusion


reserve, changes after PTCA, 1262scintigraphy, patients with coronary disease,

654(ab)Tc-99m(III)cationsas imagingagents,1870tomographic scintigraphy, children with

Kawasaki disease, 1839Myocardium

C-i 1 BMHDE synthesis, biological evaluationand, 728(ab)

contractility, radionucide assessment, 578(ab)damaged

Gd-i59 EDTMP localization in, 722(ab),729(ab)

In-ill antimyosin fab and Tc-99mpyrophosphate, 76

extraction ofl-123 IPPA, cardiomyopathy,670(ab)

fattyacidmetabolism,1-123HA,924.-926(le)free fatty acid extraction, hypertensive heart

disease, 567(ab)function, coronary artery bypass surgery effects,

179i(ab)Gd-DTPA as a perfusion agent, 871

glucose utilization, FDG and high resolutionPET, 588(ab)

1-125IHDAevaluationin, 667(ab)imaging, Tc-99m CPI, 131-123MISCwashout,sympatheticinnervation

and,608(ab)ischemia, short- and long-lived rubidium tracers

forstudy,989lipid metabolism, 3-methyl-branching effects,

720(ab),724(ab)perfused beating, quantification of granulocyte

infiltration, 667(ab)perfusionandmetabolism,aftercoronary

thrombolysis, PET, 1563quantitative imaging, Tc-99m MIBI compared

with 11-201, 653(ab)rotational 11-201 tomograms, quantification of,

673(ab)P2-30 regional distribution, animal models of

ischemia and reperfusion, 620(ab)stunned canine, prolonged metabolic

abnormalities, 558(ab)Tc-99m cations as perfusion agents, 1491Tc-99m MIBI and 11-201 uptake, comparison,

cells,667(ab)11-201 rotational tomography, evaluation of

patients without infarction, 588(ab)uptake ofTc-99m RP-30 vs. 11-201, workload

effects, 666(ab)wall thickening

pled perfusion imaging, 618(ab)11-201 SPED' quantitation, 577(ab)

Myoglobln, screening test, myocardial infarction,568(ab)

Myopathy, metabolism, P-3i MRI, 598(ab)

N

Naltrexone, oral, duration ofopiate receptoroccupation and, 6l2(ab)

NarcOleptIc drugs, distribution ofIMP and, 354Nebulizer, Tc-99m DTPA, chemical breakdown

of,378Nephrectomy, kidney function changes after, early

andlate,735(ab)Neurenteric cyst, Tc-99m pertechnetate diagnosis

of,1218Neuroblastoma

advanced, 1-131 MISC therapy, 626(ab)gangJioside Cm monoclonal antibody, 15771-123MISCuptakein, 973metastatic,extremities,1-131MISC,315

mouse, problem for 1-131 MISC studies, 255(Ie)radioimmunotherapy,tumorspheroids,626(ab)treatmentwith1-131MISC,627(ab)

Neuroendorcine tumors, 1-131 MIBG scintigraphyin, 979

Neuroreceptors, imaging, diagnosis and therapy,l786(ab)

Neutrinos, Los Alamos, conifict betweenradioisotopes and neutrinos resolved,N1378

Newsilne, Commentary: News/me begins thirdyear in JNM, Nl48

Nltrogen-13L-gjutamate, metabolic fate in transplantable

tumors, 594(ab)PET, regional pulmonary ventilation, 587(ab)stress ammonia PET imaging, 11-201

comparison, myocardial ischemia, 567(ab)Nitrogen-l3 ammonia, myocardial perfusion

reserve,changesafterPTCA,1262Nitroprusside, enoximone comparison, ventricular

volume, 669(ab)N-Nltrosourea, synthesis, brain tumor, 625(ab)NMR. See Nuclear magnetic resonanceNomenclature, Nomenclature Committee seeks

input on CPT-4, N802Noreplnephrlne, 1-125 MISC and,

adrenomedullary cells, 639(ab)Nuclear accIdents

See also ChernobylChernobyl,physicians'roleexaminedin

planningresponseto nuclearaccidents,N413

uptake ofdifferent radionuclides, Chernobylaccident, southern Sweden, 581(ab)

Nuclear magnetic resonanceacute myocardial infarction, comparison with

In-lu antimyosinimaging,590(ab)adrenoleukodystrophy, 524aseptic necrosis, femoral head, 564(ab)cardiac

functional display, 705(ab)geometrical and functional, 590(ab)

contrast agents, Gd-i53 DTPA and Mn-54DTPA comparison, 349

correlation, renal allograft assessment, 733(ab)detection offluoride, bone, 703(ab)5-fluorouraciland,drugmetabolism,599(ab)Ga-67 and, aortic root abscess, 1616gating, 545(le)Gd-based, endogenously available ions, 705(ab)Gd-DTPA, myocardial perfusion agent, 871hairy cell leukemia, marrow involvement, 690hepatic hemangioma evaluation, 1683hepatobiliary enhancement, FE@HBEDand FE

EHPG, 590(ab)high-resolution,SPED' comparison,

temporomandibularjoint, 1268localization ofGd-159 EDTMP, damaged rat

myocardium, 722(ab), 729(ab)myocardial infarction, ischemia and, segment

comparison, 260(ab)myocardium

phosphonate complexes of gadolinium,260(ab)

phosphonatecomplexesofCld,406(ab)newlesionphantom,590(ab)p.31

breast, 599(ab)metabolism ofmyopathies, 598(ab)regional signal suppression, 599(ab)

pheochromocytoma detection, 639(ab)potential pitfalls, avascular necrosis diagnosis,

1052

recombinant tissue plasminogen activator, acutemyocardial infarction, 59i(ab)

RN correlation, nodular thryoid disease,685(ab)

scrotum, 704(ab)skeletal, endocrine, and cardiovascular systems,

1786(ab)slice profile, averaging error in, 705(ab)spinal lesions, comparison with bone

scintigraphy, 590(ab)stereotactic method comparison, brain

structures on O-15-H20 PET scans, 702(ab)Tc-99mDMSAscintigraphyand,acute

hydronephrosis, pig, 598(ab)Tc-99m PYP biodistribution, myocardial

infarction imaging, 704(ab)three dimensional correlations, PET and D',

682(ab)thyroid and parathyroid, 12211-201 and, myocardial ischemia and infarction

by, 703(ab)Nuclear Magnetic Resonance (NMR)COWIcII,

SNM petitions for new councils: NMR andCommercial Sen'ices, N80i

Nuclear medicine historyEtienne LeBel recognized for leadership in

Canadian nuclear medicine, N791Eugene L Saenger honored with SNM Hevesy

NuclearPioneerAward,N793Maleah Grover-McKay receives Tetalman

Memorial Award, Ni 100Marshall Brucer still full ofacerb wit 30 yean

after serving as SNM president, fightagainst societal radiation phobia, N 1645

nuclear medicine as a practical medical science,N1647

William J. Maclntyre receives Aebersoid Awardfor outstanding achievement in basicscience applied to nuclear medicine, N795

Nuclear medicine practiceautomated cost accounting and billing program,

265(ab)Commentary: How the malpractice crisis effects

nuclear medicine physicians, Ni5l7Commentary Lines from the president

radiodiagnostics, drugs, and the FDA,N 1804

Commentary: lines from the presidentprotecting â€œwindowofexpectancyâ€•, N1381

Commentary: who speaks for nuclearmedicine?, N942

departmental quality assurance program,679(ab)

equipmentpurchasingdecisions,basedonclinical needs and facility design, transitionfrom planar to SPED', PET, N278

Harvard omits nuclear medicine from relativevalue scale study, Nl250

Nomenclature Committee seeks input on CPT4, N802

NRC removes nuclear physicians from hospitallicenses for falsifying records, proposes newrules for quality assurance, training andexperience, Ni653

proposal for physician fees paid by DRG systemfor radiology, anesthesiology, pathology(RAP-DRGs), Ni49

RAP-DRGs defeated in Congress, RVS to bedeveloped for radiologic services, Ni513

SNM Board of Trustees adopts statement oncredentialing and delineation of privileges,SNM urges US Congress to require peerreview for research grants, N165l

SNM members, focus groups, N 1248

1958

Myocardium

TheJournalof NuclearMedicine

SNM physician and scientist manpower survey,N430

used nuclear medicine equipment needed indeveloping countries, N944

Nuclear medicine researchscientific highlights, European Nuclear

MedicineCongress 1987, Ni795â€œslicesoflife,â€•scientific highlights, SNM 34th

Annual Meeting, 1987, Nl235Nuclear medicine technology

archiving imaging data, cardiac clinical databasefor, 652(ab)

information collection, systems approach,652(ab)

Nuclear Medicine Week, Nuclear Medicine Week,how it was observed in 1986, plans for1987, N418

Nuclear pharmaciesdigital, 260(ab)nuclear medicine, pharmacies, seek

indemnification, Price-Anderson Act,N 1382

Nuclear Regulatory Commission (NRC)clarifying new misadministration reporting

rules, N153NRC promulgates final rule for 10 CFR 35,

Nl2NRCremovesnuclearphysiciansfromhospital

licenses for falsifying records, proposes newrules for quality assurance, training andexperience, N 1653

NRC simplifies regulations for medical use ofbyproduct material (10 CFR 35), NlSi

Nuclear scan, duplex-sonographic correlation,renal allograft rejections, 647(ab)

0

Oncocytomas, functional, kidney, dual tracerscintigraphy,1911

Oncology, review of international NATO meeting,July, 1986, Italy, covers cancer detectionand therapy, clinical trials, labeling,dosimetry, N143

Opiate receptorsdurationof occupation,oralnaltrexoneand,

612model parameters, naloxone pre-loading effects,

70l(ab)PET, C-I 1 diprenorphine in, 635(ab)

Organ dimensions, assessment using profileanalysis, 55l(ab)

Organized medicine, organized medicine in adestabilized era, Nl247

Orphan Drug Program, osmium-i9 i/indiumi9lm generator awarded orphan productgrant, Ni54

Osteoarthropathy, diabetic, dynamic boneimaging in, 664(ab)

Osteochondritis dissecans, three-phase bonescintigraphy of, 605(ab)

Osteomyelltlsadult, IN-I 11 WBC and In-I 11 chloride

comparison, 1540axial skeleton, In-l I I leukocyte detection,

694(ab)cold bone defects, In-I I 1 leukocyte imaging,

820comparative efficacy of In-l I 1 leukocytes and

Tc-99m MDP, 193i(ab)culture proven acute, bone scans and In-l I I

leukocytes, 694(ab)cultureprovenacuteandchronic,detection,

552(ab)In-i I I labeled blood cells, localization

mechanism in dog model, 691(ab)painful prosthesis, Ga-67 citrate imaging of,

927(le)Tc-99mMDPandIn-i 1I WBC,comparative

efficacy, 586(ab)Osteopenin, bone densitometry asserts clinical role

despite lack ofreimbursement, N267Osteoporosis, spine, dual-photon absorptiometry,

665(ab)Ovarian carcinoma, intrapentoneal, IP vs. IV

delivery ofmonoclonal antibodies, 65l(ab)Ovary

dysfunction, 1-131 iodomethylnorcholesterol,685(ab)

suppression, bone mineral density inendometnosis and, 628(ab)

Oxygenend-capillary pressure, PET measurement,

656(ab)utilizationrate,PET,63l(ab)

Oxygen-ISinhaled, radiation dose from, upper airways,

234time dependence, bolus model for CMRO2

measurement by PET, 699(ab)Oxygen-iS water, PET and, cerebral blood flow,

656(ab)

P

Pacemaker, impairment of regional leftventricular relaxation, myocardial perfusionand,672(ab)

PA@Sdata collection methods, error-free, 652(ab)systems approach, information collection,

nuclear medicine department, 652(ab)Paimitate, metabolic fate of, myocardial ischemia,

I322Pancreas

membrane transport measurement, 1-123monoiodo-D-tyrosine in, 724(ab)

organ donation of, splenic artery and veinresection for, spleen imaging with Tc-99m,638(ab)

transplants, Tc-99m glucoheptonate and sulfurcolloid surveillance of, 583(ab)

Paraganglioma, familial malignant nonfunctional,1-131 MISC, 528

Parangangliomas, 1-123 MISC uptake in, 973Parathyroid

autoradiography, C-l4 amino acids, 1447dual isotope subtraction scintigraphy,

prevention of motion artifacts, 1335imaging, positron labeled specific monoclonal

antibody fragments, 582(ab)localization scans, postoperative hypocalcemia

and,583(ab)multimodality imaging of, 122preoperative localization, 1-131 toluidine blue

and Tc-99m pertechnetate imaging, 298scintigraphy

dual isotope, diagnostic sensitivity of, 583(ab)image subtraction and, 582(ab)update, 1790(ab)

Patellar tendonitis, bone scintigraphic findings,1768

Penis, bolus first pass data applied to, 406(ab)Penumbra, ischemic, evolution with time, PET,

633(ab)Perchlorste, suppression ofTc-99m pertechnetate,

lactating goats, 1187Pericardlal effusions, gated blood-pool imaging,

1419Pericardltis, constrictive, right atrial thrombus

associated with, In-I 11 oxine plateletimaging, 1344

Periprosthetic infection, Ga-67 citrate imaging of,926(le)

PET. See Positron emission tomographyPhantom, modified Iowa heart, SPED' defect

detectability, 643(ab)Pharmacokinetics, antibodies and, 1358Pharyngeal emptying, radionuclide studies,

oculopharyngeal muscular dystrophy,605(ab)

Pheochromocytomadetection with 1-131 MISC, D', MRI,

correlations, 639(ab)1-123 MISC uptake in, 973metastatic, extremities, 1-131 MISC, 315treatment with 1-131 MISC, 627(ab)

Picture archival, communication systems and,1786(ab)

Pinhole collimator sciatigraphy, metastasis,fractureand infection, spine, 447

Pituitary, tumor, dopamine D@receptors in,626(ab)

Planar scintigraphy, SPED' vs., spondylolysisdetection, 665(ab)

Planar SQ 30,217 scans, myocardial perfusiondefects, 11-201 scan comparison, 663(ab)

Plasmaclearance

comparison with Tc-99m DTPA, glomerularfiltration rate, 372

synthesis ofcontinuous infusion, 1062(Ie)renal flow, without kidney disease, 622(ab)

Plasma time-activity carve, during radionucliderenography, 1338

Plateletskinetics, mathematical model, 402(le)labeling

cheiates and incubation media with In-I I 1,223

Tc-99m, 263(ab)Pneumonitls, lymphoid interstitial, gallium

scanning, children with AIDS, 1915Point scatter distribution functions, scatter

correction and, SPED', 1861Positron camera, high density avalanche chamber,

1554PosItron emission tomography (PET)

adrenoleukodystrophy, 524brain structures on 0-15: see also H20 scans

NMR and stereotactic method comparison,702(ab)

abnormal, early Alzheimer's disease, 645(ab)accelerator system for, radiation measurements

related to, 697(ab)aginganddementia,brain,431analysis

integral model for, 587(ab)primate dopamine-D2 neuroreceptor system

with F-18, 587(ab)analytic scatter correction, object size and

spatial position, 695(ab)arterial blood dispersion effects, cerebral blood

flow, 656(ab)brain tumors, characterization by parametric

imaging ofblood volume, FDG andmetabolism, 645(ab)

caudate D2 dopamine receptor density, test ofproposed model, 700(ab)

C-l I and1-125IBZ,D2 dopaminereceptorimaging, 726(ab)

C-i 1 deprenyl, brain, baboon, 624(ab)C-I I DMPEA kinetics, brain MAO-B activity,

1006

SubjectIndexâ€¢1987 1959

Posftron emission tomography (PET)

C-l 1 eticlopride, synthesis, 625(ab)C-l I i-methionine accumulation and, brain,

645(ab)C-il methyl iodide synthesis, origin of carner

in, 728(ab)C-l 1 nitromethane, use as a radiolabeling

precursor, 636(ab)C-I 1 NMKET and, localization of serotonin-2

receptors, 600(ab)C-Il pyrilamine,synthesisandbiodistribution,

624(ab)C-il thymidine,developmentas an imaging

agent, 728(ab)cerebral blood flow

agents for measurement, 134(le)defects in chronic cocaine users, 655(ab)pre-operative mapping ofcritical function,646(ab)

stroboscopic stimulation, 702(ab)cerebralmalignancy,1251cerebral protein synthesis, C-i I leucine, 587(ab)clinical scanning, 1789(ab)CMRO2 measurement by, oxygen-l5 bolus

model, 699(ab)comparison with angiography, exercise ability

and, 26i(ab)complex partial epilepsy, comparative

investigation, 702(ab)constrained least squares filtering technique,

image count density dependence, 661(ab)copper radiopharmaceuticals

brain and heart, 407(ab)cerebral blood flow measurement, 722(ab)

cortical and subcortical metabolism, anxietyeffects, normals and schizophrenics,655(ab)

D2 dopamine receptor measurement, primates,61 l(ab)

depth-of-interaction ofscintillation crystals,temperature gradient, 64I(ab)

dosimetry estimates for, C-i I labeledthymidine, 683(ab)

end-capillary oxygen pressure, measurement of,656(ab)

equipmentpurchasingdecisions,basedonclinical needs and facility design, transitionfrom planar to SPED', PET, N278

FDA efforts to reduce radiopharmaceuticalreviewtime,advisorycommitteediscussesregulation ofPET products, NI

F-18 deoxyglucosecerebral glucose metabolism, 53, 1667myocardial glucose uptake, dopamine effects,668(ab)

rateconstants,myocardium,682(ab)F-l8 DOAL, hepatocdllular carcinoma, 706(ab)F-i8 estradiol, assessment ofestrogen receptors

in breast cancer, 56i(ab)F-I8FDG

brain tumors, 594(ab)malignant gliomas, 645(ab)

F-IS fluorocarboxylic acid ester, 634(ab)F-i8 fluorodopa,regioselective

fluorodemercuration,624(ab)F-18 fluoromisonidazole, F-18

fluoromisonidazole, 594(ab)F-18labelingofproteins,462F-18 progestin distribution, animal studies,

625(ab)functional mapping of FDO rate constants,

Aizheimer's disease, 699(ab)Ga-68 transferrin, measurement of pulmonary

vascular permeability, 1704glioma evaluation with, 1123

glucose metabolism and DNA polymorphismstudies, Huntington's disease, 655(ab)

high resolutionbrain, 608(ab)comparison ofimages from two, 608(ab)countratecapabilityanddeadtime,607(ab)heart, attenuation correction, 696(ab)myocardial glucose utilization, 588(ab)Scanditronix PC1024-7B scanner, 607(ab)stationary-sampling, 607(ab)

ischemic penumbra, evolution with time,633(ab)

large hot and cold spheres, uniform phantom,696(ab)

LCBF measurements, human data, 587(ab)local cerebral blood flow studies, 1695maximum-likelihoodreconstruction,noiseand

edge artifacts, 566(ab)melaninimaging,developmentoftracersfor,

701(ab)Monte-Carlosimulation,scatterdeconvolution

technique, 681(ab)myocardial blood flow measurement,

hypertrophic cardiomyopathy, N-l3ammonia,567(ab)

myocardial perfusion and metabolism, aftercoronary thrombolysis, 1563

myocardial perfusion reserve, changes afterPTCA, 1262

naloxone preloading effects, opiate antagonist F-18CF.70i(ab)

N-l3 and, regional pulmonary ventilation,587(ab)

neuro, F-18 fluoroprednisone synthesis andevaluation,998

newwhole-bodysystem,641(ab)nuclides, formation oftarget species during,

634(ab)opiate receptors, C-il diprenorphine for,

635(ab)oxygen-iScarbondioxide,radiationdoseto

upper airways from, 234parameters estimated with, bias and covariance

in, 682(ab)perfusion imaging, 4i0(ab)photons/PAD ratios, tracer labels, 683(ab)positron-emitting radiopharmaceuticals for,

robotforproduction,727(ab)primary lung cancer, C-il methionine uptake

and, 658(ab)quantitation in, radon transform distortions,

641(ab)radiobronsinated phosphonium cations, high

myocardial specificity, 726(ab)radiolabeled palmitate, myocardial ischemia,

1322radioligand-neuroreceptor interaction, four

compartment model, 681(ab)refractory neonatal seizures, surgical selection,

646(ab)rubidium, transient ischemia, 989sinograms, missing data, 565(ab)â€œslicesoflife,â€•scientific highlights, SNM 34th

Annual Meeting, 1987, Nl235SNM/ACNPsymposiumon PET/SPED'for

practitioners, N944steady-state, regional cerebral blood flow,

unstimulated 14 minute period, 700(ab)structural and functional images, correlation in

same patient, 634(ab)studyoftwo behaviorstates,852systematic errors in, selecting contrast

phantoms,698(ab)temporal lobe epilepsy, regional opiate receptors

andglucoseutilization,699(ab)test-retest paradigms, errors from subject

repositioning, 68i(ab)three dimensional correlations

D' and MR.I,682(ab)treatmentofaxialdata, 1717

thymidine nucleotides, cellular sources for, 1435time-of-flight, performance measurements of,

696(ab)tissue 0-15 oxygen kinetics in, oxygen

utilization rate in, 63i(ab)validation ofinput functions, RB-82 cardiac

studies, 682(ab)V-48 vanadyl(IV)-pheophorbide, cancer

diagnosis, 723(ab), 727(ab)Positron labeled antibOdies, parathyroid specific,

evaluation, 582(ab)Postprandial blush, multiphase bone scanning,

1550Pregnancy, radionucide venography in, 1290Preleukemla, following large dose radioiodide

therapy, metastatic thyroid carcinoma,1348

Pressure-volume relations, ventricular suctionmeasurements by, 557(ab)

Price-Anderson Act, nuclear medicine,pharmacies, seek indemnification, PriceAnderson Act, N1382

PrObabilIstic Image, regional wall motionabnormalities,676(ab)

Proctographyballoon, assessment ofanorectal angle, 550(ab)scintigraphic balloon, anorectal angle, 660(ab)

Profile analysis, assessment of organ dimensions,551(ab)

Progesterone, gastric emptying and, 1204Prospective Payment System (PPS)

Commentary: lines from the presidentprotecting â€œwindowofexpectancyâ€•, Nl381

proposal for physician fees paid by DRG systemforradiology,anesthesiology,pathology(RAP-DROs), N149

RAP-DRGs defeated in Congress, RVS to bedeveloped for radiologic services, Nl513

Prostate, SR-89 therapy, between patient variationin strontium kinetics, 683(ab)

infected, In-i 11 chloride imaging of, 255(k)orthopedic, suspected infection, In-Ill WBC in,

586(ab)Protein

labeling4-i000-benzoates for, 725(ab)iodophenyi conjugates for, 560(ab)

radiohalogenationof, increasedretentionoflabel, 725(ab)

Pulmonary edema, vascular permeability in, PETandGa-68transferrinmeasurements,1704

Pulmonary embolismasymptomatic, following knee replacement,

584(ab)clot localizationin, non-plateletbound

antibody, 7l8(ab)experimental

detection, antibody imaging, 584(ab)In-i11andIn-125anti-plateletantibody

behavior,720(ab)lungscanning

computerassistance,584(ab)cost-effectivenem and beneflt:risk, 1521

ventilation-perfusion scan, digital subtractionangiography compared with, 584(ab)

Putrescine, PET studies, cerebral malignancy,1251


Positronlabeled antibodies

QQuality assurance

NRC removes nuclear physicians from hospitallicensesforfalsifyingrecords,proposesnewrules for quality assurance, training andexperience,N 1653

quality assurance manual for scintillationcamera, N154

Quality control, automated, standarddeterminations,265(ab)

Quantitationmyocardial infarct size, TL-201, 325organ visualization, SPED', 334

R

Radlation doseabsorbed, Tc-99m DTPA, 240inhaledoxygen-IScarbondioxide,upper

airways, 234local, from extravasal 11-201, 684(ab)measurements, design of self-shielded

acceleratorsystem,PET,697(ab)radionuclides in the gallbladder, 1794(ab)Tc-99m RBC, critical organ, 684(ab)thyroid cancer, hematologic long-term hazards,

58l(ab)Radiation dos@Radiation risk

Chernobyl, decontaminate world threatened byfallout,riskmisperception,N933

Chernobyl, physicians' role examined inplanningresponseto nuclearaccidents,N413

Commentary: Chernobyl predictions and theChinese contribution, long-term healtheffects, N423

nuclear medicine community responds to EPAguidelines for indoor radon levels, cost/benefitanalysis,epidemiologicstudies,N1087


Radiation safetyCalifornia researchers escape criminal charges

forradiationsafetyviolations,N1655Guidelines for radiation safety, AIDS

prevention, pose conflict, Nl806NRC removes nuclear physicians from hospital

licenses for falsifying records, proposes newrules for quality assurance, training andexperience, N 1653

Radioactive waste, law-level, Cal Rad Forum,workshop, low-level radioactive waste,N 1382

Radioactivity, monitoring after 1-131 therapy,l064(Ie)

Radionermoischemical breakdown, during nebulization, 378deposition and clearance, bronchodilation and,

bronchialasthmain remission,1901ventilation scintigraphy, congenital lobar

emphysema, 1213Radlosutolysls, Y-90 antibody and, 71 l(ab)Radlochelates, serum stability of, antibody

radiopharmaceuticals, 83Radlochemistry, positron, formation of target

species, PET nuclides, 634(ab)Radlocolloid, liver examination, detection of bone

marrow metastases and, 184Radiohalogenation, protein, increased retention of

label, 725(ab)Radloimmunoassay (RIA)

choriogonadotropin, discordant inter-kit results,

719(ab)CK-BB levels, intracranial hemorrhage,

premature infant, 7l8(ab)commercial kit, calcitonin stability and, 718(ab)In-i25, for SQ 27,519 in human serum, 568(ab)measurementof thyroglobulin,differentiated

thyroid carcinoma, 685(ab)radioreceptor assay and, comparison of

cholecystokininanalogues,568(ab)RJA cost-effectiveness study moves ahead, N430T4-analoaJalbumin, binding in analog FF4

assays, chemical inhibition, 569(ab)thyroxine binding globulin, free thyroxine

index,normal,thyroiddisease,andsickeuthyroidpatients,1341

TSH kit, simultaneous free T4 and, 7l9(ab)Radloimmunodetection

anti-monoclonal antibodies, cancer, 652(ab)1-123anti-granulocytesantibodies,infectious

lesions, 6l4(ab)In-ill flab')2distribution,normalmice,

692(ab)In-i11-hapten-monoclonalantibody

normal mice, 692(ab)nudemouse-humancolontumormodel,

71 l(ab)initial studies, monoclonal antibodies

recognizing colon cancer, 713(ab)testicular cancer xenograft, athymic mice, 1gM

monoclonal antibody, 714(ab)Radloimmunosclntigraphy

absorbed dose to patient, 6i7(ab)chelation ofln-I 11 to monoclonal antibodies,

colon carcinoma xenografts on athymicmice, 861

diagnosis ofbone and joint infections, 585(ab)DTPA, efficient coagulation to 1gM monoclonal

antibody in ascites fluid, 693ocular melanomas, 637(ab)regional chemotherapy and, liver metastases,

706(ab)uptake ofln-I 1I anti-CEA, colorectal cancer,

637(ab)Radlo&mmuaotherapy

curative adjuvant, treatment planning, 6l7(ab)cutaneous T-cell lymphoma, 553(ab)

retreatment, plasmapheresis effects, 603(ab)DTPA, efficient coagulation to 1gM monoclonal

antibody in ascites fluid, 693generator-produced Yttrium-90, 1465hama-murineantibodycomplexes,614(ab)immunotherapy comparison, animal model,

691labeling ofRhenium-l86 antibodies for, 656(ab)quantitative autoradiography, micro-UD

measurements and, 617(ab)Y-90 biodistribution in patients, 712(ab)

R*dloiodlnatlon, In-I I 1 and 1-131 monocionalantibodies, biodistribution, 722(ab)

dose reevaluation, newborn, 1208nasal uptake, 686(ab)

Radlolabeling precursor, C-l 1 nitromethane,636(ab)

Radloligands, receptor-binding, estimation ofhepatic functional reserve, 627(ab)

Radlometric assay, bacterial growth, 209Radionuclide @uction

Los Alamos, conflict between radioisotopes andneutrinos resolved, N1378

physics experiment may cloud future of LosAlamos nuclear medicine program,proposals for dedicated radionuclideproduction facility, N1371

Radionuclidesdifferent, uptake from Chernobyl accident in

southern Sweden, 581(ab)dose rate effects, 617(ab)positron emitting, scintillation well-counting of

blood samples, 697(ab)R@maceu&ais

aerosolized, respiratory clearance of, 894antibody, serum stability ofradiochelates for, 83copper, PET with, brain and heart, 407(ab)heart,chemistryof, 1351in vivo evaluation, factor analysis for, 680(ab)positron-emitting, for PET, robot for

production, 727(ab)receptor-binding, 653(ab)

Radlopharmaceutical science, Committee onNuclear and Radiochemistry exploresnuclear medicine issues, trainingrequirements for nuclear medicinechemists, N15l9

Radiopharmaceutical Science Council, SadatakeKato honored with service award fromRadiopharmaceutical Science Council,N150

Radiophosphates, uptake, asymptomatic kneearthroplasty, 1546

Radloreceptor assay, radioimmunoassay and,comparison of cholecystokinin analogues,568(ab)

Radiotherapylungfunctionafter,quantitativescans,6l6(ab)monoclonal antibodies for, high efficiency

iodination, 1034Yttrium-90, intrahepatic infusion, 707(ab)

Radharacersnocarrieradded,F-i8FDOandhexokinase,

624(ab)short-lived,quantificationof regional

ventilation, I 144Radon

nuclear medicine community responds to EPAguidelines for indoor radon levels, cost!benefit analysis, epidemiologic studies,Ni087


RAP-DRGsCommentary lines from the president

protecting â€œwindowofexpectancyâ€•, N1381proposal for physician fees paid by DRO system

forradiology,anesthesiology,pathology(RAP-DROs), N149

RAP-DROs defeated in Congress, RVS to bedeveloped for radiologic services, NiSi3

Receiver operating characteristic (ROC) analysisindices ofleft ventricular function, diagnosis of

CAD and, 671(ab)SPED' error maps, improving 11-201

quantitation, 631(ab)ft-Receptors, cardiac, up-regulation by

benzazepine, cardiomyopathy patients,666(ab)

Reconstruction, three-dimensional transferfunction, filtered backprojection, 630(ab)

Rectum, anorectal angle, scintigraphic balloonproctography,660(ab)

Reductive carboxylatlon, approach to C-I 1 methylbenzazepine synthesis, 625(ab)

Regional wall motiondetection ofabnormalities, probabilistic image,

676(ab)perfusion defects and extent of ischemia,

thallium scintigraphy, 598(ab)

1961SubjectIndexâ€¢1987

Re@Ionelwall motion

Scatter deconvolution technique, PET, MonteCarlo simulation, 68i(ab)

Schizophreniaon and offmedication, cerebral glucose

consumption, 702(ab)regional cerebral blood flow measurements,

SPED', 698(ab)Scintillation camera

dual-photon absorptiometry, spine, 665(ab)F-l8 FDG, imagingofthyroid carcinoma, 910para-axialneurofibromatosis, 1688quality assurance manual for, Nl54Wads test, epileptic patients before and during

Wadatest,1763Scintillation crystals, depth-of-interaction,

determination a temperature gradient,64i(ab)

Scintillation well-counting, blood samples,positron emitting radionucides, 697(ab)

Sclerodernsahepatobiiary imaging in, gnstroesophageal

reflux, 387metaclopramideesophagealstimulation,

scintigraphic detection, 810Sclerosis, progressive systemic, gastric emptying

in, metoclopramide effects, 688(ab)Scrotum, MRI, 704(ab)75-SeHCAT test, diagnosis ofileal dysfunction,

Crohn's disease, 688(ab)Seminoma, immunoassay for choriogonadotropin,

discordant inter-kit results, 7l9(ab)Serotosiln receptors

equilibrium binding kinetics, brain, 61l(ab)irreversible agonist, CNS, 725(ab)

Serotonln-2 receptors, localization, C-i I NMKET,600(ab)

Sex differences, 11-201 SPED', bullseye display,642(ab)

Single-photon ab.orptlometry (SPA)SeealsoAbsorptiometrybone densitometry asserts clinical role despite

lack of reimbursement, N267OHTA advises HCFA to deny Medicare

coverageforSPA,DPA, N 1656osteoporotic fractures ofspine and distal

forearm, 960Single-photon emission computed tomography

(SPED')acceptance testing, quality control and, 1221angular sampling, 1308aseptic necrosis, femorai head, 564(ab)attenuation correction

equation, 1925(le)simultaneous transmission and emission

tomography, 677(ab)blood flow measurements, regional cerebral,

schizophrenia, 698(ab)bone grafts, therapeutic evaluation of, 564(ab)brain

delayedscan with 1-123IMP, 559(ab)xenon-133and1-123,570(ab)Tc-99m HM-PAO, 1657

brain perfusion, Tc-99m HM-PAO, 569(ab)C-l 1 and 1-125 IBZ, D2 dopamine receptor

imaging, 726(ab)cerebral blood flow

arteriovenous malformations, 59i(ab)1-123 IMP brain imaging, 570(ab)1-123 IMP tracer kinetics for measurement,

569(ab)infarct hyperemia, Tc-99m HM-PAO, 633(ab)measurement with 1-123 IMP, 558(ab)subcortical stroke, SPED', 699(ab)Tc-99m, Wade test and, 592(ab)

Relative value scale (RVS) payment system,Harvard omits nuclear medicine fromrelative value scale study, N 1250

Renal arteryflow defects, radionuclide angiography and

renography, 6l3(ab)stenosis, MRI, angiography, and nuclear

medicine, 736(ab)Renal calculi, pre- and post-extracorporeal shock

wave lithotripsy, radionuclide evaluation,1284

Renal cell carcinomaphase I-Il trials, 1-131 monoclonal antibody,

603(ab)xenografts, 1-131 monoclonal antibody

immunoradiotherapy, 651(ab)Renography

captoprilGoldblatt hypertension, I 171renovascular hypertension, 613(ab), 735(ab)

radionuclide, plasma time-activity curve during,1338

radionuclide angiography and, renal artery flowdefects, 613(ab)

Tc-99m DTPA, glomerular filtration ratemeasurement, 399(le)

Research fundingE&R Foundation, student fellowships, Ni250E&R Foundation plans permanent endowment,

N801SNM testifies in Congress on DOE research

funding, DOE offers grants forepidemiologic studies, N1249

Respiratory clearance, aerosolized radioactivesolutes, varying molecular weight, 894

Reticuloendothellal system, function, criticalcolloid dose studies in, 1424

Revascularization therapy, renovascularhypertension, 406(ab)

Rhenlum-186 antibodies, labeling forradioinsmunotherapy, 656(ab)

Rhenlum-188, improved generator,radiotherapeutics, 656(ab), 657(ab)

Rheumatic disorders, bone scanning in, 262(ab)Ribbing'sdisease,Engelmann'sdisease

comparison, 245Risk perception. See Chernobyl; RadonRotating display, subjective characteristics of,

678(ab)Rubidium, short- and long-lived tracers, transient

ischemia, 989Rubldium-82, skeletal muscle blood flow, glucose,

insulin, and exercise effects, 1155Rubidlum-83, myocardial uptake, alterations in

perfusion and oxidation, heart, 878Rubldlum-56, cardiac transport, hypoxia and,

620(ab)Rubidium-Sd chloride, metabolic marker, brain

tumor response to chemotherapy, 595(ab)Ruthenlum-97 DISIDA, duodenogastric reflux,

gastric emptying and, 596(ab)

S

Sasuger, Eugene L, Eugene L Saenger honoredwith SNM Hevesy Nuclear Pioneer Award,N793

Sagittal venus sinus, visualization, scintigraphicevaluation ofbrain death, 1279

Samarlum-153 chelates, skeletal localization, 495Samarlum-153 EDTMP, injections, radiation dose

calculations, 505Sarcoldosis, childhood, value ofoa-67 in, 7l6(ab)Sarcoma, osteogenic, xenografts, In-ill

monoclonal antibody localization of, 342

Tc-99m HM-PAO, 559(ab)transient ischemic attacks, 633(ab)

cerebral perfusion imaging, 1364(le)clinical images, nonuniform attenuation

correction improvement of, 661(ab)collimators, measurement of hole angulation

and camera head tilt, 1592compensation for attenuation, tumor activity,

577(ab)cone beam detector system, estimating

parameters of, 661(ab)3-D, cone beam collimation, 678(ab)defect detectability, modified Iowa heart

phanton, 643(ab)epinephrine, intra-arterial infusion, hepatic

tumor blood flow, 659(ab)equipment purchasing decision, based on

clinical needs and facility design, transitionfrom planar to SPED', PET, N278

fan beam collimation, high resolution 1-123HIPDM brain imaging, 570(ab)

femoral head, following acetabular fracture,664(ab)

filtering and scatter correction, 410(ab)functional thyroid volume determination,

575(ab)Ga-67, asbestosis, 7l8(ab)gamma camera based systems, noise

characteristics, 696(ab)gated cardiac blood-pool scanning

problem in data sampling, 668(ab)regurgitant fraction ofleft ventricle, 19

hepatic hemangioma, differentiation fromhepatoceliular carcinoma, 688(ab)

hepatobiliary, deconvolution analysis, 689(ab)high resolution, 409(ab)

astigmatic collimator, brain, 576(ab)cone beam collimator, brain, 577(ab)fan beam collimator, brain, 576(ab)

high-resolution MRI comparison,temporomandibularjoint, 1268

HIPDM, radioactive iodine exchange reaction,360

1-123 HIPDM, complex partial seizure foci,600(ab)

1-123 IMP distribution, temporal changes in,brain, 623(ab)

1-123 iodoamphetaminecardiovascular disease, 622(ab)regional cerebral blood flow, 6I9(ab)

1-123 MIBO, after transmural myocardialinfarction, dog model, 669(ab)

1-123 spiperone, high-yield labeling, animalstudies, 570(ab)

1-125 dimethyl fatty acidsmeasurement of myocardial fatty acid uptake,

724(ab)myocardial uptake and clearance kinetics of

DMIPP analogues, 571(ab)image interpretation, 11-201, feature extraction,

618(ab)image reconstruction, detector responses in,

566(ab)improved, simultaneous emission and

transmission tomography, 844improved myocardial imaging, 11-201, energy

weighted acquisition, 577(ab)In-l I 1, new collimator for, 696(ab)In-l I 1 anti-CEA monoclonal antibody,

abdominal colorectal cancer, 604In-i 11 leukocytes, inflammatory bowel disease

diagnosis, 659(ab)instrumentation and image processing

techniques, l788(ab)

1962

R&atlve value scale (RVS) payment system

The Journal of Nuclear Medicine

interactive visual optimization of, 1192Inverse Monte Carlo, improved lesion

detectability, 566(ab)isoproterenol infusion, assessment of

myocardial perfusion after, 62i(ab)large hot and cold spheres, uniform phantom,

696(ab)lower back pain, evaluation and improvement,

564(ab)maximum-likelihood reconstruction, noise and

edge artifacts, 566(ab)Metz restoration filter, image-dependent,

565(ab)new cardiacphantomfor,1791(ab)noise power spectrum for, 630(ab)nonisotropic attenuation in, 1584

compensation for, 66i(ab)patient motion during, cross-correlation

function and, 97perfusion imaging

brain, 1012colorectal tumors, 408(ab)

photons/RAD ratios, tracer labels, 683(ab)planar vs., spondylolysis detection, 665(ab)portal hypertension, portosystemic collaterals in,

627(ab)prazosin treatment, cerebral blood flow and,

elderly patients, 623(ab)pulmonary blood flow, normal regional

distribution, gravity independent planes,1758

quantitation, 11-201, myocardial wall thickness,577(ab)

quantitative organ visualization, 334radiation-induced lung damage, early detection,

659(ab)rCBF assessment, tracer for, 70i(ab)reconstruction, elliptical orbits and distance

weighted backprojection, 564(ab)resolution recovery, image processing

techniques, 566(ab)scatter correction

germanium detector use in, 1853point scatter distribution functions, 1861

segmental perfusion lung anatomy, 585(ab)6-slice ring detector, clinical evaluation, 697(ab)â€œslicesoflife,â€•scientific highlights, SNM 34th

Annual Meeting, 1987, Ni235SNM/ACNP symposium on PET/SPED' for

practitioners, N944Tc-99m brain scintigraphy, Huntington's

disease, 406(ab)Tc-99m DTPA

application of deconvolution analysis to,734(ab), 735(ab)

para-axial neurofibromatosis, 1688Tc-99m HM-PAO

acute cerebral infarction, 622(ab)brain, epileptic patients, Wads test, 1763distribution in cerebrovascular disease,

591(ab)primary brain tumors, 59l(ab)

Tc-99m HM-PAO and 1-123, subacute strokes,623(ab)

Tc-99m MIBI, imaging malignant tumors,562(ab)

Tc-99m PYP and DTPA aerosols, comparisonfor lung imaging, 585(ab)

Tc-99m RP-30 perfusion tomography,myocardial, 620(ab)

Tc-99m sulfur colloid, spleen/liver ratio,675(ab)

texture analysis, organ distribution of perfusion,405(ab)

thoracic and lumbar spine, suspected vertebralmetastases, 665(ab)

three-dimensional, two-dimensional mapping,405(ab)

three-dimensional spatially-variant point spreadfunction, algorithm for compensation,662(ab)

three-dimensional transfer function, filteredbackprojection,630(ab)

11-201alterationsindistribution,chronic

hypertension, 673(ab)bullseye display, sex differences, 642dipyridamole with, coronary disease, 642(ab)estimation ofleft ventricular mass, normal

andinfarctedheart, 1315image artifacts that decrease specificity,

672(ab)LAD disease with left bundle branch block,

589(ab)left-ventricular aneurysm, 168leg muscle perfusion, 717(ab)measurementofventricularmass,heartrate

and contractility effects, 408(ab)motion during, 642(ab)myocardiai, following dipyridamole for CAD,

408(ab)myocardial infarct size, 325oral dipyridamole and, CAD, 579(ab)patient and cardiac movement in exercise,

630(ab)peripheral arterial disease, leg, 717(ab)quantitative analysis for myocardial images,

643(ab)quantitative criteria to read defects, 674(ab)stress-induced myocardial perfusion defects,

642(ab)11-201 DDC, cerebral blood flow, 17811-201 rotational, evaluation of coronary

disease following MI, 674(ab)transverse, pinhole collimator, 678(ab)uniform attenuation in, convolution algorithm

for,677(ab)Xe-i33

cryptogenic West syndrome, 592(ab)inhalation, demented patients, 599(ab)

Sm-153 EDTMPautoradiographic evaluation, radiotherapeutics

for primary bone cancer, 709(ab)osseous metastasis, 708(ab)

Society of Nuclear Medicine (SNM)Commentary: assembling the SNM scientific

program, N792Commentary: lines from the president

protecting â€œwindowofexpectancyâ€•, N1381Commentary: lines from the presidentâ€”SNM

1986.-l987yearin review,Nl099(correction, N 1249)

Commentary: Lines from the presidentradiodiagnostics, drugs, and the FDA,Nl804

Commentary: lines from the presidentpragmatists prevail at Winter Meeting,N277

Commentary: Newsline begins third year, N148Commentary: rationale for â€œSNMin Canadaâ€•,

Nl0Commentary: who speaks for nuclear

medicine?, N942E&R Foundation, student fellowships, N 1250E&R Foundation plans permanent endowment,

N80iEtienne LeBel recognized for leadership in

Canadian nuclear medicine, N791

Eugene L Saenger honored with SNM HevesyNuclear Pioneer Award, N793

FDA efforts to reduce radiopharmaceuticalreview time, advisory committee discussesregulation ofPET products, Nl

Maleab Grover-McKay receives TetalmanMemorial Award, Ni 100

Marshall Brucer still full ofacerb wit 30 yearsafter serving as SNM president, fightagainst societal radiation phobia, N 1645

Nuclear Medicine Week, how it was observed in1986,plansfor1987,N418

RIA cost-effectiveness study moves ahead, N430Sadatake Kato honored with service award from

Radiopharmaceutical Science Council,NISO

â€œslicesoflife,â€•scientific highlights, SNM 34thAnnual Meeting, 1987, N1235

SNM/ACNP symposium on PET/SPED' forpractitioners,N944

SNM Asia tours, two international nuclearmedicine conferences in China, N 1806

SNM Board ofTrustees adopts statement oncredentialing and delineation of privileges,SNM urgesUS Congressto requirepeerreviewforresearchgrants,Ni65i

SNM Board ofTrustees meeting, Brain ImagingCouncil, chapter representation,credentialing statement, N426

SNM Computer Council plans buyers' guide,NI54

SNM councils report at Winter Meeting, N802SNM 1987electionresults,N1250SNM expands criteria for Berson-Yalow Award,

N944SNM InstrumentationCouncilpromotes

electronic mail, Nl656SNM issues first call for abstracts, 35th Annual

Meeting, San Francisco, N1516SNM members, focus groups, N 1248SNM members offered special enrollment for

insurance plan, N1520SNM petitionsfor newcouncils:NMR and

Commercial Services, N801SNM physician and scientist manpower survey,

N430SNM Technologist Section names Barbara

Horton as distinguished honoree, NationalCouncil holds strategic planning session,N 1652

SNM testifies in Congress on DOE researchfunding, DOE offers grants forepidemiologic studies, Nl249

SNM 34th Annual Meeting, Toronto, Canada,1987, N789

SNM Winter Meeting, perfusion imaging, Nl2Technologist Section, National Council

meeting, professional identity within alliedhealth, N799

Technologist Section nominations for 1987election, N430

William J. Maclntyre receives Aebersold Awardfor outstanding achievement in basicscience applied to nuclear medicine, N795

SPED'. See Single-photon emission computedtomography

Spinal bone mineral, loss with inactivity, 260(ab)Spinal cord

injurybone mineral loss in femur in, 1792(ab)biliary kinetics, 688(ab)gallbladder motility in, 596(ab)

Spinal lesions, bone scintigraphy, comparisonwith NMR, 590(ab)

1963

Spinal lesions


Spine

Spinelumbar, regional differences in mineral density,

663(ab)upright, scintigraphy, 664(ab)

Spiperonefluoroalkylated, cerebral D2 binding, 612(ab)receptor-mediated endocytosis, 612(ab)

Spleenaugmented radiocolloid uptake, malignant

melanoma, 262(ab)autologous implantation, splenosis

differentiation from, 638(ab)blunt trauma, colloid shift following, 188Fc-receptor function, pre- and post-treatment,

690(ab)pancreas organ donation, artery and vein

resection for, Tc-99m, 638(ab)ratio ofTc-99m sulfur colloid, transaxial

SPED' images, 675(ab)Splenosis, differentiation from autologous spleen

implant, spleen scan, 638(ab)Spondylitis, bacterial, early diagnosis with bone

scan, 254(le)Spondylolysis, detection, planar and SPED'

scintigraphy, 665(ab)Sternum, lesions, breast cancer, 606(ab)Streptokinase, intravenous, treatment of

experimental frostbite, rabbit, 606(ab)Strontlum-89, metastatic bone pain and, 553(ab)Subarachnoid hemorrhage, blood flow

abnormalities following, brain, 634(ab)Sulfur colloid, Tc-99m, pancreatic allograft,

583(ab)Sympathetic nervous system, 1-123 MIBG

imaging, idiopathic congestivecardiomyopathy, 667(ab)

Syphilis, tertiary, liver and bones, radionuclideimaging in, 1047

Systemic perfusion, method of uptake,radioiabeled monoclonal antibodies,715(ab)

T

Technetium, chemistry and design implications,593(ab)

Technetlum-99magents for brain scintigraphy, 1787(ab)automated edge detection technique,

intracoronary thrombolysis, 135(le)bolus first pass analysis, renal transplants and

penis, 406(ab)bone scintigraphy, pateilar tendonitis, 1768cholecystokinin cholescintigraphy, gallbladder

contractility in fundal adenomyomatosis,1771

complexescomparison with 11, myocardial perfusion,

405(ab)multiple small chain alkylation, 729(ab)stereoisomers of, 60l(ab)

dose calibrator response, varying geometryeffects,1478

emissions in water, effective attenuationcoefficient for, 678(ab)

first pass analysis, renal blood flow, 405(ab)isonitrile complexes, 602(ab)labeling ofplatelets with, 263(ab)lesion detectability, thresholds, 706(ab)lymphocyte radiolabeling, l228(le)monitoring oflag phase, gastric emptying,

563(ab)neutral complexes, synthesis, characterization,

and reactivity, 728(ab)perfusion-function imaging, CAD, 597(ab)

radiopharmaceutical preparation, surfaceabsorbed stannous ions, 1041

reference level, gastric emptying, 563(ab)scintigraphic balloon proctography, anorectal

angle, 660(ab)tin colloids, leukocyte labeling with, 147111-201, improvement in subtraction, nonlinear

regression transformation technique,687(ab)

tris @9-diketonecomplexes, synthesis andbiodistribution, 730(ab)

Technetlum-99m albumin, first-pass anger cameraradiocardiography, ventricular ejectionfraction, 950

Technetlum-99m albumin collold, leukocytepreparation, characteristics, 574(ab)

Technetlum-99m antibodyblood clearance of, ester bonds and, 602(ab)metastatic melanoma, known and occult,

573(ab)Technetium-99m BAT

brain perfusion imaging, SPED', 1012stereoisomers of, structure-biodistribution

relations, 1930(ab)Technetium-99m callous, inorganic chemistry of,

1491Technetlum-99m colloids, adverse reactions to,

178l(le)Technetium-99m CPI

interspecies comparison ofdistribution, 60l(ab)myocardial imaging, 13

Technetium-99m DADTchemical structure, accumulation and retention,

brain, 594(ab)complexes, pulmonary accumulation of, 729(ab)site selective localization, brain hippocampus,

rat, 73l(ab)Technetium-99m diphosphonates, phosphate

transport and, renal cell line, 602(ab)Technetium-99m disofenin, biliary kinetics, spinal

cord injury, 688(ab)Technetium-99m DMSA

clearance, renal amyloidosis, 734(ab)imaging ofmedullary thyroid carcinoma,

252(k), 253(le)meduilary carcinoma, thyroid, 561(ab)MRI and, hemodynamic changes in

hydronephrosis, pig, 598(ab)Technetium-99m DTPA

aluminemic disturbance, renal functionmeasurement, 383

ANF effects, Goldblatt hypertension, 734(ab)captopril renography, 733(ab)chemical breakdown, during nebulization, 378differential renal function, rapid method for

measurement, 829distribution and relaxivity ofOd-153 chelates,

mouse tumors, 705(ab)dynamic scan

deconvolution analysis application to,734(ab), 735(ab)

renal excretion evaluation, 733(ab)enhanced by captopril, renovascular disease,

613(ab)extrapulmonary radioactivity, lung permeability

measurements, 903glomenilar filtration rate measurement, 372,

S10, 399(le)-labeled tablets, dissolution rate and transit

times, 1199PYP comparison, lung imaging, 585(ab)radiation absorbed dose from, 240renal allograft assessment, MRI/RN correlation,

733(ab)

renal blood flow, non-invasive measurement,646(ab)

single-dose captopril and, renovascularhypertension, 1383

SPED', pare-axial neurofibromatosis, 1688split renal function, renovascular hypertension

or urinary obstruction, 73l(ab)uptake, bone, blood clearance and, 1461

Technetium-99m GHA, granulocyte labeling,690(ab)

Technetium-99m GH-SC, patterns, pancreaticallograft, 583(ab)

Technetlum-99m glucoheptonate, comparison withGa-67 citrate, pulmonary malignancies,442

Technetlum-99m HES, preparation andevaluation, lymphoscintigraphic agent,730(ab)

Technetium-99m HMDP, bone, early diagnosis ofbacterial lymbar spondylitis, 254(le)

Technetium-99m HM-PAObrain scintigraphy, Huntington's disease,

406(ab)brain SPED' imaging, 569(ab)

comparative, 1-123 amphetamines and,569(ab)

initial experience with, 1657regional blood perfusion, 191Wada test and, 592

cerebral blood flow, 407(ab)compartmental model, 559(ab)SPED', 559(ab)triple label digital autoradiography, 559(ab)

cerebral kinetics, first minutes after injection,baboon, 593(ab)

clinical use in adults and pediatric patients,1793(ab)

comparison with In-I ii, imaging inflammation,574(ab)

decomposition, aqueous media, 593(ab)early and late SPED', distribution in

cerebrovascular disease, 591(ab)evaluation,leukocytelabeling,638(ab)granulocyte labeling, 690(ab)1-123 1MB SPED' and, subacute strokes,

623(ab)kinetic considerations, clinical evaluation and,

701(ab)labeled leukocytes, imaging inflammation with,

648(ab)metabolic marker, brain tumor response to

chemotherapy, 595(ab)mixed leukocytes with, clinical protocol for

radiolabeling, 694(ab)RBC SPED' and, cerebrovascular disease,

600(ab)SPED'

acute cerebral infarction, 622(ab)primary brain tumors, 591(ab)

vs. 11-201 DDC, subcellular distribution,593(ab)

Technetium-99m lISA, In-I I 1 platelets and,antithrombotic drug effects on plateletdeposition, carotid atherosclerosis, 701(ab)

Technetlum-99m IDA, septo-optic dysplasia,neonatal jaundice, 966

Technetium-99m(III)catlons, development,myocardial perfusion imaging agents, 1870

Technetium-99m IsOnitrIlecardiac transport, hypoxia and, 620(ab)myocardial imaging, 13myocardial perfusion imaging, ischemic heart

disease, 675(ab)Technetlum-99m LDL, lipoprotein receptor


activity with, liver, 610(ab)Technetium-99m MAA

aerosol, tracheo-bronchial clearance,scintigraphic monitoring, 161

hepatic arterial perfusion pattern, intra-arterialchemotherapy for colorectal carcinoma,708(ab)

perfusion imaging, hepatic arterial perfusionchemotherapy, 41 l(ab)

perfusion scintigraphy, detection of pulmonaryemboli, 584(ab)

Technetlum-99m macroaggregated albumin, lungscans, post-radiotherapy pulmonaryfunction, 616(ab)

Technetlum-99m MAG3biological characterization, 732(ab)comparison with HPLC-purified Tc-99m

MAO3, 1881comparison with 1-131 and 1-123 OIH, renal

work, 647(ab)kit formulation, patients with renal failure,

647(ab)physiologic factor effects, renal, 732(ab)potential renal imaging agent, I 180

Technetium-99m MAGAG,I, renal excretioncharacteristics, 731(ab)

Technetium-99m MDPbone scanning

adductor insertion avulsion syndrome, 1835ischemia effects, 108

comparative efficacy, osteomyelitis, 586(ab),193i(ab)

high dose methotrexate and, diffuse hepaticuptake, 532

infraction ofsecond metatarsal, 249metastasis, fracture and infection, spine, 447radiophosphate visualization, total knee

prosthesis, 915soft-tissue accumulation, unilateral thoracic,

1275suspected vertebral metastases, thoracic and

lumbar spine, 665(ab)uptake

asymptomatic knee arthropiasty, 586(ab)ectopic bone, rats, 665(ab)

Technetlum-99m MIBIassessment ofmyocardial function, 674(ab)coronary occlusion and reperfusion

comparison with microspheres, 620(ab)during reperfusion, 654(ab)

evaluation, coronary artery disease, 655(ab)myocardial perfusion imaging, intervals between

rest and stress, 662(ab)new cardiac imaging agent, 1790(ab)SPED', imaging malignant tumors, 562(ab)Tc-99m TBI and 11-201, compared

biodistribution, heart, 654(ab)11-201 comparison

coronary artery disease, 654(ab)myocardial perfusion scintigraphy, coronary

disease and, 654(ab)quantitative myocardial imaging, 653(ab)uptake, myocardial cells, 667(ab)

Technetlum-99m mlcrocolloid, MRI, bone marrowinvestigation, malignant lymphoma disease,705(ab)

Technetium-99m monoclonal antibodiesantiglobulin responses and, 615(ab)

labeling ofproteins, 72l(ab)metastatic melanoma, known and occult,

650(ab)preclinical evaluation, melanoma antibodies

and fragments, 69l(ab)preserved immunoreactivity, high in vivo

stability and, 1027specific localization, tumor xenografts use CE

DTS, 720(ab), 730(ab)Technetium-99m NGA

estimation ofhepatic functional reserve, 627(ab)radiopharmacokinetic system, receptor-binding,

653(ab)Technetium-99m PAHIDA, renal clearance, 907Technetium-99m PentAO, diamine dioxime

complexes, 601(ab)Technetium-99m pertechnetate

per-rectal portal scintigraphy, evaluation ofportal circulation, 689(ab)

radionuclide imaging, sequential torsions ofappendix testis, I 19

sequential scintigraphy, neurenteric cyst, 1218superimposed, preoperative parathyroid

localization by, 298suppression by perchlorate, milk of lactating

goats, 1187testicular imaging, undescended testis, 106l(le)

Technetium-99m phosphonate, glucocorticoideffects on, bone imaging for trauma,606(ab)

Technetium-99m PMT, delayed imaging,hepatocellular carcinoma, 689(ab)

Technetium-99m PnAO, alkylated derivatives,729(ab)

Technetium-99m PYPbiodistribution, myocardial infarction imaging,

704(ab)myocardial damage, 76

Technetium-99m red blood cellsdosimetry of, Critical organ, 684(ab)gastrointestinal bleeding detection, bleeding

rates necessary for, 514gated heart studies, problem in data sampling,

668(ab)hemangiomas of the liver

evaluation, 1683infants and children, 1412

ionic and nonionic contrast agent effects,574(ab)

pre- and post-treatment, Fc-receptor function,690(ab)

total knee arthroplasty, postoperative bleeding,565(ab)

venography, clinical suspected deep veinthrombosis and, 649(ab)

Technetium-99m rhenium-suffid-colloid,submucosal cheek injection, cervicallymphoscintigraphy by, 707(ab)

Technetium-99m RP-30gated myocardial images, left ventricular

ejection fraction, 662(ab)myocardial ischemia and reperfusion, regional

myocardial distribution, animal model,620(ab)

myocardial perfusion, ventricular function and,662(ab)

perfusion tomography, myocardial, 620(ab)retention, heart, cytosolic protein and, 61911-201 comparison

coronary heart disease, 620(ab)myocardial uptake, workload effects, 666(ab)

Technetlum-99m SQ 30,217, pharinacokinetics,comparison with SQ 30,214, 674(ab)

Technetium-99m SQ 32,014, compared with SQ30,217, 730(ab)

Technetium-99m SQ 32,097cerebral extraction efficiency, 729(ab)synthesis, regional cerebral blood flow, S92(ab)

Technetium-99m sucralfate, gastroduodenal ulcerdetection, 521

Technetium-99m sulfur colloldblunt trauma, spleen, 188colloid shift following trauma, 1366(le)duodenogastric reflux, gastric emptying and,

596(ab)interpretation oflymphoscintigraphy, factor

analysis and condensed image in, 716(ab)intraperintoneal scan, continuous ambulatory

peritoneal dialysis, 1930(ab)pharyngeal emptying studies, oculopharyngeal

muscular dystrophy, 605(ab)reticuloendothelial function, 1424SPED', spleen/liver ratio, 675(ab)splenic artery and vein resection, pancreas organ

donation, 638(ab)tracheobronchial ciliary function, heart-lung

transplant, 6l6(ab)ventilation scintigraphy, congenital lobar

emphysema, 1213Technetium-99m TBI, Tc-99m MIBI and 11-201,

compared biodistribution, heart, 654(ab)Technetlum-99m TETA, gastric emptying studies,

anorexia nervosa and, 816Technetium-99m triaminedithiol complex, cerebral

blood flow, regional assessment, 1064(le)Technologist Section

SNM Technologist Section names BarbaraHorton as distinguished honoree, NationalCouncil holds strategic planning session,N1652

Technologist Section nominations for 1987election, N430

Technologist Section, National Councilmeeting, professional identity within alliedhealth, N799

Tellurium, effects ofposition, 1-125 uptake and,heart, 571(ab)

Temporal lobe, epilepsy, PET, 699(ab)Temporomandlbularjoint, high-resolution MRI,

SPED' bone scintigraphy comparison,1268

Teratoma, ethiodol, dosimetry of, 582(ab)Ter-Pogosslan, MICheI, Michel Ter-Pogossian

elected to IOM, N1520Testicular torsion, sequential, radionuclide

imaging, 119Testis, undescended, missed torsion of, 106l(le)Tetraethylammonium, no carner added reactions,

F-18 fluoride, 635(ab)Texture, analysis, organ distribution of perfusion,

SPED' images, 405(ab)Thallium

amyl nitrite inhalation and, detection ofcoronary artery stenosis, 597(ab)

comparison with Tc-99m, myocardial perfusion,405(ab)

dipyridamole scintigraphy, CAD in diabetics,i780(le)

fatty acids imaging and, myocardial infarctionand ischemia, 632(ab)

myocardial SPED', following dipyndamole forassessment ofCAD, 408

polar coordinate plots, artifact identification in,265(ab)

quantitation, myocardial perfusion SPED',405(ab)

quantitative studies, myocardial ischemia,179l(ab)

redistribution, cardiac, 588(ab)SPED', patient and cardiac movement in

exercise, 630(ab)tomographic, intravenous dipyridamole in

conjunction with, children, 262(ab)washout analysis, 1058


Thallium

Thallium-20lauto-transplanted thyroid glands, l230(le)brain scintigraphy, increasing specificity,

658(ab)brain tumor imaging, 47cardiac transport, hypoxia and, 620(ab)coronary artery disease, alternatives to dynamic

exercise for, 1788(ab)correlation with 1-131 and thyroglobulin assays,

follow-up ofthyroid cancer, 686(ab)diagnosis ofmyocardial infarction, emergency

room, 598(ab)diethyldithiocarbamate, cerebral blood flow, 178differentiated thyroid carcinoma, 685(ab)dipyridamole and

improved criteria for interpretation, 580(ab)quantitative emission tomography, 579(ab)silent myocardial ischemia in, 580(ab)

dual isotope parathyroid scintigraphy, diagnosticsensitivity of, 583(ab)

estimation ofleft ventricular mass, normal andinfarcted hearts, SPED', 1315

exercise scintigraphy, diagnosis of myocardialischemia,673(ab)

exercise SPED', silent ischemia in, 589(ab)extravasal, local radiation dose from, 684(ab)fast washout of, myocardial infarction, 945Ga-67 uptake ratio, pulmonary neopiasms,

707(ab)high grade astrocytoma, tumor/cardiac ratio

method, 706(ab)Hodgkin's disease, with hypercalcemia, 1121-123 IPPA comparison, coronary artery disease,

669(ab)intravenous dipyridamole and, elderly patients,

670(ab)kinetics, hypoxia effects, myocardial cells, 1453left ventricular mass measurement, heart rate

and contractility effects, 408(ab)lung/heart ratio, coronary arterydisease, 1531MRI combined with, myocardial ischemia and

infarction, 703(ab)multivessel PTCA outcome, accurate

identification, 631(ab)myocardial infarction, ischemia and, segment

comparison, 260(ab)myocardial rotational tomography, without

myocardial infarction, 588(ab)myocardial SPED' quantitation

energy weighted acquisition, 577(ab)wail thickness effects, 577(ab)

myocardial uptake, alterations in perfusion andoxidation, heart, 878

normal images, strongly positive exercise ECOand, prognosis, 643(ab)

perfusion-function imaging, CAD, 597(ab)perfusion scintigraphy, EKO T wave

normalization, 673(ab)planar studies, CAD, new approach to

interpretation, 588(ab)post-exercise motion, perfusion defects and

extent ofischemia, 598(ab)post-perfusion scintigraphy, coronary

angioplasty following thrombolysis,myocardial salvage, 674(ab)

quantitation, SPED' error maps for, 631(ab)scan defects, prognosis in CAD, 643(ab)SPED'

alterations in distribution, chronichypertension, 673(ab)

antianginal medical effects, 644(ab)bullseye display, sex differences, 642cardiac events and risk, elderly patients,

644(ab)

coronary stenosis, 666(ab)dipyridamole with, coronary disease, 642(ab)image artifacts that decrease specificity,672(ab)

image interpretation, feature extraction,6i8(ab)

isoproterenol infusion, assessment ofmyocardial perfusion after, 621(ab)

LAD disease with left bundle branch block,589(ab)

left-ventricular aneurysm, 168leg muscle perfusion, 7l7(ab)motion during, 642(ab)myocardial infarct size, 325peripheral arterial disease, leg, 7 17(ab)prediction ofdeath and myocardial

infarction, CAD, 644(ab)quantitative criteria to read defects, 674(ab)stress-induced myocardial perfusion defects,

642(ab)stress N-i3 ammonia PET comparison,

myocardial ischemia, 567(ab)subclavian vein obstruction, 254(le)Tc-99m MIBI and TBI comparison,

biodistribution, heart, 654(ab)Tc-99m MIBI comparison

coronary artery disease, 654(ab)improvement in subtraction, nonlinear

regression transformation technique,687(ab)

myocardial perfusion scintigraphy, coronarydisease and, 654(ab)

quantitative myocardial imaging, 653(ab)uptake, myocardial cells, 667(ab)

Tc-99m RP-30 comparisoncoronary heart disease, 620(ab)myocardial uptake, workload effects, 666(ab)

thrombolytic therapy, nuclear cardiologytechniques,632(ab)

tomograms, myocardial, 673(ab)tumor vs. sarcoidosis differentiation, hilar and

mediastinal adenopathy, 56l(ab)uptake

blood flow relations and, heart, 399(le),400(le)

exercise and dipyridamole effects, myocardial,580(ab)

Thaffium-201 DDCautoradiographic comparison, cerebral blood

flowtracers,481vs. Tc-99m HM-PAO, subcellular distribution,

593(ab)Therapeutic nuclear medicine

B-cell lymphoma, autologous bone marrowtransplant and 1-131 anti-Ia, 692(ab)

between patient variation in strontium, SR-89dosimetry, 683(ab)

Br-80m labeled estrogen receptor bindinguganda, synthesis and biodistribution,572(ab)

generalized dosimetry schema, tumor uptake ofmonoclonal antibodies, 680(ab)

1-131 accumulation, pericardial effusion, i33(le)1-131 lipiodol, hepatoma, 707(ab)1-131 MIBG

diagnosis ofcarcinoid syndrome, 658(ab)neural crest tumors, 308pheochromocytoma and neuroblastoma

treatment, 627(ab)toxicity, blood radiation dosimetry, 6l8(ab)

in vivo generator, radioimmunotherapy, 72i(ab)1-131 therapy, parotid oncocytoma, 626(ab)low vs. high dose 1-131, thyroid remnant

ablation, 686(ab)

skeletal metastases, 626(ab)Sm-153-EDTMP

osseous metastasis, 708(ab)primary bone cancer, 709(ab)

thyroid cancer, hematologic long-term hazards,581(ab)

Tungsten-l88/Rhenium-188 generator, 656(ab),657(ab)

Y-90,livertumors, 708(ab)Thiolates, chemistry and design implications,

593(ab)Thoracic surgery, gallium uptake and, chest, 1831Thrombi, deep venous, detection with In-Ill

antifibrin monoclonal antibodies, I930(ab)Thrombolysis

coronary, myocardial perfusion andmetabolism, PET, 1563

intracoronary, automated edge detectiontechniques, 135(le)

Thrombophlebitis, deep vein, In-i I 1 plateletscintigraphy, 649(ab)

Thrombosisdeep vein, Tc-99m RBC venography role in,

649(ab)experimental, In-l ii and In-125 anti-platelet

antibody behavior, 720(ab)intracardiac, detection by In-li 1 platelets,

blood-pool subtraction effects, 639(ab)pregnancy, radionucide venography, 1290

Thrombusleft atrium, Ga-67 imaging, 69l(ab)prevention with Ga-67-DFO-DAS-flbrinogen,

following myocardial infarction, leftventricle, 609(ab)

ThymldineC-il

development as an imaging agent, 728(ab)dosimetry estimates for PET studies, 683(ab)

Thymidine nucleotides, cellular sources, PET,1435

Thymus, lymphoid and non lymphoid tumors,Ga-67 localization, pediatric patients, 293

ThyTOgIObU1In,serum TSH and thyroidaldisorders, atomic bomb survivors exposedinyouth,1115

Thyroidauto-transplanted, 11-201 imaging in, l230(ie)cancer

differentiated, risk factors, 576(ab)newly developed monoclonal antibodies

against, 714(ab)11-201 correlation with 1-131 and

thyroglobulin assays, 686(ab)undiagnosed metastases, therapeutic dose of I-

131, 1881carcinoma

differentiated, 11-201 imaging, 685(ab)imaging ofmetastases, l782(le)imagingwithF-i8FDG, 910

congenital hypothyroidism, scintigraphy,687(ab)

differentiated carcinoma, thyrogiobulin levelsand 1-131 total body scan in, 685(ab)

disorders, atomic bomb survivors exposed inyouth, 1115

functional volume, determination by SPED',575(ab)

longitudinal emission tomography, 1892malignant cell line, labeled immunogiobulin

aggregates to, 71 i(ab)meduilary carcinoma

1-131 MIBO uptake in, 265(ab), 576(ab),1820

radiolabeled monoclonal antibody to


Thallium-201

calcitonin in, 263(ab)spinal bone mineral density in, 685(ab)Tc-99m DMSA in imaging of, 252(le),

253(Ie), 561(ab)metastatic carcinoma, large dose radioiodide

therapy for, preleukemia following, 1348multimodality imaging of, 122nodular disease

fine needle aspiration biopsy, 575(ab)MR/RN correlation, 685(ab)

radioiodine dose reevaluation, newborn, 1208remnant ablation

correlation of scan findings and quantitativesuptakes, 687(ab)

low vs. high dose I-13l(ab)screening, 1-131, after Chernobyl accident, 535thyroxine replacement therapy, elevated T4

levels in, 575(ab)Thyroid disease, free thyroxine index, thyroxine

bindingglobulin assay in, 1341Thyroiditis, subacute, presenting as painless cold

nodule, 1488Thyroid-stimulating hormone (@ISH)

radioimmunoassay kit, simultaneous free T4and, 7i9(ab)

thyroglobulin and thyroidal disorders, atomicbomb survivors exposed in youth, 1115

Thyroxideelevated levels, patients on thyroxine

replacement therapy, 575(ab)free estimation, analog assays employing

chemical blockers, 568(ab)simultaneous free, TSH radioimmunoassay kit

and, 719(ab)Thyroxine, free index, calculation in normal,

thyroid disease, and sick euthyroid patients,1341

Thyroxine-binding globulin, free thyroxine index,calculation in normal, thyroid disease, andsick euthyroid patients, 1341

Transplantation, heart-lung, tracheobronchialciliary function in, 616(ab)

Tricarboxylic add, myocardial cycle tracer, C-i Ilabeled acetate, 61 l(ab)

Tumor necrosis factor, radioiabeled metabolicprobes in, liver, 640(ab)

Tumorsactivity, compensation for attenuation, SPED',

577(ab)antigen density, new in vitro method, 719(ab)brain

characterization by parametric imaging ofblood volume, FDG and metabolism,645(ab)

incorporation ofamino acids in, 595(ab)11-201 scintigraphy, 658(ab)

carcinoid, imaging with 1-123 MIBO, 1907colorectal, SPED' perfusion imaging, 408(ab)drug metabolism in, non-invasive monitoring,

595(ab)Gd-i53 chelates, distribution and relaxivity,

705(ab)giiomas, PET evaluation of, 1123high grade astrocytoma, tumor/cardiac ratio

method, 706(ab)hypoxia, F-18 fluoromisonidazole, 594(ab)immunodetection, implications for, 711(ab)intraperitoneal, monoclonal antibody delivery,

715(ab)localization, clinical parameters related to, 25lymphoid and nonlymphoid, thymic

localization ofGa-67, pediatric patients,293

malignant brain, assessment of chemotherapy,

cisplatin PET, 1844malignant gliomas, F-18 FDG, 645(ab)melanoma, comparison ofsize, In-i 11

antibody, 71 l(ab)monoclonal antibody uptake in, model related

to surface area, 713(ab)neural crest, 1-131 MIBO diagnosis and therapy,

308, 1787(ab)neuroendocrine, 1-131 MIBG scintigraphy in,

979nude mouse-human model, In-i 11 monoclonal

antibody intratumoral injection, 712(ab)oxygenation, monocional antibody uptake and,

709(ab)para-axial neurofibromatosis, SPED' with Tc

99m DTPA, 1688parotid oncocytoma, radioactive 1-131 therapy

for,626(ab)pheochromocytoma and neuroblastoma, 1-131

MIBO scintigraphy, 315pituitary, dopamine D@receptors in, 626(ab)primary pericardial mesotheioma, Ga-67 citrate

detectionof, 1201pulmonary neopiasms, Ga-67 to 11-201 uptake

ratio, 707(ab)radiolabeled monoclonal antibody metabolism,

methods for study, 390regional recurrence, sternal lesions in breast

cancer, 606(ab)response to chemotherapy, Tc-99m HM-PAO

and Rb-86 chloride as markets of, 595(ab)skeletal, therapeutic nuclear medicine, 626(ab)squamous cell, lung, immunoscintigraphy,

637(ab)targeting, highly immunoreactive monoclonal

antibodies, 651(ab)transplantable, metabolic fate of L-glutamate,

594(ab)uptake, monoclonal antibodies, 715(ab)Y-90 monoclonal antibodies, purification

method and coinjection, 721(ab)Tumor-seeking agents

abdominal colorectal cancer, SPED', 604against synthetic carbohydrate antigens, cancer

immunoscintigraphy, 7i2(ab)antibody DTPA conjugates with different

linkages, comparison, 572(ab)antibody tumor targeting, chemical

modification with ester bond, 572(ab)avidin and biotin, imaging applications, 560(ab)B-cell lymphoma, 692(ab)bloodclearanceof, esterbonds,602(ab)brain tumor imaging, 47breast tumor imaging, radiolabeled bacterial

immunomodulator, 658(ab)chimeric antibodies, immunoscintigraphy with,

56i(ab)chimeric monoclonal antibody, characterization

by 1-125, 560(ab)chronic lymphocytic leukemia with,

radioimmunoscintigraphy, 602(ab)colonic cancer, whole-body autoradiography,

683(ab)comparison of tumor size, melanomas, 71 l(ab)continuous regional chemotherapy and, liver

metastases, 706(ab)coupling agents, tumor targeting and, 7l2(ab)C-i 1 SarCNU, no carrier added, 625(ab)detection ofhuman melanoma, athymic mice,

708(ab)F-18 EDO, imaging ofthyroid carcinoma, 910Ga-67 vs. In-I 11 DTPA, detection of metastatic

melanoma, 573(ab)gynecologic carcinoma, recurrences, 1807

hepatoma, hepatobiliary imaging, 628(ab)imaging ofhypoxia, 68immunoscintigraphy, clinical assessment,

637(ab)In-iIi

chelation to monoclonal antibodies, 861localization, melanoma, 65i(ab)

In-l 11 and 1-131 comparison, cutaneous T-celllymphoma, 281

In-i 11 porphyrins, synthetic, 724(ab)in vivo generator, rndioimmunotherapy, 72i(ab)labeling ofproteins, 72l(ab)long term fate, BALB-C mice, 692(ab)meduilary carcinoma, thyroid, 561(ab)monocional antibody localization

human colon carcinoma, 709targeting radiopharmaceuticals, 561(ab)

monoclonal antibody uptake, tumor, modelrelated to surface area, 713(ab)

monoclonal anti-colon/ovarian antibody,potential imaging agent, 710(ab)

MRI, melanomas in nude mice, 704(ab)newly developed monoclonal antibodies,

thyroid cancer, 714(ab)non-specific Fc receptor binding, tumor

detection, 572(ab)optimal tumor localization, clinical parameters

related to, 25osseous metastasis, 708(ab)pharmacokinetics, cancer patients, 7l4(ab)radioimmunodetection, colon tumor model,

71 l(ab)renal cell carcinoma, phase I-Il trials, 603(ab)Re-186,labelingofantibodies, 656(ab)Re-i88, generator system for therapeutic

applications, 657(ab)sensitive IRMA, detection ofCAi25 antigen,

568(ab)subcutaneous injection of, lymphoma after, 42Tc-99m antibody, known and occult metastatic

melanoma, 573(ab)Tc-99m DMSA, medullary thyroid carcinoma,

252(ie), 253(le)11-201, differentiated thyroid carcinoma,

685(ab)tumor xenografts, CE-DTS, 720(ab), 730(ab)V-48 vanadyl(IV)-pheophorbide, cancer

diagnosis, 723(ab), 727(ab)

UUhrasound

duplex, correlation with nuclear scans, renalallograft rejections, 647(ab)

Tonnessen formula vs., kidney depthdetermination, 647(ab)

Urinary tractactivity, 20 mm fractional, 735(ab)obstruction, volume expansion diuretic renal

scan, 824Uroflowmetry, electronic, bladder emptying rate

compared to urinary flow rate, 733(ab)

V

Vanadlum-48, new diagnostic agent, cancer,723(ab), 727(ab)

Vasoreacth4typartial complex epilepsy, 408(ab)patients with dementias, 407(ab)

Venographyradionucide

pregnancy, 1290upper extremity and superior vena cava,

1794(ab)Tc-99m RBC, role in suspected deep vein


Venography

thrombophiebitis, 649(ab)Venous leakage, detection, Xe-l33 corporeal

washout, 650(ab)Venous pump, staged maximal exercise and,

contribution to cardiopulmonary bloodvolume, 650(ab)

Ventilation-perfusion scandigital subtraction angiography comparison,

pulmonary emboli, 584(ab)radiation-induced lung damage, early detection

with SPED', 659(ab)Ventilation studies

asymptomatic pulmonary embolism, followingknee replacement, 584(ab)

extrapulmonary radioactivity, lung permeabilitymeasurements, 903

N-13, PET and, 587(ab)radioaerosols, congenital lobar emphysema,

1213regional, short-lived radiotracer, steady-state

model,1144respiratory clearance, aerosolized

radiopharmaceuticals, 894Tc-99m PYP and DTPA aerosols, comparison

for SPED', 585(ab)Ventricular aneurysm, SPED' Thallium-201, 168Ventricular dysfunction, minimal or no symptoms,

prognosis, 644(ab)Ventricular filling, analysis, CAD detection, 837Ventricularfunction

left diastolic, age-related changes in CAD,670(ab)

left dysfunction, chest pain and, CAD patients,67i(ab)

measurement, gated pressure-volume loopdeterminations, 676(ab)

myocardial perfusion and, Tc-99m RP-30,662(ab)

regional dyssnergy, radionucide angiography,1725

right, pre- and post-operative, valvular heartdisease, 671(ab)

suction measurements, pressure-volume

relations, 557(ab)Ventricular mass, measurement with 11-201, heart

rate and contractility effects, 408(ab)Ventricular scans, gated xenon, 26i(ab)Ventricular volume

calculation, radionuclide, 578(ab)determination by standard voxel counting,

579(ab)enoximone effects, 669(ab)left, attenuation-corrected radionuclide, 552(ab)measurement, correction factor, 401(le)radionucide measurement, attenuation

coefficient, i363(le)Ventricular wall

computer simulation of motion, finite elementmethod, 557(ab)

damage, 266(ab)Ventriculography

age effects, maximal upright exercise, 578(ab)dobutamine infusion, pediatric patients, 621(ab)left ventricular functional recovery, after

exercise, CAD, 579(ab)myocardial ischemia, mental stress and, 597(ab)radionucide

beyond the ejection fraction, 266(ab)cardiac probe system, 670(ab)coronary artery disease, 666(ab)following thrombolytic therapy, 632(ab)left and right ventricular function,

spontaneous respiration effects, 173mortality risk indicator, after myocardial

infarction, 670(ab)volume measurementsattenuation coefficients for, 102

ventricular function, valvar regurgitation and,aortic or mitral valve lesions, 621(ab)

Vertebral metastases, thoracic and lumbar spine,SPED', 665(ab)

Vesicoureteral reflux, siblings ofchildren with,silent renal damage, 62l(ab)

Vitamin B. analog, synthesis, 636(ab)Volume expansion diuretic renal scan, urinary

expansion, 646(ab)

Voxel counting, determination ofleft ventricularvolume, 579(ab)

wWade test

Tc-99m HM-PAO brain SPED'blood flow, 592(ab)epileptic patients, 1763

xxenon-133

balloon catheter and, measurement of liverblood flow, 628(ab)

brain SPED', cryptogenic West syndrome,592(ab)

coronary flow and, 609(ab)corporeal washout, detecting venous leakage,

650(ab)inhalation SPED', demented patients, 599(ab)lower extremity imaging, detection of venous

thrombosis, 1792(ab)mammary grafts, internal, 632(ab)uptake, hepatic steatosis in kwashiorkor,

622(ab)ventilation studies, lung, 616(ab)

V

Yttrium-90activable glass, radiotherapy of liver tumors,

708(ab)antibodies

biodistribution in patients, 7i2(ab)radioautoiysis effects, 71 i(ab)

brake radiation dose due to, anthropomorphicphantom, 684(ab)

generator-produced, rndioimmunotherapy, 1465intrahepatic infusion, radiotherapy by, 707(ab)monoclonal antibodies

selective cytotoxicity, malignant T-cell line,710(ab)

unlabeled, purification method andcoinjection of, 721(ab)


Vennousleakage

REFERENCESReferences must be typed double spaced on a separate sheet and numbored consecutively as they are cited in the text. References includedin a table or illustration are also numbered sequentially with those inthetext.Whenmorethanthreeauthorsappear,theadditionalauthorsare listed as â€œetal'@The Journal uses the Index Medicus style for references. Journal names are abbreviated according to the List of JournalsIndexed in Index Medicus. Sample references are:

1. Burton OH, Vernon P, Seed WA: An automated quantitativeanalysisofventilation-perfusionlungscintigrams.JNuclMed25:564-570,1984

2. Freeman LM, Weissmann HS: Nuclear Medicine Annual, NewYork,RavenPress,1980,pp224-225

3. Odstrchel 0, Hertl W, Ward FB, Ctal: New concepts for the assayofunbound thyroxine (FF4) and thyroxine binding globulin (TBO).InRadioimmunoassayand ReloiedProceduresin Medicine,vol.2. Vienna, IAEA, 1978, pp 369-378

4. Clouter Ri, Edwards CL, Snyder WS, eds: Medical Radionuclides:Radiation Dose and Effects, AEC Symposium Series 20,CONF-601212, Oak Ridge, TN, 1970

5. Dannais RF: The preparationand characterizationof nitrogen-sulfurdonorligandsandtheirtechnetiumcomplexes.PhDThesis,JohnsHopkinsUniversity,Baltimore,MD, 1981,pp98-205

6. SnyderWS,FordMR:AdosimetricstudyfortheadministrationsofNeohydrinlabeledwith203Hgandâ€˜97Hg.InHealthPhysicsDivisionAnnual ProgressReport, Oak Ridge, TN, ORNL 4168,July31, 1967, pp 267-273

7. Brown HS, GrayD': Newtraces inoldspaces. JNucIMed: inpiess.

Numbered references to personal communications, unpublished data,manuscripts in preparation, or manuscripts submitted for publicationare not acceptable.

TABLES

Thbles should be self-explanatory and supplement, not duplicate, thetext. Eachtablemustbe citedin numericalorderin the textandtypedon a separate sheet of paper after the references. Number the tablesconsecutively with an arabic number following the word TABLE. Thetitles should be descriptive, brief, and centered in upper and lower caseletters. Include explanatory material in the footnotes or the text. Placehorizontal lines below the title, below column headings, and at the endof thetable.Do notuseverticalrules.

ILLUSTRATIONS

Illustrations should be limited to those which clarify and augment thetext. Since imaging is one of the major aspects of nuclear medicine,theselectionofhigh-qualityhalftoneillustrationsisofparamountimportance. High-contrast glossy prints should be submitted instead of film.Original line drawings and graphs are preferred foroptimal reproductionandshouldberenderedprofessionallyonwhitedrawingpaperinblackIndia ink. Template or typesetlettering should be used. No hand drawings, typewritten art, or computer-generated art will be accepted. Figuresofinfenorqualitywillbereturnedtotheauthorforcorrectionandreplacement. Details to be emphasized orcrop marks should be indicatedon a tissue overlay. Each illustration must be numbered and cited inorder in the text. The following information should be typed on agummed label and affixed to the back ofeach illustration: figure number,seniorauthor,titleofmanuscript,andarrowindicatingâ€œtop.â€•Authorsare responsiblefor the costsof colorreproduction.

LEGENDS FOR ILLUSTRATIONS

Submit a separate legend page with descriptive paragraphs for each figure,typeddoublespacedin numericalorderwithanarabicnumberfollowing the word FIGURE. Ifillustrations have been published previously, authors are responsible for obtaining permission to reproducethem from both the original author and publisher. The source must becited in the references and the following credit line must appear in thelegend: (Reprinted by permission of Ref. X.) All permission releasesmust be submitted to the Editor at the time of acceptance.

UNITS AND ABBREVIATIONS

Nomenclature, units, and abbreviations should conform to IUPAC recommendations and Systeme Internationale (SI). Chemical formulaefollow the recommendations of the American Chemical Society.Abstracts must be limited to 150 @vordsand typed on a separate page.

Information for Authors

EDITORIAL POLICY

The Journal ofNuclear Medicine publishesseveraltypesof originalarticles in the clinical and basic sciences, case reports, technical notes,special contributions, editorials, letters to the editor, news items pertinentto the practice of the field, and articles of general medical interest.Manuscripts submitted must be original, including illustrations andtables, and not under consideration by another publication.

MANUSCRIPT SUBMISSION

Submit all manuscripts to the Editor: Thomas P. Haynie, MD, The Jouriial ofNuclear Medicine, Office ofSpecial Publications, The UniversityoflexasM.D.AndersonHospital,6723BertnerAvenue,Houston,TX7'@30; (713)m-6015. Send an original and t@vcopies ofthe manuscriptwith three sets of unnwun:ed illustrations (glossies, no smaller than3Â½â€œx5â€œor larger than 8 â€œx10â€•).

COPYRIGHT

In compliance with the Copyright Revision Actof 1976,effective January1, 1978,the Ibilowing written statement must accompany all submissions:â€œUponacceptance by The Journal ofNuclear Medicine, all copyrightownership of the article (complete title of the article in this space) istransferred to The Society ofNuclear Medicine. On behalfofany andall co-authors, I accept the responsibility for release ofany part or allofthematerialcontainedwithinthearticlenotedabove.Theundersignedstipulates thatthe material submittedto The Journal of Nuckar Medkineis original and has not been submitted to another publication fbr concurrent consideration.â€•Copyright requirement does not apply to wrk prepared by United States government employees as part of their officialduties.

REVIEW PROCEDURE

SubmittedmanuscriptsarereviewedforcontentonthebasiSoforiginality,significance, adequacy ofdocumentation, reader interest, and composition. All manuscripts judged suitable for review by the editorial staffare reviewed by a minimum of two referees. Accepted manuscripts aresubject to editorial revision for scientific accuracy and for clarity inthe office of the Editor.

MANUSCRIPT FORMAT

Begin each manuscript componenton a new page in the Ibllowing order:title page, abstract, text, footnotes, acknowledgments, references, tables(each on a new page), and legends for illustrations.

1. Every page must be typed double spaced, including title page,abstract, text, references, legends, acknowledgments, and footnotes,on nonerasablewhite bond (8Â½â€œx11â€œ).

2. Leave a 2-in. margin on all sides of typewritten pages.3. Reference numbers in the text should be underlined and in paren

theses.Do not underlinein the referencelist.4. Paragraphsshould begin with an indentation ofat least five spaces.5. Number all pages at the top right-hand side with names ofthe au

thor(s) or title of the article.6. Handwrittenchangesarenotacceptable.7. Papers must be written in English.8. References in the text should not be made to institutions or locales

exceptwhengermaneto thatparticulararticle.9. Genericnamesshouldbeused.Manufacturersof instrumentsor

radiopharmaceuticals should not be named in the manuscript unlesstheir inclusion is absolutely essential to the content. When necessary,however,manufacturersshouldbe identifiedbyfootnotes.Consecutiveorder of footnote symbols is: @,t, @.

TITLE PAGE

The title should be as short as possible, with a maximum of72 charactersincluding spaces. The title page should include: the first and last namesofall authors; departmental and institutional affiliations ofall authors;and complete mailing address, telephone number, and zip code of theauthorresponsiblefor correspondenceand reprints.

ABSTRACT

Page Number ReaderServiceNumber

Atomic ProductsShirley,NY (516)924-9000 14A 29

BiosourcesNashua, NH (800)248-2006 30A 89

Data Spectrum CorporationChapelHill, NC (919)942-6192 1OA 27

Radiology Research and Education FoundationSan Francisco, CA (415)476-5808 30A 86

Trionix Research Labor@toriesTwinsburg, OH (216)425-9055 12A, 13A 85

Information for Classified Advertisers 1988 20A

SNM Councils VA

SNM MeetingsAnnual Meeting Call for Scientific Exhibits 23A 188Winter Meeting 30A 160

SNM Membership 24A,25A,26A 161

SNM PublicationsChromatography of Tc-99m Radiopharmaceuticals 29A 176Patient Pamphlets 19A 177SPECT, A Primer 28A 170

Diagnostix Plus, Inc.Mineola,NY (516)742-1939

Diversified Diagnostic Products, Inc.Houston, TX (713)955-5323

Elscint,Inc.Boston, MA (617)739-6000

General Electric Medical SystemsMilwaukee, WI (800)624-5692

ON! IncorporatedWebster,TX (713)332-3581

JRT AssociatesDobbs Ferry, NY (914)693-3939

Medi-Physics, Inc.Paramus, NJ (800)MEDI-123

Nuclear AssociatesCarle Place, NY (516)741-6360

hA 31

8A 33

7A 36

9A 40

IBC 41

hA 43

IFC, 1A, OBC 1, 30, 83

2A 2

32A The Journalof NuclearMedicine

Indexto AdvertisersAdvertiser Telephone Number

AuthorIndexâ€”1987jnm.snmjournals.org/content/28/12/local/back-matter.pdf ·...

Documents

Transcript of AuthorIndexâ€”1987jnm.snmjournals.org/content/28/12/local/back-matter.pdf ·...